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Abstract 
 
Use of Micro-Computed Tomography to Evaluate the Changes to Bone 
Structure due to Ovariectomy and Polyunsaturated Fatty Acid Intervention 
in a Rat Model of Postmenopausal Osteoporosis 
 
Amanda B. Longo 
Doctor of Philosophy 
Health Biosciences 
Brock University, 2016 
 
The testing of osteoporosis-related therapies and the investigation into their mechanism 
of action largely relies on the use of the preclinical model of postmenopausal 
osteoporosis, the ovariectomized (OVX) rat.  Study 1 evaluated the time-course of 
changes to the trabecular and cortical microarchitecture of the proximal tibia of the 
Sham-control and OVX rat over a 3-month period following surgery at 3-months of age, 
a typical period used in the testing of nutritional and/or drug intervention.  This study 
confirmed the use of the 3-month OVX rat as a model for trabecular microarchitecture 
changes, but did not support its use as a model for cortical bone changes.  The OVX rat 
was also used to test its resistance to repeated radiation exposure from micro-computed 
tomography (µCT), a method necessary for the longitudinal evaluation of a single animal 
(Study 2).  The method of µCT and its scanning parameters were also investigated to 
confirm their use in appropriately quantifying the 3-dimensional microarchitecture of the 
rat hind limb both in vivo and ex vivo (Study 3).  Together, findings from these 
methodological studies led to its use in the evaluation of changes to bone structure in 
response to a nutritional intervention in the OVX rat (Study 4).  Previous studies of 
growing rats and of OVX rats suggest a benefit to bone with supplementation with a 
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lower n-6 to n-3 polyunsaturated fatty acid (PUFA) dietary ratio, and to altered sources of 
n-3 PUFA, but no study has investigated the impact of these nutritional patterns over the 
life course.  Therefore, Study 4 determined the effect of the dietary ratio and source of n-
3 PUFA on bone during periods of growth (1 through 3 months of age) and following 
Sham or OVX surgery (at 3 months of age).  A low PUFA ratio with n-3 provided from 
flaxseed oil provided benefits to bone health during growth, but these changes were not 
maintained following OVX.  These data suggest that dietary PUFA, at levels attainable in 
humans through a healthful diet, are not an adequate strategy for the prevention of the 
rapid and drastic bone loss induced by OVX. 
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Chapter 1: Introduction 
 
 2 
Introduction  
Osteoporosis is a disease of the skeleton, characterized by a decline in bone mass 
(bone quantity) and a deterioration of the bone tissue (bone quality) (1).  Together, the 
decline in bone quantity and quality lead to an increased risk of sustaining a fragility 
fracture, often resulting in substantial morbidity and a reduced overall quality of life.  
Women are disproportionately affected by osteoporosis, with 1 in 3 women and only 1 in 
5 men suffering from an osteoporotic fracture in their lifetime (1).  This imbalance in 
fragility fracture incidence is due to the loss of endogenous estrogen, experienced by 
women following menopause, causing an imbalance in bone turnover, favouring bone 
resorption.  One potential strategy for reducing the incidence of experiencing a fragility 
fracture later in life is by increasing the peak bone mass acquired during periods of 
growth and development in early life.  Although approximately 20% of peak bone mass is 
determined by genetic factors (2), other strategies including exercise and healthful 
nutrition can increase peak bone mass.  This ultimately leaves more bone mass (quantity) 
available to be resorbed during the menopausal transition before a high risk of fragility 
fracture is reached. 
 One potential strategy for increasing bone mass (quantity) and bone structure 
(quality) during growth and for preserving bone mass and structure following the loss of 
endogenous hormone production is with the incorporation of PUFA in the diet.  The n-6 
and n-3 series of PUFA, and their ratio within the diet, have been shown to influence 
bone cell metabolism, and ultimately alter bone health-related outcomes.  Therefore, a 
main objective of this thesis (Study 4, Chapter 7) was to determine how the ratio of n-6 to 
n-3 PUFA in the diet, at levels attainable through healthful dietary patterns, affect bone 
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quantity and bone quality throughout periods of growth, and following the cessation of 
estrogen production.  The source of n-3 provided from plant or marine oil sources was 
also tested.  Findings from Study 4 showed that providing diets with a lower n-6 to n-3 
PUFA diet with n-3 provided from flaxseed oil resulted in changes to bone health during 
periods of growth in a pre-clinical model.  These results suggest that bone health can be 
altered by a dietary intervention during periods of life predominated by bone modeling.  
The effects of these diets are not maintained following the removal of the ovaries in the 
preclinical model, suggesting that diet is not an adequate strategy for protecting against 
hormone-related bone loss in females. 
 The use of the OVX rat model as a preclinical model for postmenopausal 
osteoporosis has been well characterized and has long been used in the literature for the 
assessment and development of osteoporosis-related treatments.  However, with the 
advent of in vivo µCT, a method that allows for the repeated assessment of bone quantity 
and 3-dimensional bone quality (trabecular and cortical microarchitecture), the changes to 
bone microarchitecture in the OVX rat model must be further elucidated.  Therefore, a 
primary objective of this thesis (Study 2-3, Chapter 5 and 6) was to characterize a reliable 
method for the repeated in vivo quantification of trabecular and cortical bone of the 
proximal tibia of the rat.  These methods were used to determine the time-course of 
trabecular and cortical microarchitecture changes to the proximal tibia of Sham-operated 
and OVX rats (Study 1, Chapter 5).  Results from Study 1 led to the recommendation for 
the use of the 3-month OVX Sprague-Dawley (SD) rat as a model for trabecular bone 
loss.  The proximal tibia of this model should not however, be used for the assessment of 
changes to cortical bone. 
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 The overall experimental approach of this thesis provided a comprehensive 
understanding of the method of in vivo µCT scanning, the characterization of the 
trabecular and cortical microarchitecture outcomes of the 3-month OVX rat model of 
postmenopausal osteoporosis, and the effect of exposure to a nutritional PUFA 
intervention over the life course.  The primary research presented in this thesis provides 
the basis for the experimental design of future studies utilizing µCT and the 3-month 
OVX rat model and provides a foundation for future studies to be conducted using male 
rats and other aged rodent models.  This thesis also provides an experimental basis for 
future studies aimed at assessing the effects of PUFA ratio and n-3 source on the 
attainment of peak bone mass in humans, during adulthood, throughout the menopausal 
transition and following menopause, and throughout the entire lifespan.
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Chapter 2: Literature Review 
 
Modified in part from (3):  
 
Longo AB, and Ward WE.  PUFAs, Bone Mineral Density, and Fragility Fracture: 
 Findings from Human Studies.  Adv Nutr 2016; 7: 299-312.
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The Skeleton 
 
 The skeleton is a specialized supporting framework of the body which provides 
shape and support, protection for vital organs, facilitates the production of hematopoietic 
marrow, and acts as a mineral reserve for calcium and phosphorus homeostasis (4).   
Bone Structure and Function 
 
 Bone is made up of a series of woven type I collagen fibers that is stiffened by 
hydroxyapatite molecules (made from calcium and inorganic phosphate) and undergoes 
constant remodeling to obtain an optimal mass, shape, and architecture (5).  The calcium 
and phosphorous in hydroxyapatite molecules in bone can be mobilized to maintain 
mineral homeostasis in the body when needed for other functions (4).  As well as acting 
as a storage unit for minerals, the skeleton is a metabolically active organ constantly 
undergoing the process of remodeling to adapt to the mechanical loads being applied and 
to maintain its structural integrity, all the while retaining its flexibility and remaining as 
light as possible to allow for efficient locomotion.  While changes to bone mass and 
structure are dominated by mechanical factors, non-mechanical agents such as nutrition, 
hormones, and genetics can also influence bone mass (6).  Thus, bone is a dynamic tissue, 
constantly undergoing changes to its shape and architecture at the microscopic level.  For 
this thesis, I focused on the individual and combined effects of nutrition and hormones, 
specifically PUFA and the presence or absence of estrogen on bone health in the OVX rat 
model of postmenopausal osteoporosis. 
 Trabecular and cortical bone are the predominant forms of bone tissue in the 
skeleton (Figure 2-1).  Trabecular bone makes up roughly 20% of the adult skeleton and 
is primarily found in the epiphysis and metaphysis of the long bones, and in the vertebral 
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bodies.  Trabecular bone consists of a network of trabeculae whose 3-dimensional 
distribution is directionally controlled by the mechanical strains applied to it (7).  
Because the surface area to volume ratio is so much greater in trabecular than in cortical 
bone (trabecular bone surface represents 60% of the total surface), the metabolic rate is 
nearly 10 times higher in trabecular bone (8).  Cortical bone is dense and solid and forms 
the outer shell of the long bones and is more stiff and rigid than trabecular bone.  Cortical 
bone has an outer periosteal surface and an inner endocortical surface.  With aging, 
resorption typically exceeds formation on the endocortical surface, leading to an increase 
in bone diameter and an expansion of the marrow cavity (9).  Therefore, it was important 
to differentiate and to assess trabecular and cortical bone separately to fully understand 
the response of the skeleton to an intervention and to hormone status.
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Figure 2-1.  Structure of the trabecular and cortical bone of the rat tibia 
 
Representative image from a 6-month SD rat having undergone Sham surgery at 3 
months of age.  Trabecular bone is prevalent in the epiphysis and metaphysis of the long 
bones, which are compartments separated by the epiphyseal growth plate.  The shaft of 
the long bones contains a high proportion of cortical bone that surrounds the medullary 
(marrow) cavity and trabecular bone.  The surfaces of the inner and outer cortical bone 
are the endocortical and periosteal surfaces, respectively.   
 
(Image by Longo AB, unpublished, 2016). 
 
Epiphyseal growth plate
Trabecular bone
Endocortical Surface
Periosteal Surface
Medullary (Marrow) Cavity
Epiphysis
Metaphysis
Diaphysis
Cortical Bone
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Bone Cells 
 
 Osteoblasts are mononucleated cells, derived from mesenchymal stem cells, and 
are responsible for the secretion and deposition of bone matrix for the process of 
ossification (4).  The major product of osteoblasts is type 1 collagen, which is 
mineralized with hydroxyapatite crystals (10).  Osteoclasts are multinucleated cells, 
derived from hematopoietic stem cells, and resorb bone mineral by secreting protons and 
the proteolytic enzyme, cathepsin K, through highly active ion channels on the 
membranes into the extracellular space, ultimately lowering the pH in the environment 
near the bone surface and dissolving hydroxyapatite (11, 12).  Osteocytes are the third 
major cell type of the bone, which are a series of terminally differentiated osteoblasts that 
have become trapped in their own secreted bone matrix.  Osteocytes are the most 
abundant cell type in bone and act as mechanosensors (13).  These cells extend processes 
through the surrounding bone matrix to communicate with each other through gap 
junctions to synchronize bone metabolism (14, 15). 
Bone Modeling and Remodeling 
 
 The cellular mechanisms responsible for the constant turnover and adaptation of 
bone to external forces are modeling and remodeling.  Bone modeling (formation) occurs 
at the level of the osteoblast, and involves a change in shape of the bone when new 
mineral matrix is deposited on surfaces without previous bone resorption (5).  Bone 
remodeling (reconstruction) occurs when new bone is laid down onto surfaces that have 
been resorbed by osteoclasts.  The osteoblast and the osteoclast are the two main cell 
types of the bone, and together make up the bone multicellular unit that is responsible for 
the constant turnover of bone in small pockets on its surfaces throughout the life course. 
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 Bone formation and resorption is under strict control by an ever-changing 
combination of genetic, mechanical, hormonal, and nutritional factors (6).  During growth 
and development, bone formation outweighs resorption to establish peak bone mass, the 
highest quantity of bone mass present at the end of skeletal maturation.  In adulthood, 
bone resorption to remove damaged bone is balanced with formation to restore the 
underlying structure, resulting in no net change in bone mass (16).  With aging and 
estrogen deficiency, as seen with menopause, the rate of resorption exceeds the rate of 
formation on the endocortical surfaces of bone (4).  This leads to a decrease in bone mass 
and compromised bone structure.  For this thesis, I have intervened during both the 
process of modeling and of remodeling.  I have introduced a dietary intervention at age 1 
month, during bone modeling, with the intervention continued through periods of 
remodeling when estrogen deficiency was induced by OVX at 3 months of age through to 
6 months of age (Study 4). 
Current Methodologies for the Assessment of Bone Health 
 
 There are many current methodologies to assess bone health.  These 
methodologies are ultimately used to identify individuals at risk for sustaining a fragility 
fracture and to monitor changes to bone health in response to an intervention in both 
humans and rodents (Table 2-1).  Bone health can be assessed by two underlying 
concepts, bone quantity and bone quality.  The assessment of bone mineral content 
(BMC) and bone mineral density (BMD) provides a measure of the amount of mineral in 
a defined region.  Bone quantity, in the form of BMC and BMD, can be measured with 
imaging techniques such as dual energy X-ray absorptiometry (DXA), peripheral 
quantitative computed tomography (pQCT), and µCT.  The assessment of the underlying 
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bone structure provides a measurement of bone quality using imaging techniques such as 
pQCT (in humans and animals) and µCT (in animals).  Computed tomography imaging 
provides quantification of the microarchitecture of the trabecular and cortical bone.  
Collectively, bone quantity and bone quality contribute to bone strength and ultimately to 
its resistance to fragility fracture.
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Table 2-1.  Strengths and limitations of current methodologies used for the 
assessment of bone health in humans and rodent models 1 
 
Method Strengths Limitations 
DXA • Gold standard for clinical 
practice and osteoporosis 
diagnosis 
• Used to measure BMD at 
multiple sites 
• Low radiation dose, high 
precision, fast measurement 
time, relatively low cost 
• Human and animal use 
• Bone size dependent 
• Does not distinguish between 
trabecular and cortical bone 
• BMD does not always predict 
fracture occurrence 
Risk of Fragility 
Fracture 
(FRAX/CAROC) 
• Clinically relevant measure 
• Incorporates multiple risk 
factors to determine 10-yr 
fracture risk 
• Geographical region-
dependent 
• Online algorithm used 
• Human use only 
Bone Derived 
Biochemical 
Markers 
• Changes suggest either 
formation or resorption 
• Respond quickly to an 
intervention 
• Can be measured more 
frequently than imaging 
methods 
• Human and animal use 
• High intra-individual 
variability 
• Expression is influenced by 
circadian variation, sampling 
in a fed or fasted state 
• Reflect systemic changes; not 
site-specific 
Biomechanical 
Strength Testing 
• Direct measure of bone 
strength 
 
• High variability 
• Limited to ex vivo 
• Animal use only 
pQCT • Quantifies 3D bone structure 
at higher resolution than 
DXA 
• Can differentiate between 
trabecular and cortical bone 
• Low radiation dose, high 
precision 
• Human and animal use 
• Limited to the axial skeleton 
in humans 
• Require specialized scanners 
and image analysis software 
µCT • Gold standard for pre-clinical 
studies of bone trabecular and 
cortical microarchitecture 
• Non-destructive method to 
produce high resolution 
images in vivo 
• Exposure to radiation 
• Requires animals to be 
anaesthetized 
• Requires specialized scanners 
and image analysis software 
• Animal use only 
 
1 CAROC; Canadian Association of Radiologists and Osteoporosis Canada, FRAX; 
fracture risk assessment tool
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DXA 
 
 BMD as quantified by DXA is currently the gold standard in clinical practice for 
the diagnosis of osteoporosis by the World Health Organization guidelines (17, 18).  The 
dual energy projection scanning works to quantify BMC in grams by alternative pulses of 
low current X-ray through the region of interest (ROI) (i.e., hip, wrist, spine, total body), 
where a detector quantifies X-ray attenuation through the hard and soft tissue and 
produces an image.  BMD is a derived measure and is expressed in g/cm2 based on an 
areal projection.  Thus, BMD determined using DXA will differ depending on bone size, 
and this can cause complications when comparing values across individuals or across 
studies (19).  DXA does not distinguish between trabecular and cortical bone, which can 
cloud the interpretation of results as changes to areal BMD can be caused by alterations 
in trabecular bone or from the endocortical surfaces of cortical bone, or both (20). 
 DXA is advantageous in clinical practice because of its low radiation dose, high 
precision, fast measurement times, relatively low cost, and ease of use for the technician.  
BMD can be measured at multiple skeletal sites with ease, including the forearm, hip, 
lumbar spine, and total body.  In one longitudinal study of postmenopausal women, 
percent changes to BMD over 3 years showed the greatest changes in the spine, followed 
by the total body and the hip (21), suggesting the lumbar spine may be best when 
quantifying the response to a treatment in humans.  Site-specific BMD measurements 
show the highest gradients of risk for their respective sites (i.e., forearm BMD best 
predicts risk of forearm fragility fracture) (22).  In fact, measuring changes to BMD using 
DXA is such common practice that these criteria are recommended for the development 
and assessment of pharmaceutical interventions in osteoporosis (23).  Although the 
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quantification of BMD by DXA is a well-defined and widespread method, many fragility 
fractures occur in individuals with T scores above the threshold defined for a diagnosis of 
osteoporosis (24-26).  For this reason, an estimation of fragility fracture risk based on 
multiple lifestyle factors was developed. 
Risk of Fragility Fracture 
 
 Arguably the most relevant bone health assessment method, the fracture risk 
assessment tool (FRAX) was developed by the World Health Organization to estimate an 
individual’s 10-year major osteoporotic and hip fracture risk (27).  Using this online 
algorithm, the probability of fragility fracture can be calculated by combining an 
individual’s femur neck BMD with known risk factors for osteoporosis: gender, age, 
body mass index, prior fragility fracture, parental history of hip fracture, current tobacco 
use, long term use of glucocorticoids (past or present), rheumatoid arthritis, daily 
consumption of alcohol (>3 servings/day), and other causes of secondary osteoporosis.  
BMD values are continuously distributed in the population, leaving no guarantee that a 
fragility fracture will occur at or below a specific threshold.  For this reason, the inclusion 
of several clinical risk factors allow for the more accurate prediction of fracture risk than 
with BMD alone (22).  By incorporating information for the risk factors prior fracture, 
glucocorticoid use, and a family history of fracture, the 10-year probability of a major 
osteoporotic fracture for a 65 year old Caucasian women from the United States with a T 
score of -2.5 increases from roughly 15 to 65% (27).  This increase in fracture risk with 
the inclusion of risk factors highlights the importance of assessing the whole individual, 
rather than simply the measure of BMD.  In addition to the individual clinical risk factors, 
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fracture probability varies depending on geographical region (28, 29), all of which is 
taken into account when calculating 10-year fragility fracture risk.   
 In Canada, the Canadian Association of Radiologists and Osteoporosis Canada 
risk assessment tool uses criteria similar to FRAX to determine the probability of an 
individual’s major osteoporotic fracture risk.  This assessment method predicts risk of 
fracture more accurately than with BMD alone (30).  From this assessment, a person is 
classified as having low (<10% 10-year fracture risk), moderate (10-20%), or high risk 
(>20%) (31).  This tool uses BMD, age, gender, prior fragility fracture, and 
glucocorticoid use and demonstrates high concordance with the Canadian FRAX tool 
(32).  
Bone Derived Biochemical Markers 
 
 Derived from the cellular and non-cellular components of bone tissue, bone 
biochemical markers can be quantified in the blood or urine of subjects to determine bone 
cell activity and bone turnover.  These markers are generally classified as either 
formation or resorption markers and can be measured frequently and relatively non-
invasively.  Generally, bone formation markers are osteoblast-specific proteins or are 
from collagen synthesis and bone resorption markers are products of the osteoclast or are 
a byproduct of collagen breakdown (33). 
The RANKL/RANK/OPG Triad 
 
 The process of bone remodeling, involving the osteoblast and the osteoclast, is 
regulated in part by the RANKL/RANK/OPG triad (Figure 2-2).  Receptor activator of 
nuclear factor κβ ligand (RANKL) is a protein secreted by osteoblastic stromal cells, 
which binds to its receptor RANK, a trans-membrane protein member of the tumor 
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necrosis factor superfamily (34).  Binding of RANKL with its receptor on the surface of 
osteoclasts and on osteoclast precursors can increase osteoclast activity and induce 
osteoclast differentiation, respectively (35, 36).  Disruption of the RANKL gene in mice 
results in severe osteopetrosis (abnormally dense bone) and a lack of osteoclasts due to 
the osteoblasts inability to produce RANKL and drive osteoclastogenesis (37).  While 
ubiquitous overexpression of RANKL in mice is embryonic lethal, overexpression of 
soluble RANKL expression in the liver after birth results in an increase in osteoclast 
number with no change in osteoblast number on the surface of trabecular bone (38).  
These transgenic mice also experience decreases in femur BMD, femur strength, and 
trabecular bone mass compared to their non-transgenic littermates (38). 
 Osteoprotegerin (OPG) is a soluble receptor antagonist for RANKL secreted by 
the osteoblast.  OPG functions as a dimer and prevents the binding of RANKL to RANK 
(39), suggesting its role as an anti-resorptive mediator and RANKL as a promoter of bone 
resorption during periods of balanced bone metabolism.  Studies of transgenic mice 
deficient in OPG exhibit a decrease in total bone density and an increased incidence of 
fracture (40), but these outcomes can be reversed with injections of soluble OPG (41).  
Some studies in humans have even linked polymorphisms in the OPG gene with altered 
BMD and the risk of osteoporotic fracture (42-44). 
 OPG and RANKL expression by the osteoblast is tightly regulated by cytokines, 
hormones, and growth factors (45), and in general, when RANKL expression is up-
regulated, OPG expression is down-regulated (36) and vice versa.  It has been suggested 
that OPG concentration should be interpreted as a reflection of overall bone turnover 
rather than the strict inhibition of resorption because of its increase in serum 
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concentrations observed with aging and after menopause (46-49).  These findings suggest 
that OPG may provide protection to the skeleton in times of high resorption by inhibiting 
osteoclast formation, although the relationship between serum OPG concentrations and 
BMD and fracture risk in postmenopausal women is conflicting (46, 47, 50-52).  For this 
reason, the ratio of serum OPG to serum RANKL is an important factor to consider when 
examining the balance between bone formation and resorption.
 18 
 
 
Figure 2-2. Mechanism of action of the RANKL/RANK/OPG triad in the osteoblast 
and osteoclast  
 
RANKL is a protein secreted from the osteoblast that binds to its receptor, RANK, 
expressed on the surface of the osteoclast and its precursor cells.  RANKL binding to 
RANK causes the differentiation of and activation of the osteoclast.  OPG is a soluble 
decoy receptor for RANKL, also secreted by the osteoblast.  OPG and RANKL secretion 
by the osteoblast is tightly regulated. 
 
(Image by Longo AB unpublished, 2016.  Based on data from (53))
Pre-osteoclast
Mature Osteoclast
Activated Osteoclast
RANKL
OPG
RANK
Osteoblast
Bone Surface
 19 
Biomechanical Strength Testing 
 
 To functionally measure the mechanical integrity of a bone, biomechanical 
strength testing can be employed.  With this method, the strength of a bone can be 
quantified by determining the amount of compressive stress it can withstand before 
breaking (54).  There are several limitations with this method including: the 
quantification of the strength of a bone to only one type of stress applied to it (when in 
nature, multiple stresses and strains are applied at all times) and the high variability 
associated with the results (55).  For these reasons, biomechanical strength testing may be 
a poor predictor of overall bone strength.  Replacing this method, as the new standard for 
the determination of bone strength, are computational models which can interpret the 
entire three-dimensional arrangement of bone materials in space, and the anticipated 
loading patterns to predict bone strength and resistance to fracture (56). 
Peripheral Quantitative Computed Tomography 
 
 While DXA can only directly measure BMC and derive BMD, the quality of the 
underlying structure of a bone is also a determining factor when quantifying bone 
structural integrity (57).  In humans and animals, non-destructive imaging technologies 
such as pQCT, can differentiate between trabecular and cortical bone at a given skeletal 
site and provide information regarding morphological parameters with high precision 
(20).  Recently, low-trauma fragility fractures in postmenopausal women have been 
associated with negative changes to trabecular and cortical microarchitecture as assessed 
with pQCT, but most of these associations were independent of BMD as measured with 
DXA (58).  Although results from pQCT are powerful in their precision, and provide 
only a low local radiation dose, they require specialized scanners and software for the 
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image analyses and their measurements in humans are limited to the axial skeleton.  
Current commercially available pQCT scanners are able to acquire images of sufficient 
resolution for imaging human trabecular bone, however trabeculae of pre-clinical rodent 
models are substantially thinner and require higher resolutions, capable with µCT 
imaging, for the attainment of high quality images (59). 
Micro-computed Tomography 
 
 First introduced in 1989 (60), µCT imaging is the gold standard for the direct 3-
dimensional modeling and assessment of the trabecular and cortical microarchitecture in 
pre-clinical rodent studies (61-63).  The latest µCT scanners available are able to resolve 
detail as low as 0.35µm (ex vivo), which provides sufficient detail for the imaging of fine 
trabecular structures in small rodents.  Because µCT is a non-destructive method, it can 
be used to follow one animal longitudinally, rather than multiple animals cross-
sectionally, and measure the response of bone microarchitecture to an intervention in vivo 
at multiple time points throughout the life course.  This technology substantially reduces 
the number of animals required and allows for the repeated measurement of the same 
animal over time, which minimizes any impact of inter-animal variability that can arise 
with a cross-sectional study design. 
 Although the data obtained from repeated µCT scanning may provide powerful 
evidence for a change in bone health in response to an intervention within the same 
animal, the effect of repeated exposure to the conditions needed for proper image 
acquisition including exposure to radiation and to general anesthesia may be detrimental 
to the animal under investigation.  Some studies investigating the effect of radiation 
exposure by repeated µCT scanning to the hind limb of rats suggest a resilience to 500 
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and 900 mGy radiation (64, 65), although one study of 10-month female rats found a 
difference between irradiated and non-irradiated controls after exposure to 400 mGy, 
repeated five times over 54 weeks (66).  The differences observed in this study could be 
due to the old age of the rats, the sample size (n=4 non-irradiated controls), or because a 
control group rather than the contralateral limb was used for comparison (66).  To our 
knowledge, these are the only studies of the effect of radiation exposure by µCT to the 
structural parameters of the tibia, all of which occur in older rats (7.5 to 10-months of 
age) that were no longer experiencing bone growth and modeling.  Moreover, only one 
study assessed the effect of repeated radiation on cortical bone.   
 A summary of the effect of repeated radiation by µCT to bone microarchitecture 
of the proximal tibia in rats is included in Table 2-2.  Because no study to date has 
followed the same rat over a 12-week study period following OVX at 12 weeks of age, 
this thesis investigated the effect of repeated monthly irradiation to bone structure of the 
proximal tibia by comparing the irradiated hind limb to the contralateral non-irradiated 
hind limb (Study 2).  The repeated use of general anesthesia in order to minimize 
movement of the animal under investigation must also be considered during experimental 
design as this process may have negative health impacts on the animal and can become 
costly and time consuming for the researcher.  Studies in rats have demonstrated more 
aversive behaviours (67), decreased cerebral blood flow (68), and learning and memory 
impairment in aged rats (69, 70) with repeated isoflurane administration.  No studies have 
investigated the effect of repeated anesthesia exposure on bone health.  Monitoring food 
intake and body weight over the duration of a longitudinal study can assess the overall 
health status of an animal.
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Table 2-2. Summary of the effects of radiation by µCT to bone microarchitecture of the proximal tibia in rats 1 
 
Reference Age 
(Gender), 
Species, 
Notes 
Radiation 
Dose/Scan 
(mGy) 
Scanner, 
Voxel Size 
Scanning 
Frequency 
Comparison Bone Structure Outcome 
Waarsing, 
2006 (66) 
10-month (F), 
Wistar, Sham-
operated 
400 SkyScan 
1076, 20µm 
Baseline, 4, 
14, 34, 54 
weeks 
Non-irradiated 
control scanned at 
54 weeks only 
• No difference in BV/TV 
• SMI, Tb.Th. differ from 
non-irradiated limb 
Brouwers, 
2007 (64) 
7.5-month (F), 
Wistar, retired 
breeder 
993 (air) 2 
441 (plexiglass) 
Scanco 
vivaCT 40, 
15µm 
1, 2, 3, 4, 5, 6, 
7, 9 weeks 
Contralateral limb 
scanned at first and 
final time-point 
• No difference for any 
structural parameter at 
first or final time-point 
• No difference in viability 
of bone marrow cells 
Klinck, 
2008 (65) 
8-month (F), 
Wistar, retired 
breeder, OVX 
and Sham-
operated 
597 (air) 2 
502 (plexiglass) 
Scanco 
vivaCT 40, 
12.5µm 
Baseline, 2, 4, 
6, 8, 12 weeks 
Contralateral limb 
scanned at endpoint 
only 
• No difference for any 
trabecular or cortical 
parameter in either OVX 
or Sham 
 
1 BV/TV; percent bone volume, F; female, OVX; ovariectomy, SMI; structure model index, Tb.Th.; trabecular thickness. 
 
2 Radiation dose was measured either in air or at the center of a plexiglass cylinder used to mimic the effect of soft tissue surrounding 
the bone in vivo on X-ray attenuation, ultimately lowering the dose of radiation experienced at the proximal tibia.
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 When performing µCT scanning, the preparation of the sample and the scan 
settings are important factors that must be considered during the experimental design as 
they have a profound effect on the results (Table 2-3).  In vivo imaging of the tibia 
involves scanning of the whole hind limb, including fur, skin, and soft tissue surrounding 
the bone, which may affect the image quality and subsequent outcomes.  In a study of the 
effect of varying thickness of water surrounding an aluminum tube used to represent 
bone, a greater thickness of surrounding water resulted in a reduction of beam hardening 
due to peripheral filtration of the X-rays away from the bone (71).  But, by changing the 
scanning scenario from one material (aluminum) to two materials (aluminum surrounded 
by water), the effectiveness of the beam hardening correction software (where a single 
polynomial correction term is applied as in the commercial reconstruction software 
available from SkyScan) was reduced or eliminated.  Also, different thickness of 
surrounding medium can change the reconstructed attenuation so that the same bone in 
different parts of an animal can be assigned different density values, artificially.  In 
general, the surrounding medium complicates the task of correcting beam hardening 
artifact, which is necessary for the accurate quantification of bone densitometry and 
morphology.   
 One study of female Wistar rats found all trabecular morphological outcomes of 
the tibia, as measured by µCT at a 26µm voxel size (3-dimensional pixel), were 
correlated between in vivo and ex vivo scanning protocols (72), but no study has directly 
compared these scan protocols at a higher resolution and in an OVX rat model, where a 
significant loss of trabecular bone volume and structure has occurred.  Study 3 of this 
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thesis determined how the quantification of trabecular and cortical microarchitecture of 
the proximal tibia differs depending on whether measured in vivo compared to ex vivo. 
 When performing µCT scanning, the scan settings that must be considered before 
image acquisition include the resolution, rotation step, exposure time, voltage and 
amperage, all of which can be adjusted to improve image quality and increase the signal-
to-noise ratio (61).  When changes to the scan settings to improve signal-to-noise ratio are 
made, a higher acquisition time and increased radiation dose are the tradeoffs, which 
must be strongly considered when performing in vivo scanning (73).  In fact, doubling the 
resolution of a scan (halving the voxel size) causes a four-time longer scan time for which 
the animal must remain motionless under general anesthesia.  For this thesis, µCT was 
used to evaluate the changes to bone outcomes in vivo and ex vivo in the rat model of 
postmenopausal osteoporosis, a skeletal disease characterized by compromised bone 
quantity and bone quality, ultimately leading to an increased risk of fragility fracture in 
women following the menopausal transition. 
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Table 2-3. Aspects to consider when designing µCT experiments 
 
Animal • Exposure to radiation 
• Exposure to general anesthesia 
• Species 
• Skeletal site 
• Animal age 
• Hormone status of the animal 
Scanning Settings • in vivo versus ex vivo sample preparation 
• Resolution, voltage, amperage, exposure time, rotation step 
• Image acquisition time 
• Scan length (i.e., field of view length)  
• Data file size 
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Age-Related Bone Loss in Women 
 
 Several studies have used the 3-dimensional imaging technique, high-resolution 
pQCT, to quantify the age-related changes to BMD and structure in response to normal 
aging.  In a large cross-sectional study of 373 women between the ages of 20-97 years, 
high-resolution pQCT of the distal radius revealed that cortical BMD remains stable until 
approximately mid-life, followed by a gradual decline, while declines in trabecular BMD 
of the lumbar spine begin in young adulthood (20-29 years) and continue throughout life 
(74).  Longitudinal analysis of the same cohort confirmed the substantial trabecular bone 
loss beginning in young adulthood and continuing throughout life with acceleration 
during menopause (75). 
 Assessment of the trabecular and cortical microarchitecture provides even more 
information regarding the age-related changes to bone.  In one cross-sectional study of 
324 women (21-97 years of age), changes to trabecular bone volume (-27%), trabecular 
number (Tb.N.) (-13%), trabecular separation (Tb.Sp.) (+24%), cortical BMD (-22%), 
cortical thickness (Ct.Th.) (-52%), and endocortical area (+27%) were observed with 
high-resolution pQCT imaging of the wrist between the ages of 20-90 years (76).  These 
structural changes with aging account for an increased fracture risk with age.  The loss of 
trabeculae contributes to the biomechanical instability and an overall decrease in bone 
strength (77), but eventually the loss of trabecular bone stops because so few trabeculae 
are left to lose (78).  Cortical bone loss follows trabecular loss more slowly because its 
surfaces are less accessible to the bone multicellular units responsible for bone 
remodeling (79, 80).  In postmenopausal women, most cortical bone loss occurs in pores 
and on the endocortical surface (80).  With the loss of bone (both trabecular and cortical), 
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the proportion of the total load carried by the cortex is increased (81).  To maintain its 
strength and resistance to bending, the distribution of cortical bone mass is modified 
away from the central axis along a larger perimeter through endocortical resorption and 
concomitant periosteal apposition (82).  In a large 7-year prospective study of over 800 
women, endocortical resorption and periosteal apposition rates were measured in pre-, 
peri-, and postmenopausal women (83).  With advancing age and menopausal status, 
endocortical resorption increased and periosteal apposition decreased, resulting in an 
overall thinning of the cortex of the distal radius and decreased resistance to bending.  
Fracture risk was doubled in those women with a one standard deviation lower estimate 
of bending strength, highlighting the clinical relevance of age-related changes to cortical 
bone structure (83).  The loss of trabeculae, increased medullary cavity area and the 
changes to bone volume ultimately causes a reduction in bone mass and a compromised 
bone structure, predisposing a women to fragility fracture and the diagnosis of 
osteoporosis. 
Osteoporosis 
 
 Osteoporosis is a disease of the skeletal system characterized by a low bone mass 
and compromised bone microarchitecture.  Together, these outcomes result in an 
increased risk of fragility fracture, often resulting in increased morbidity, chronic pain 
and a reduced quality of life (84-88).  The most common sites of osteoporotic fracture 
include the hip, spine, and wrist.  The total annual incidence of fragility fracture in 
Canadian women is greater than heart attack, stroke, and breast cancer combined (1).  
Currently, an estimated 1.5 million Canadians aged 40 years and over have reported 
being diagnosed with osteoporosis (89) with at least 1 in 3 women and 1 in 5 men 
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suffering from an osteoporotic fracture within their lifetime (1).  The diagnosis of 
osteoporosis is defined as a BMD, measured with DXA at the proximal femur, 2.5 or 
more standard deviations below the average value for premenopausal women (22).  The 
average values, or reference ranges, used as comparative criteria for the diagnosis of 
osteoporosis come from the National Health and Nutrition Examination Survey 
(NHANES) reference database in non-Hispanic white women aged 20-29 years.  Fracture 
risk assessment tools are also available to Canadians to estimate 10-year fracture risk, and 
as mentioned previously, these tools take into account other clinical risk factors. 
 Although osteoporosis is generally diagnosed in older individuals, it has been 
termed a ‘pediatric disease with geriatric consequences’ due to the importance of 
developing strong bones during growth and development (90).  At the end of skeletal 
maturation when peak bone mass is reached (91) a slow and steady decline in BMD 
occurs.  Only at the onset of menopause do women begin to lose bone mass at a faster 
rate than men due to the loss of endogenous estrogen production, which can lead to a 
diagnosis of postmenopausal osteoporosis (Figure 2-3).  Peak bone mass is influenced by 
a variety of genetic and environmental factors including, gender, race, hormonal factors, 
nutrition, physical activity level, age at menarche, body weight, and other lifestyle 
behaviours.  
 Mathematical modeling using several experimental variables to predict their 
relative influence on the development of osteoporosis resulted in peak bone mass being 
the single most important factor (92).  Using this model, a 10% increase in peak bone 
mass would delay the onset of osteoporosis by 13 years, whereas a 10% increase in the 
onset of menopause would delay osteoporosis by only 2 years (92).  For these reasons, 
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lifelong habits including the intake of nutrients that support bone health is important for 
the early and continued bone accrual and a postponed onset of postmenopausal 
osteoporosis.
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Figure 2-3. Age-related changes to bone mineral throughout the lifespan in females 
 
From birth to late adolescence, the skeleton experiences rapid increases in bone mineral 
until the attainment of peak bone mass.  At the end of skeletal maturation, a slow and 
steady decline in bone mass occurs until the onset of menopause in women, which 
coincides with a more rapid loss of bone mineral during the menopausal transition.  The 
solid and dashed lines represent the trajectory of bone mineral throughout the lifespan 
when peak bone mass is attained through proper environmental factors and full genetic 
potential (solid line) or when inadequate environmental and genetic factors (dashed line) 
influence the attainment of peak bone mass.  With a greater peak bone mass at young 
adulthood, there is more bone available to be lost before reaching a fracture threshold 
later in life, providing protection against fracture in late adulthood.  
 
(Image by Longo AB, unpublished, 2016.  Based on data from (93))
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Estrogen as a Mediator of Bone Turnover 
 
 Estrogen plays an integral role in the maintenance of bone structure in adult 
women by maintaining a balance between bone resorption by osteoclasts and bone 
formation by osteoblasts (94).  To preserve this balance, estrogen functions to suppress 
the activation frequency of bone multicellular units (95).  Estrogen has direct effects on 
bone turnover, by inducing the differentiation of precursor cells to mature to osteoblasts 
(96, 97), to prevent the apoptosis of osteoblasts (98), and to induce apoptosis of 
osteoclasts (99, 100).  To prevent bone resorption indirectly, estrogen increases OPG 
production (101) and reduces RANKL production (102) by the osteoblast and modulates 
RANK signaling in osteoclasts (103). 
Endogenous Estrogen Deficiency Leads to Bone Loss 
 
 During the menopausal transition, endogenous estrogen levels decline 
substantially and this results in accelerated bone loss that has been well characterized in 
women (104).  The greatest rate of bone loss is observed during trans-menopause 
(coinciding with 1 year before and 2 years after final menses) followed by a slightly 
decelerated rate of loss 2-5 years following final menses (104).  During this period of 
interrupted hormone production, trabecular bone loss is 3-5 fold greater than cortical 
bone loss (105) due to an increased activation frequency of bone multicellular units on 
the trabecular surfaces with an imbalance that favours bone resorption (106).  This 
imbalance occurs mainly because of an increase in osteoclast formation, activation, and 
lifespan with the loss of endogenous estrogen production (107).   
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OVX Rat Model of Postmenopausal Osteoporosis 
 
 Studies of bone health in humans rely mainly on self-reported fracture occurrence 
and surrogate markers such as BMD by DXA and serum biochemical markers because of 
the obvious limitations with obtaining bone biopsies from human subjects.  The use of 
animal models however allows for the timely and direct measure of changes to bone 
quantity and bone quality in response to specific interventions.  The OVX rat is a well-
established animal model, which results in the rapid loss of bone mass and bone strength 
followed by a slower more gradual rate of bone loss following the surgical removal of the 
ovaries, similar to the changes observed in human bone during and following the 
menopausal transition (108-114).  Similar to the response in humans, bone multicellular 
unit-based remodeling causes bone loss on the endocortical surfaces following OVX in 
rats (115, 116), making this an appropriate model for the study of the pathogenesis and 
progression of osteoporosis. 
 The development of in vivo imaging techniques have allowed for the longitudinal 
investigation of the impact of OVX on the microarchitecture of skeletal-specific sites in 
the rat model of osteoporosis. 
Site-Specific Effect of OVX 
 
 OVX causes a highly reproducible skeletal response involving site-specific bone 
loss and the subsequent development of osteoporosis (108, 110, 111, 113, 117).  
Following OVX, the proximal tibia is the first skeletal site to experience changes to 
trabecular bone volume after only 8-14 days following surgery (113, 117, 118).  This site 
also experiences the earliest reduction in BMD and deterioration in trabecular 
microarchitecture compared to other skeletal sites (119).  The trabecular bone of the 
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femur and lumbar vertebrae (LV) experience changes similar to the proximal tibia, but at 
slower rates (109, 119, 120).  In one of the most comprehensive studies of the site-
specific effect of OVX in 6-month SD rats, the long bones (femur and tibia) showed the 
largest changes from baseline in most trabecular microarchitecture outcomes (121).  The 
LV showed similar patterns of bone loss 36-weeks post-OVX (121).  While these bones 
experience similar overall patterns of loss following OVX at 6-months of age, the rate of 
these changes is different.  In general, OVX caused significant and sustained reductions 
to trabecular BMD, percent bone volume (BV/TV), and Tb.N. after only 4 weeks and 12 
weeks (24 weeks for Tb.N. reductions) in the long bones and LV, respectively.  Tb.Sp. of 
the long bones was increased in only 12-weeks post-OVX and 24-weeks in the LV.  
Varying rates of bone loss between the proximal tibia, proximal and distal femur, and LV 
has been supported by other comprehensive, cross-sectional studies of the rat skeleton in 
response to OVX (119).  Together, these findings confirm a systemic effect of OVX, but 
that the resulting outcome of this effect is not equal across all skeletal sites.  Therefore, I 
determined the changes to bone microarchitecture at multiple skeletal sites to fully 
establish the skeletal response to an intervention (Study 4). 
 Similar to the changes to cortical bone experienced in humans following 
menopause, OVX causes changes to Ct.Th. of the long bones at a slower rate than 
changes observed in trabecular bone (110).  This is because as bone is being resorbed 
from the endocortical surfaces (interior), it is being formed on the periosteal surface 
(outer) (110, 122-125).  For this reason, an increase in the medullary area (Ma.Ar.) 
should be considered the most sensitive measure of cortical bone loss in the OVX rat 
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(110), rather than a change in Ct.Th.  The earliest changes to Ma.Ar. following OVX 
occur in the mid-shaft of the tibia (126).  
Longitudinal Changes to Bone Following OVX 
 
 To characterize the changes to bone quantity and bone quality, several cross-
sectional and longitudinal studies have been conducted in the preclinical model of 
postmenopausal osteoporosis and have been summarized in Table 2-4 and the findings 
are discussed below. 
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Table 2-4. Longitudinal changes to bone following OVX 1 
 
Reference Age at OVX 
(Strain) 
Experimental 
Timeline 
Skeletal 
Site 
Bone-Related Outcome of OVX rats (Compared to) 
DXA, Strength Testing, Histology, Biomarkers 
Bagi, 1997 
(127) 
4-month 
(SD) 
0, 4, 8, 12 
weeks 
Femur 
Neck 
• Decrease BMD (DXA) by 4 weeks (Sham) 
• Decrease ultimate strength and stiffness by 4 weeks (Sham) 
• Increase trabecular mineralized surface (%), bone formation rate, 
Tb.Sp. by 4 weeks (Sham) 
• Decrease Tb.Th., Tb.N. by 4 weeks (Sham) 
• Increase periosteal and endocortical mineralized surface (%) and 
bone formation rate by 4 weeks (Sham) 
Zhang, 2007 
(128) 
13-week 
(Wistar) 
0, 4, 18 weeks Femur 
Diaphysis 
• No change in any bone mechanical properties (Sham) 
Campbell, 
2008 (118) 
6 to 8-month 
(Wistar) 
0, 2, 4, 6, 8, 
12 weeks 
Femur 
Midpoint, 
LV4 
• Decrease ultimate stress (femur) (Sham) 
• Decrease ultimate load (LV4) (Sham) 
Abuohashish, 
2015 (129) 
3-month 
(Wistar) 
7 weeks Distal 
Femur 
• Decrease calcium and phosphorous content (Sham) 
• Increase all formation and resorption markers (Sham) 
Microarchitecture 
Lane, 1998 
(117) 
6-month 
(SD) 
0, 5, 8, 13, 16, 
29, 33, 42, 50 
days 
Proximal 
Tibia 
• Decrease connectivity by 5 days (Baseline) 
• Decrease BV/TV by 8 days (Baseline) 
• Increase Tb.Sp. (Sham) 
• Decrease Tb.N. (Sham) 
• Increase bone formation and resorption markers (Sham) 
Laib, 2001 
(113) 
6-month 
(SD) 
0, 12, 35, 60, 
110 days 
Proximal 
Tibia 
• Decrease in BV/TV, connectivity, Tb.Th., and Tb.N. by 12 days 
(Baseline) 
• Increase Tb.Sp. at 110 days (Sham) 
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Waarsing, 
2004 (130) 
10-month 
(Wistar) 
0, 4, 14 weeks Proximal 
Tibia 
• Decrease BV/TV, Tb.Th. by 4 weeks (Baseline) 
• Increase periosteal resorption, endocortical apposition, and Ct.Th. 
(Sham) 
Waarsing, 
2006 (66) 
10-month 
(Wistar) 
0, 4, 14, 34, 
54 weeks 
Proximal 
Tibia 
• Decrease BV/TV and connectivity by 4 weeks (Baseline) 
• Increase Tb.Th. by 14 weeks (Baseline) 
• Increase periosteal resorption, endocortical apposition, and Ct.Th. 
(Sham) 
Boyd, 2006 
(131) 
8-month 
(Wistar) 
0, 1, 2, 3, 4, 5, 
6 months 
Proximal 
Tibia 
• Decrease BV/TV, Tb.N., Tb.Th. by 4 weeks (Baseline) 
• Increase Tb.Sp. by 4 weeks (Baseline) 
Zhang, 2007 
(128) 
13-week 
(Wistar) 
0, 4, 18 weeks Proximal 
Tibia 
• Decrease trabecular BMD by 4 weeks (Sham) 
• No change in cortical outcomes (Sham) 
Campbell, 
2008 (118) 
6 to 8-month 
(Wistar) 
0, 2, 4, 6, 8, 
12 weeks 
Proximal 
Tibia 
• Decrease BV/TV, Tb.N., Tb.Th., and connectivity by 2 weeks 
(Baseline) 
• Decrease Tb.Sp. by 4 weeks (Baseline) 
• Increase Ct.Th. by 6 weeks (Baseline) 
Klinck, 2008 
(65) 
8-month 
(Wistar) 
0, 2, 4, 6, 8, 
12 weeks 
Proximal 
Tibia 
• Decrease BV/TV, Tb.N., Ma.Ar. over 12 weeks (Baseline) 
• Increase Tb. Sp., Ct.Th., Ct.Ar. over 12 weeks (Baseline) 
• No change in Tb. Th. over 12 weeks (Baseline) 
Francisco, 
2011 (119) 
3-month 
(Wistar) 
2, 5, 10, 15, 
20, 25, 30 
weeks 
Proximal 
Tibia 
• Decrease BMD, Tb.N. by 5 weeks (Sham) 
• Increase Tb. Sp. by 5 weeks (Sham) 
Distal 
Femur 
• Decrease BMD by 15 weeks, decrease Tb.N. by 10 weeks (Sham) 
LV • Decrease BMD by 20 weeks (Sham) 
• Decrease Tb.N. by 10 weeks (Sham) 
5-month 
(Wistar) 
2, 5, 10, 15, 
20, 25, 30 
weeks 
Proximal 
Tibia 
• Decrease BMD, Tb.N. by 2 weeks (Sham) 
• Increase Tb.Sp. by 10 weeks (Sham) 
Distal 
Femur 
• Decrease BMD by 15 weeks, decrease Tb.N. by 20 weeks (Sham) 
LV • Decrease BMD by 10 weeks, decrease Tb.N. by 15 weeks (Sham) 
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11-month 
(Wistar) 
2, 5, 10, 15, 
20, 25, 30 
weeks 
Proximal 
Tibia 
• Decrease BMD by 2 weeks, decrease Tb.N. by 5 weeks (Sham) 
• Increase Tb.Sp. by 15 weeks (Sham) 
Distal 
Femur 
• Decrease BMD by 10 weeks, decrease Tb.N. by 15 weeks (Sham) 
LV • Decrease BMD by 25 weeks, decrease Tb.N. by 20 weeks (Sham) 
• Increase Tb.Sp. by 20 weeks (Sham) 
Shin, 2012 
(132) 
3-month 
(SD) 
4, 8 weeks Femur • Decrease BMD, BV/TV, Tb.N. (Sham) 
• Increase Tb.Th., Tb.Sp. by 8 weeks (Sham) 
LV • Decrease BMD, BV/TV, Tb.N., Tb.Th. (Sham) 
• Increase Tb.Sp. by 8 weeks (Sham) 
Liu, 2015 
(121) 
6-month 
(SD) 
0, 2, 4, 12, 24, 
36 weeks 
Distal 
Femur, 
Proximal 
Tibia 
• Decrease BMD, BV/TV, Tb.N. by 4 weeks (Sham) 
• Increase Tb.Sp. by 12 weeks (Sham) 
• Decrease Tb.Th. at 4 weeks, only (Sham) 
LV3 • Decreased BMD, BV/TV by 12 weeks (Sham) 
• Increase Tb.Sp. by 24 weeks (Sham) 
• Decrease Tb.N. by 24 weeks (Sham) 
• Decrease Tb.Th. at 4, 12, 24 weeks, only (Sham) 
Hatori, 2015 
(133) 
3-month 
(SD) 
4, 14 days Proximal 
Tibia 
• Decrease BV/TV, Tb.N., Ct.Th. (Sham) 
• Increase Tb.Sp., Ec.Pm., Ma.Ar. (Sham) 
Abuohashish, 
2015 (129) 
3-month 
(Wistar) 
7 weeks Distal 
Femur 
• Decrease BMD, BV/TV, Tb.Th., Tb.N., Ct.Th., Ct.Ar. (Sham) 
• Increase Tb.Sp., Ec.Pm., Ps.Pm. (Sham) 
 
1 BMD; bone mineral density, BV/TV; percent bone volume, Ct.Ar.; cortical area, Ct.Th.; cortical thickness, DXA; dual energy X-ray 
absorptiometry, Ec.Pm., endocortical perimeter, LV; lumbar vertebrae, Ma.Ar.; medullary area, OVX; ovariectomy, Ps.Pm.; periosteal 
perimeter, SD; Sprague-Dawley, Tb.N.; trabecular number, Tb.Sp.; trabecular separation, Tb.Th.; trabecular thickness.
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Changes to Bone Mass, Structure, and Strength Following OVX 
 
 The first studies to investigate the longitudinal change in BMD, derived structural 
indices, and strength following OVX used DXA, histomorphometry, and biomechanical 
strength testing, respectively and have provided contradicting results (Table 2-4).  
Significant reductions in BMD, ultimate strength, and trabecular thickness (Tb.Th.) and 
Tb.N. in the femur neck occurred following only 4-weeks post-OVX (127).  This study 
also observed increases in periosteal, endocortical and trabecular mineralized surface 
with concomitant increases in bone formation rates suggesting an increased rate of bone 
turnover following OVX at the femur neck (127).  The mechanical properties of ultimate 
stress and ultimate load have been shown to decrease in response to OVX in the femur 
midpoint and LV, respectively (118).  In contrast, bone mechanical properties of the 
femur midpoint were not affected 4- or 18-weeks post-OVX compared to baseline values 
(128).  To resolve these conflicting results, higher-resolution imaging using µCT has 
been used to more fully characterize the longitudinal changes to bone following OVX in 
the rat model of postmenopausal osteoporosis. 
Changes to Bone Microarchitecture Following OVX 
 
 The earliest deterioration to trabecular bone connectivity and bone volume 
following OVX was observed after only 5 and 8 days, respectively, in the right tibia of 
the 6-month old SD rat (117).  In this model, OVX caused a rapid phase of bone loss in 
the first 5-8 days followed by a slower, steadier decline up to 50 days post-OVX.  The 
rapid deterioration of trabecular bone tissue followed by a slow decline has been 
observed in other, similar longitudinal studies (66, 113, 118, 128, 130-132).  Generally, 
bone volume and Tb.N. is decreased (65, 113, 117-119, 121, 129, 131-133) and Tb.Sp. is 
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increased (65, 113, 117, 118, 121, 129, 131-133) as early as 2- and 4-weeks following 
OVX, respectively.  These changes have been suggested to be due to an imbalance in 
bone turnover as both bone formation and resorption markers are elevated in OVX rats 
compare to Sham-control (117, 118, 128, 129, 132). 
 Of particular interest is the rate and direction of change of Tb.Th. following OVX 
surgery.  Some studies report increases (66, 133), no change (65, 117), or sustained 
declines (129), but most have reported an initial decrease in Tb.Th. that eventually 
plateaus (113, 118, 121, 131).  The time at which this plateau is reached varies from 2 
weeks (118) to 6 months (131).  Changes to Tb.Th. also seem to be site-specific, as the 
LV experiences declines earlier than the tibia and femur (121).  At the cortex of the 
proximal tibia, resorption at the periosteal surfaces and apposition at the endocortical 
surfaces result in net increases in Ct.Th. (118, 130) and these changes can occur for up to 
34-weeks post-OVX (66).  OVX causes significant declines in Ct.Th., cortical area (Ct. 
Ar.), and increases in Ma.Ar., endocortical perimeter (Ec.Pm.) and periosteal perimeter 
(Ps.Pm.) of the tibia compared to baseline and Sham values (65, 129, 133).  In the femur 
and LV, decreases in cortical BMD compared to Sham have also been observed (132).  
However, analysis of the tibia diaphysis by ex vivo µCT 4- or 18-weeks following OVX 
did not reveal changes compared to Sham (128).  Changes to the cortical bone proceed 
slower than on the trabecular surfaces, which is a possible reason for these 
discrepancies.  Very few studies have investigated the changes to cortical 
microarchitecture including the indices, Ma.Ar., Ps.Pm., Ec.Pm., Ct.Th., and cortical 
area fraction (Ct.Ar./Tt.Ar), which together provide a more comprehensive 
understanding of any hormone-related changes to structure.  This thesis more thoroughly 
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investigated the changes to cortical bone following OVX at 3 months (Study 1 and 4) by 
quantifying a wide-range of cortical and trabecular parameters. 
 Most studies assessing the longitudinal effect of OVX on bone microarchitecture 
have used an aged model (≥6 months at time of OVX), but the long-term impact of 
undergoing OVX during periods of modeling and growth (3 months of age), as was done 
in this thesis, have not been as extensively studied in the rat.  Three months of age is a 
common time point used in studies of nutritional interventions in the OVX rat model 
(134-141), and so the longitudinal impact of OVX on bone microarchitecture at this stage 
of bone modeling was characterized.  Studies of older rats are less common in the 
literature because of the higher cost and longer study periods associated with aged rats.  
Rats over 3-months of age are substantially more expensive when ordering from a large 
supplier, such as Charles River Canada, than younger (<3 months of age) rats.  Receiving 
young rats from a supplier and aging them on-site is also costly and an inefficient use of 
time and resources.  Many of the studies of older rats in the literature (>8 months of age) 
involve retired breeders.  Often poor records, involving the exact age and the number of 
pregnancies (and number of pups in a litter), are kept by the supplier, which provide 
many uncertainties and limitations in bone characterization studies.  Pregnancy and 
lactation cause significant changes to the skeleton in the rat, but the bone formation that 
occurs during the period after pregnancy and lactation does not restore the bone mass to 
that of age-matched nulliparous control rats (142).  For all of these reasons, studying rats 
having undergone OVX at 3-months of age is a practical and cost-effective solution for 
researchers.  Therefore, further studies for the characterization of the changes to bone 
microarchitecture were necessary (Study 1). 
 41 
Effect of OVX on Food Intake, Body Weight, and Body Composition 
 
 Following OVX, rats experience a transient hyperphagia for roughly 6 weeks 
following surgery (143).  This transient increase in food intake compared to Sham-
operated rats causes the characteristic increase in body weight seen following OVX.  The 
higher body weight is usually maintained past study endpoints (143).  Along with this 
increase in body weight, body composition is altered with OVX and rats experience 
significant increases in fat mass compared to their Sham-counterparts (143).  While food 
intake, body weight, and body composition are altered with OVX-surgery, these factors 
do not modulate bone mass, BMD, or biomechanical strength of the femur or LV 14-
weeks post-OVX (143).  Changes in trabecular bone mineral and microarchitecture of the 
proximal tibia and distal femur are also maintained despite weight differences in Sham 
compared to OVX rats (119) Therefore, increased weight gain and fat mass as a result of 
transient hyperphagia induced by OVX do not modulate the estrogen-deficiency induced 
bone loss in OVX rats. 
Strengths and Limitations of the OVX Rat Model of Postmenopausal Osteoporosis 
 
The strengths and limitations of the OVX rat model of postmenopausal osteoporosis are 
outlined in Table 2-5 and are discussed below. 
Strengths 
 
 There are several advantages to utilizing the OVX rat as a model for 
postmenopausal osteoporosis.  For example, the response at the proximal tibia, distal 
femur, and LV mimics the loss that occurs in postmenopausal women making it the 
appropriate model for investigating the pathogenesis of osteoporosis (144).  In fact, the 
OVX rat is the Food and Drug Administration-approved model for the evaluation of 
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agents used in the treatment or prevention of postmenopausal osteoporosis (144).  There 
is also literature regarding the characterization of the model and the longitudinal effect of 
OVX on bone quantity and bone quality, but as discussed previously, most work has been 
done when OVX occurs at 6-months of age or greater.  The OVX rat model provides 
researchers with a time and cost-effective solution to investigating the effects of various 
interventions on bone health.  In the rat and the human, the average remodeling cycle is 
roughly 40 and 200 days, respectively (144, 145).  Therefore, a 12-week trial in the OVX 
rat (a typical study duration) results in approximately two complete remodeling periods, 
which is roughly equal to a 1.5 year clinical trial in humans.  The rat model of 
osteoporosis also provides the advantage of being able to undergo repeated in vivo high 
resolution imaging at any skeletal site (central or axial), although the effect of repeated 
radiation exposure to the quality of the bone is not well understood. 
Limitations 
 
 The OVX rat model does have some limitations to consider, the first of which is 
the lack of Haversian systems in cortical bone (146).  Haversian systems are concentric 
rings surrounding blood vessels that increase the porosity of cortical bone and function as 
areas of bone remodeling (147).  Without Haversion systems in the rat model, effects of 
various interventions on cortical remodeling and cortical porosity cannot be fully 
extrapolated to the human skeleton.  Also, linear growth of the long bones of the rat 
continues longer than their human equivalent.  In female SD rats, the growth of the tibia 
is rapid until 6 months, declines up to 12 months, and growth ends after 18 months (115).  
The epiphyseal growth plate does not fuse until after 6.5-months of age (148).  Another 
difference between the OVX rat model and humans involves the weight-distribution on 
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skeletal sites.  Humans are bipeds whereas rats are primarily quadrupeds, altering in 
which direction and the relative load applied to common sites of fracture including the 
wrist, LV, femur neck, and tibia.    
 Although there is a multitude of literature available on the OVX rat model, there 
is no consensus surrounding the ideal age of the rat at OVX.  Several authors have 
suggested performing OVX at 9-months of age or later, coinciding with the attainment of 
peak bone mass (110, 124, 149), although some authors have suggested OVX as early as 
6 weeks of age is sufficient (150).  One study investigating the relationship between age 
and time post-OVX on bone mineral and trabecular microarchitecture performed either 
Sham-control or OVX surgery on Wistar rats at 12, 24, and 44 weeks of age and 
subsequently sacrificed these rats at intervals over 30 weeks post-surgery (119).  
Although OVX caused significant reductions in BMD compared to Sham, authors of this 
study found increases in bone mineral up to 10-weeks post-surgery in the rats having 
undergone OVX at 12 weeks of age, suggesting they were still experiencing growth and 
that OVX inhibited this growth rather than inducing bone loss at the proximal tibia (119).  
Therefore, older Wistar rats (6 through 9 months of age) are ideal when studying the 
skeletal response to OVX, but as previously discussed, the high cost associated with 
ordering and maintaining rats older than 3-months of age is a major limitation for many 
researchers.  To avoid the issue of continued growth in the 3-month OVX rat model, 
measurements of the trabecular bone should be taken at least 1mm distal to the growth 
plate (124). 
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Table 2-5. Strengths and limitations of the OVX rat model 1 
 
Strengths • Similar skeletal response to loss of estrogen production as occurs in 
postmenopausal osteoporosis 
• FDA-approved model of postmenopausal osteoporosis 
• Characterization of the model (when OVX is performed at 6 months) 
• Time and cost effective alternative to human trials 
• Ability to quantify outcomes not available in human trials 
Limitations • Lack of Haversian canals may limit applicability of findings in 
cortical bone 
• Extended periods of linear growth and epiphyseal growth plate 
fusion of the long bones 
• Altered load distribution on skeletal sites (quadruped versus biped) 
• Lack of consensus on the ideal age to perform OVX 
• Immediate loss of endogenous estrogen production compared to 
slow transition in the human 
 
1 FDA; Food and Drug Administration, OVX; ovariectomy
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 Dietary interventions have the potential to modulate bone health in the OVX rat.  
Most studies of nutritional interventions however, involve introduction to the nutrient 
following OVX as a treatment strategy.  But, very few studies have investigated a dietary 
intervention as a preventative strategy by introducing the dietary intervention prior to 
OVX.  This thesis investigated the potential protective effect of PUFA on bone health by 
altering the PUFA content of the diet of 1-month SD rats for 2 months prior to OVX at 3-
months of age, and following these rats through to 6-months of age (Study 4). 
Polyunsaturated Fatty Acids 
 
 The fatty acids that are found in lipid molecules are the major components of 
dietary fats.  Once in the body, fatty acids are oxidized for fuel or incorporated in blood 
lipids, fat deposits, and as the structural unit of cell membranes.  The resultant health 
effects of fat and fatty acids depend largely on the saturation properties of the fatty acids.  
Fatty acids exist in varying chain lengths, ranging from 4 to 30 carbon atoms and can be 
saturated (contain no double bonds), monounsaturated (contain 1 double bond), or 
polyunsaturated (contain more than 1 double bond).  In almost all naturally occurring 
PUFA, the double bond is found on either the 3rd, 6th, or 9th carbon atom from the 
terminal methyl group, deeming them n-3, n-6, or n-9 series PUFA. 
Food Sources and Recommended Intakes of PUFA 
 
 The n-6 and n-3 PUFA series are of major importance because of their known 
impact on health.  Linoleic acid (LA, 18:2n-6), and alpha-linolenic acid (ALA, 18:3n-3) 
cannot be synthesized in the body and thus are called the essential fatty acids.  Through a 
process of desaturation and elongation, LA and ALA can be converted to the longer chain 
PUFA, arachidonic acid (AA, 20:4n-6) or eicosapentaenoic acid (EPA, 20:5n-3) and 
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docosahexaenoic acid (DHA, 22:6n-3), respectively.  LA is found in very high 
proportions in many vegetable oils, including sunflower, safflower, soybean and corn oils 
and is the predominant PUFA consumed in Western diets (151).  ALA contributes 
approximately 10% of the total PUFA intake in Western diets and is found in high 
concentrations in flaxseed, perilla oil, walnuts, and many n-3 fortified food products 
(Table 2-6).  
 ALA can be converted by desaturase and elongase enzymes to longer chain n-3 
PUFA, but this conversion is relatively inefficient, with only 21% and 9% of ALA 
converted to EPA and DHA, respectively (152).  While increasing ALA intake has been 
shown to increase EPA concentrations, only by simultaneously reducing LA intake can 
DHA status be increased (153).  Therefore, increasing ALA intakes may not be an 
effective strategy for increasing concentrations of the longer chain n-3 PUFA in the body.  
This also indicates that the health benefits that have been associated with higher intakes 
of ALA are not likely due to the downstream activity of their long chain derivatives, EPA 
or DHA.  Fatty fish such as salmon, herring, mackerel, sardines, and smelt are good 
sources of EPA and DHA and incorporating these foods in the diet is the best way to 
increase EPA and DHA in the body.  
 Currently, Health Canada recommends an adequate intake for LA and ALA for 
women and men (154) (Table 2-6).  Based on levels in a 100 g serving (half a cup), 
safflower and sunflower oil provide approximately 74 g and 65 g of LA, respectively.  
Vegetable oil and soybean oil provide 57 g and 50 g of LA in a 100g serving.  A 100 g 
serving of flaxseed oil will provide approximately 53 g of ALA, while canola oil and chia 
seeds provide 9 g and 17 g of ALA, respectively.  Therefore, roughly one 15 g serving of 
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safflower oil and only 500 mg of flaxseed oil provides the recommended daily adequate 
intake for LA and ALA, respectively, for women over 50 years of age.  Although no 
recommendations exist for AA or the long chain n-3 PUFA, EPA and DHA, it is 
suggested that up to 10% of the acceptable macronutrient distribution range for n-3 
PUFA can be consumed as EPA and/or DHA.  Based on an 85 g serving, salmon, herring, 
and mackerel provide roughly 1.8, 1.7, and 1.6 g EPA+DHA, respectively.  Shellfish and 
canned tuna provide roughly 0.2 g EPA+DHA in an 85 g serving.  Therefore, 10% of the 
acceptable macronutrient distribution range for n-3 PUFA can be consumed as 1 to 2 
servings of fish per week, depending on the type of fish consumed.   
 Because LA and ALA compete for the same pool of elongase and desaturase 
enzymes for conversion to their longer chain PUFA and their subsequent metabolites, the 
ratio of n-6 to n-3 intake is of particular importance.  The excess of LA in the average 
Western diet results in ratios as high as 15 through 17:1 in the American population 
(155), although ratios from 7 through 8:1 are consumed by Canadians (89).  The 
discrepancy in LA to ALA intakes in North American populations is most likely due to 
the primary oil used in each country.  Soybean oil (high in LA) is the predominant oil 
used in USA while canola oil, which provides less LA, is the predominant oil used in 
Canada (89).  Excess n-6 PUFA intake can lead to a state of chronic inflammation in the 
body through production and downstream signaling of PUFA-derived molecules.
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Table 2-6. Adequate intakes and common sources of LA (n-6), ALA (n-3), and EPA and DHA (n-3) recommended by Health 
Canada 1 
 Females Males 
(g/d) 9-13y 14-18y 19-30y 31-50y 51-70y >70y 9-13y 14-18y 19-30y 31-50y 51-70y >70y 
LA  
(n-6) 
10 11 12 12 11 11 12 16 17 17 14 14 
5-10% of energy 5-10% of energy 
Sources • Safflower oil, sunflower oil, vegetable oil, soybean oil, corn oil, margarine, salad dressings 
ALA  
(n-3) 
1.0 1.1 1.1 1.1 1.1 1.1 1.2 1.6 1.6 1.6 1.6 1.6 
0.6-1.2% of energy 0.6-1.2% of energy 
Sources • Canola oil, flaxseed oil, perilla oil, walnuts, chia seeds 
EPA/DHA 
(n-3) 
0.1 0.11 0.11 0.11 0.11 0.11 0.12 0.16 0.16 0.16 0.16 0.16 
Up to 10% AMDR of n-3 PUFA can be consumed as EPA and/or DHA 
Sources • Fatty fish such as salmon, herring, mackerel, sardines, shellfish, and fish oils 
 
1 ALA; alpha-linolenic acid, AMDR; acceptable macronutrient distribution range, DHA; docosahexaenoic acid, EPA; 
eicosapentaenoic acid, LA; linoleic acid, y; year
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Mechanisms of Action of PUFA on Bone Health 
 
 Although there is no single mechanism that explains the actions of n-6 and n-3 
PUFA, there are several potential physiological processes that affect bone health either 
directly or indirectly.  Studies of calcium balance have reported an increase calcium 
absorption in the small intestine (156-159) and a decrease in calcium excretion (160, 161) 
with n-3 PUFA supplementation in animal models.  These studies support the direct 
effect of dietary PUFA on bone metabolism by increasing the availability of calcium in 
the body. 
 Dietary PUFA directly affect mesenchymal stem cell differentiation, which have 
the genetic potential to differentiate into adipocytes or osteoblasts, through activation of 
the peroxisome-proliferator activator receptor (PPAR) family of transcription factors 
(162).  The n-6 PUFA, AA, is a potent stimulator of adipogenesis, whereas, EPA and 
DHA have benefits to osteoblastogenesis (162).  Therefore, n-3 PUFA directly influence 
bone metabolism through the differentiation and increased expression of the osteoblast. 
 The literature is replete with evidence supporting the incorporation of dietary 
PUFA into the cell membranes as phospholipids in various tissue types.  Bone fatty acid 
composition has been extensively studied after dietary supplementation in animal models 
and the composition of the diet is generally well reflected in the bone fatty acid 
composition (139, 141, 163-170).  PUFA incorporated into the membrane as 
phospholipids can be cleaved, releasing the longer chain PUFA – primarily AA, EPA and 
DHA – substrates of the enzymes cyclooxygenase (COX) (constitutive COX-1 and 
inducible COX-2), and lipoxygenase (LOX) for the production of small signaling 
molecules called eicosanoids (Figure 2-4).  AA and EPA are the key regulators of 
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inflammation in the body.  The eicosanoids derived from AA are generally considered to 
be pro-inflammatory in nature, whereas EPA-derived eicosanoids are less inflammatory 
or even anti-inflammatory (171).  However, the overall physiological outcome of these 
regulators depends upon the nature and timing of the eicosanoid production, the 
concentration of the eicosanoids, and the sensitivity of the target cells to the eicosanoid 
present (172).   
 PUFA of the n-6 and n-3 series are in direct competition for these key conversion 
enzymes, but COX-1 exhibits the greatest specificity for AA, and so the 2-series 
prostaglandin (PGE2) is preferentially produced (173).  PGE2 has biphasic properties and 
can act as a modulator of bone formation at low concentrations (174) and bone resorption 
at high concentrations in human cell culture (175).  Prostaglandins and their downstream 
metabolites can influence the expression and activity of growth factors (i.e., TGF-ß, IGF-
1), cytokines (i.e., IL-1, IL-6, IL-10, TNF-α), and transcription factors (i.e., NFκB, 
PPAR), having further indirect effects on bone metabolism (176).  The long chain n-3 
PUFA, EPA and DHA, are substrates for the production of 3-series of prostaglandins, 
thromboxanes, and resolvins, all generally considered to have anti-inflammatory 
properties.  
 Although it has been suggested that AA, EPA, and DHA elicit their inflammatory 
effects in the body through downstream signaling of their respective eicosanoids, the 
physiological effect of LA and ALA are likely independent of these signaling molecules 
since their conversion rate to longer chain PUFA is low.
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Figure 2-4. Metabolism of the essential fatty acids: LA and ALA 
 
N-6 (yellow) and n-3 (blue) PUFA compete for the same pool of elongase, desaturase, 
COX, and LOX enzymes.  AA, EPA, and DHA are substrates for the production of 
eicosanoids generally considered to be pro-inflammatory (red) and anti-inflammatory 
(green) in nature, respectively.  
 
(Image by Longo AB, adapted from (3))
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PUFA and Bone Cells 
 
 The impact of PUFA and their derivatives on the osteoblast and osteoclast have 
been extensively studied.  PUFA metabolism and their impact in vitro have been 
summarized in Figure 2-5 and are discussed below. 
Effects of PUFA on the Osteoblast 
 
 Several studies have investigated the effects of PUFA on the proliferation, 
differentiation, and rate of activity of cells of the osteoblast lineage.  In 2003, Watkins et 
al. reported the expression of the earliest and most specific marker of osteoblastogenesis 
(177), Runx2 was stimulated by AA, LA, and EPA in mouse calvarial osteoblasts, and 
that the rate of expression was time- and dose-dependent (178).  While both n-3 and n-6 
PUFAs were able to stimulate Runx2 expression, EPA-treatment resulted in a greater 
bone alkaline phosphatase activity, a marker of bone formation, compared to treatment 
with the n-6 PUFA, AA (178).  Similar studies have demonstrated an increased 
expression of certain pro-inflammatory cytokines in a time- and dose-dependent manner 
in response to AA-treatment (179, 180) but that this effect can be inhibited by treatment 
with EPA (180).  This could be due to the opposing inflammatory and anti-inflammatory 
effects of the prostaglandin derivatives of AA and EPA, respectively (171).  Both AA and 
DHA have been found to cause a dose-dependent inhibition of the proliferation of 
osteoblast cells in vitro (181, 182), but this inhibition is thought to be through different 
mechanisms, as incubation with AA caused an increase in PPAR-γ expression that was 
not found with DHA incubation (183).   
 Exposure of the murine osteoblast cell line to AA and DHA at varying 
concentrations and varying lengths of time in vitro, resulted in a dose- and time-
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dependent response of bone alkaline phosphatase activity (184).  With only acute 
exposure (48 hours), increasing concentrations of DHA caused a decrease in bone 
alkaline phosphatase activity, whereas with chronic exposure (14 days) increasing 
concentrations of AA caused a decrease in activity (184).  The current dietary patterns of 
Western countries suggest a chronic excess of n-6 PUFA intake with n-6 to n-3 PUFA 
ratios from 15 through 17:1 (155).  As a consequence, the resulting chronic exposure of 
n-6 PUFA in the body may cause detrimental effects to osteoblast cells and to osteoblast 
differentiation and maturation.  Together, these results highlight the complexity of 
timing, dose, and PUFA source on the function of the osteoblast. 
Effects of PUFA on the Osteoclast 
 Osteoclastogenesis is primarily controlled by the RANKL/RANK/OPG triad 
(185).  In mouse calvarial osteoblasts, treatment with the highest concentration of AA or 
DHA (20 µg/ml) caused a decrease in OPG secretion in the surrounding media (186).  
AA treatment also caused increased secretion of the soluble RANKL, although statistical 
testing could not be performed because the control cells produced RANKL 
concentrations lower than the detectable limit of the assay.  AA ultimately lowered the 
ratio of OPG to soluble RANKL, but whether this change was sufficient to increase 
osteoclastogenesis and ultimately lead to enhanced bone resorption was not investigated 
(186).  As a supportive follow-up to this study, treatment of mouse osteoblast-like cells 
with the n-6 PUFAs, γ-linoleic acid and AA, caused an increased percentage of RANKL-
expressing cells compared to cells treated with the long chain n-3 PUFAs, EPA and DHA 
(187).  AA decreased OPG secretion by 20%, but γ-linoleic acid, EPA, and DHA did not 
have an effect (187).  These studies support the role of n-6 PUFA in stimulating 
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osteoclastogenesis through the RANKL/RANK/OPG biochemical marker triad.  In 
primary murine bone marrow cell culture, EPA, DHA, or their combination inhibited 
tartrate resistant acid phosphatase staining, a marker of osteoclast maturation, compared 
to LA, AA, or their combination (188), further supporting the role of n-6 PUFA as a 
mediator of osteoclastogenesis and osteoclast activity. 
 The study of cell culture models allows a researcher to ask and to answer specific 
questions without the influence of other systems.  While this technique allows for the 
investigation into the mechanisms responsible, studies of humans and animal models 
provide insight into how diet can affect changes at the organ and whole-body level, 
ultimately affecting overall health. 
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Figure 2-5. Concentration-dependent effects of LA, AA, EPA, and DHA on bone 
health outcomes in cell culture and animal models 1 
 
A dose-dependent effect of treatment with AA, and DHA has been observed with serum 
or urinary markers of bone formation and resorption and on bone cell proliferation and 
activity.  AA concentrations can be increased with increasing dietary ratios of n-6 to n-3 
PUFA.  Higher concentrations of AA and DHA have been linked to increased markers of 
bone resorption and lower concentrations of AA has been linked to markers of bone 
formation.  Large inverted triangles are used to represent dose-dependent effects of AA 
and DHA.  Serum or urinary markers outlined in green and red are generally considered 
to be either bone formation or bone resorption markers, respectively. 
(Image by Longo AB, unpublished, 2016) 
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PUFA and Human Studies 
 
 Multiple large observational studies and randomized controlled trials (RCT) have 
investigated the associations between dietary intake patterns and bone-related health 
outcomes.  Specifically, individual fatty acid intake, ratio of fatty acid intake, or fish 
consumption has been quantified and compared to either the risk of fragility fracture, 
BMD, biochemical markers, or a combination of these outcomes to identify associations 
in women.  A summary of the findings from these studies is outlined in Table 2-7 and is 
discussed below.
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Table 2-7.  Summary of findings from observational studies concerning PUFA intake and bone health 1 
 
Reference Population Characteristics PUFA Intake Bone-Related Outcome 
Cross-Sectional Studies 
Weiss, 
2005 (189) 
564 PM women, Caucasian 
American, Rancho-
Bernardo Study 
Ratio of n-6 to n-3: Mean ± SD n-6 to n-3 PUFA: 
7.9 ± 2.2, Mean ± SD LA to ALA: 8.4 ± 2.3 
Ratio of n-6 to n-3: Inverse 
association with total hip (LA to 
ALA only) and LS BMD 
Muraki, 
2007 (190) 
632 PM women, Japanese Fish: ≤5 servings/wk vs. >5 servings/wk Fish: No difference in LS BMD 
Zalloua, 
2007 (191) 
6207 women (32% PM), 
Rural Chinese 
Fish: >250 g seafood/wk Fish: Increase hip and total body 
BMD 
Rousseau, 
2009 (192) 
118 men and 129 women, 
Caucasian (98%) American 
Total n-3: >1.27 g/d (men and women) Total n-3: Increase femur neck and 
total femur BMD (men and women) 
Chen, 2010 
(193) 
685 PM women, Chinese Fish: Quintile 1 (0.6 g/d) vs. Quintile 5 (64.7 g/d) 
from sea fish 
Fish: Positive dose-dependent 
relationship with hip, LS, and 
whole body BMD and BMC, 
Decrease hip and total fracture risk 
Nawata, 
2013 (194) 
205 PM women, Japan Total n-3: Average: 2.7 g/d Total n-3: Increase LS BMD 
Mangano, 
2014 (195) 
2125 older men and women 
(48% women), multi-ethnic 
American, NHANES 2005-
08 
EPA+DHA: 0.15 g/d from supplements (men and 
women) 
EPA+DHA: Increase LS BMD 
(men and women) 
Harris, 
2015 (196) 
266 PM women, multi-
ethnic American, BEST 
Study 
Total n-6: Tertile 1 (<8.51 g/d) vs. Tertile 3 
(>11.46 g/d) 
AA: Average: 0.11 ± 0.06 g/d 
Total n-3: Tertile 1 (<0.99 g/d) vs. Tertile 3 
(>1.40 g/d) 
Ratio of n-6 to n-3: Mean ± SD n-6 to n-3 PUFA: 
8.27 ± 1.74, Mean ± SD LA to ALA: 9.15 ± 2.04 
Total n-6: Decrease total body 
BMD 
AA: Increase trochanter BMD 
Total n-3: Decrease total body 
BMD 
Ratio of n-6 to n-3: Decrease total 
body BMD 
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Prospective Studies 
Feskanich, 
2003 (197) 
72,000 PM women, 18yr 
follow-up, multi-ethnic 
American, NHS 
Fish: Quartile 1 (<1 serving/mo) vs. Quartile 4 
(>1 serving/wk) 
Fish: Decrease hip fracture risk 
Orchard, 
2010 (198) 
137,486 PM women, 7.8yr 
follow-up, multi-ethnic 
American, WHI 
Total PUFA: Quartile 1 (0.71-5.16% energy) vs. 
Quartile 4 (7.90-31.84% energy) 
Total n-6: Quartile 1 (0.61 g/d) vs. Quartile 4 
(6.94 g/d) 
Total n-3: Quartile 1 (0.08 g/d) vs. Quartile 4 (2.1 
g/d) 
ALA: Quartile 1 (0.08 g/d) vs. Quartile 4 (0.84 
g/d) 
EPA+DHA: Quartile 1 (0 g/d) vs. Quartile 4 (0.09 
g/d) 
Ratio of n-6 to n-3: n-6 to n-3 PUFA >6.43 
Total PUFA: Decrease total 
fracture risk 
Total n-6: Decrease total fracture 
risk 
Total n-3: Decrease total fracture 
risk2 
ALA: Decrease total fracture risk 
EPA+DHA: Decrease hip fracture 
risk2, Increase total fracture risk 
Ratio of n-6 to n-3: Decrease total 
fracture risk 
Virtanen, 
2010 (199) 
2239 men and 2962 women, 
11yr follow-up, multi-ethnic 
American, Cardiovascular 
Health Study 
Fish: Quartile 1 (<1 serving/mo) vs. Quartile 4 
(≥3 serving/wk) (men and women) 
Fish: Decrease femur neck BMD 
(women only) 
Farina, 
2011 (200) 
530 PM women, 4yr follow-
up, elderly Caucasian 
American, Framingham 
Osteoporosis Study 
Fish: ≥3 servings/wk Fish: Maintenance of femur neck 
BMD 
Virtanen, 
2012 (201) 
75,878 women free of 
osteoporosis at baseline, 
24yr follow-up, multi-ethnic 
American, NHS 
Total PUFA: Quintile 1 (7.9 g/d) vs. Quintile 5  
(13.9 g/d) 
Total n-6: Quintile 1 (6.9 g/d) vs. Quintile 5  
(12.4 g/d) 
LA: Quintile 1 (6.8 g/d) vs. Quintile 5 (12.1 g/d) 
Total n-3: Quintile 1 (0.9 g/d) vs. Quintile 5 (1.6 
g/d) 
Total PUFA: Decrease hip fracture 
risk 
Total n-6: Decrease hip fracture 
risk 
LA: Decrease hip fracture risk 
Total n-3: Decrease hip fracture 
risk 
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ALA: Quintile 1 (0.7 g/d) vs. Quintile 5 (1.2 g/d) 
EPA+DHA: Quintile 1 (0.07 g/d) vs. Quintile 5 
(0.37 g/d) 
Fish: Quintile 1 (<1 serving/month) vs. Quintile 5 
(≥5 servings/week) 
ALA: No change in fracture risk 
EPA+DHA: Decrease hip fracture 
risk3 
Fish: Decrease hip fracture risk 
 
 
Jarvinen, 
2012 (202) 
554 PM women, 3yr follow-
up, Finnish, Kuopio 
Fracture Prevention Study 
Total PUFA: Quartile 1 (≤7.11 g/d) vs. Quartile 4 
(>10.24 g/d) 
Total n-6: Quartile 1 (4.89 g/d) vs. Quartile 4 
(6.89 g/d) 
LA: Quartile 1 (4.8 g/d) vs. Quartile 4 (6.77 g/d) 
Total n-3: Quartile 1 (1.31 g/d) vs. Quartile 4 
(2.21 g/d) 
ALA: Quartile 1 (1.02 g/d) vs. Quartile 4 (1.73 
g/d) 
Total PUFA: Increase LS BMD 
Total n-6: Increase LS and total 
body BMD 
LA: Increase LS and total body 
BMD 
Total n-3: Increase total body 
BMD 
ALA: Increase LS BMD 
 
1 AA; arachidonic acid, ALA; alpha-linolenic acid, BEST; The Bone and Estrogen Strength Training Study, BMC; bone mineral 
content, BMD; bone mineral density, DHA; docosahexaenoic acid, EPA; eicosapentaenoic acid, LA; linoleic acid, LS; lumbar spine, 
NHANES; National Health and Nutrition Examination Survey, NHS; Nurses’ Health Study, PM; postmenopausal, PUFA; 
polyunsaturated fatty acid, WHI; Women’s Health Initiative 
 
2 Associations lost after multivariate adjustment for age, race-ethnicity, education, marital status, family history of fracture, fracture 
after age 54yr, number of falls in past 12 months, height, weight, total vitamin D intake, calcium intake, hormone therapy use, 
antianxiety or antidepressant medication use, bisphosphonate use, corticosteroid use, smoking status, arthritis, depression, general 
health, parity, treated diabetes, and weekly exercise. 
 
3 Associations lost after multivariate adjustment for age, body mass index, smoking status, physical activity, thiazide-type diuretic use, 
multivitamin use, osteoporosis, cardiovascular disease and cancer, intakes of total energy, calcium, protein, vitamin D, vitamin K, 
retinol, caffeine, alcohol, and postmenopausal hormone use.
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Findings from Observational Studies 
 
Fatty Acid Intake: LA, ALA, EPA, DHA, total PUFA, total n-6, and total n-3 
 
Risk of Fracture: 
 Examination of the association between dietary intake of PUFAs and the risk of 
hip fracture has resulted in conflicting findings in several large observational studies.  
Analysis of the Nurse’s Health Study (NHS), in which postmenopausal women were 
followed for 24 years, showed a significant age-adjusted reduction in risk of hip fracture 
of 0.78 [95% CI 0.64, 0.94] among women in the highest quintile of total n-3 PUFA 
intake (1.6 g/day) compared to those in the lowest quintile (0.9 g/day) (201).  EPA and 
DHA intake also showed a significant age-adjusted, hip fracture risk reduction of 0.88 
[95% CI 0.72, 1.07] between women in the highest (0.37 g/day) and the lowest (0.07 
g/day) quintile of intake, but after further multivariate-adjustment, all associations were 
lost.  No associations with ALA, the major constituent of total n-3 PUFA in the diet, were 
observed with hip fracture risk.  Inverse associations between LA intake and hip fracture 
risk were found among women in the highest (12.1 g/day) compared with the lowest (6.8 
g/day) quintile of intake.  The multivariate-adjusted relative risk was 0.81 [95% CI 0.67, 
0.98] in the highest compared to the lowest quintile of LA intake among women.  
Although LA has long been considered a precursor of pro-inflammatory eicosanoids, 
which have a negative impact on bone metabolism, these results suggest a benefit to 
consuming more than 6.8 g/day, and possibly up to 12.1 g/day.  While a significant 
reduction in risk was observed between the highest and lowest quintile of LA intake, a 
modest reduction in risk was evident in the second quintile, with little to no additional 
benefit with higher intake of LA (201).  These findings support a minimum requirement 
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of more than 6.8 g/day of LA intake to provide a benefit to bone health in women, and 
that intake as high as 12.1 g/day does not cause a detriment. 
 In another large cohort of 137,486 postmenopausal American women enrolled in 
the Women’s Health Initiative (WHI), a higher intake of total PUFAs, supplied primarily 
from n-6 fatty acids, was associated with a lower total fracture risk after an average 
follow-up of 7.8 years (198).  Age-adjusted total fracture rates decreased with increasing 
n-3 PUFA intake when stratified by quartiles and the lowest hip fracture rates were 
associated with the highest n-3 intake (2.1 g/day).  ALA was the main n-3 PUFA in the 
diet, with women consuming an average of 1.27 g/day and an average EPA+DHA intake 
of 0.13 g/day.  A significant reduction in total fracture risk was observed in women in the 
highest quartile of ALA consumption when adjusted for age and ethnicity but not with 
further adjustment.  While women with the highest intake of EPA+DHA (0.17 g/day) 
experienced a lower risk of hip fracture in a model adjusted for age and ethnicity, an 
increased risk of total fractures was reported after multivariate adjustment.  This 
multivariate model adjusted for factors including family history of fracture, previous 
fracture incidence, intake of bone-positive nutrients, exercise, parity, and smoking status.  
Because the intake of EPA+DHA was very low in this population (0.08 – 0.17 g/day), it 
is not possible to examine associations at higher PUFA intakes.  Similar to associations 
observed with ALA intake, high consumption of n-6 PUFAs (6.94 g/day), predominately 
in the form of LA, was also associated with a decrease in total fracture risk compared to 
women in the lowest quartile (0.61 g/day) of n-6 PUFA consumption (198).  Together, 
findings from these large prospective studies support a lower risk of fragility fracture 
with higher total n-6 PUFA intake (primarily from LA).  No other associations remained 
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after multivariate adjustment.  The large prospective studies adjusted for a multitude of 
covariates, including anthropometric measures (Table 2-7).  Authors of the NHS study 
included the use of multiple medications and general health status as covariates (201).  
Authors of the WHI however, adjusted for the total intake of bone-supporting nutrients in 
their population as well as general health status.  The independent effect of each variable 
on the association between n-3 PUFA (ALA or EPA and DHA) and risk fracture is 
unknown. 
BMD: 
 In a 3-year prospective study of postmenopausal women from Finland, a 
significant increase in multivariate-adjusted lumbar spine BMD was observed with 
increasing intake of certain PUFA types (202).  From the lowest to highest quartiles of 
intake of total PUFA, LA, ALA, and total n-6 fatty acid, an increase in BMD of the 
lumbar spine was observed (202).  A similar significant pattern was observed for total 
body BMD with increasing LA, total n-6 fatty acid, and total n-3 fatty acid intake.  No 
associations were found for EPA+DHA, or AA intake with lumbar spine or total body 
BMD.  Similarly, in a pooled population of older men and women, above average total n-
3 fatty acid intake (>1.27 g/day) was associated with greater femur neck BMD and total 
femur BMD (192).  No associations were observed with ALA, EPA, DHA, or 
EPA+DHA intake in women, suggesting that an overall increase in total n-3 PUFA is 
important for bone health in this population.   
 In a cross-sectional study of postmenopausal Japanese women, total n-3 fatty acid 
intake, where the primary source of n-3 PUFA was from fish, was positively associated 
with lumbar spine BMD (194).  The average daily n-3 PUFA intake was 2.7 g/day and 
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these findings were independent of bone resorption and formation markers.  Results from 
a secondary analysis of 266 postmenopausal women enrolled in the Bone Estrogen 
Strength Training (BEST) Study found a positive association between AA intake (0.11 ± 
0.06 g/day) and trochanter BMD in women not receiving hormone replacement therapy 
(196).  A significant negative association in total body BMD was observed with 
increasing tertiles of n-6 and n-3 fatty acid intake (196). 
 Most recently, the relation of n-3 PUFA supplement use and BMD was examined 
in a diverse dataset of the US population using the NHANES (2005-08) (195).  In a 
population of 2125 men and women over 60, use of n-3 fatty acid supplements showed a 
positive association with lumbar spine BMD, but not femur neck or total femur BMD 
using DXA.  Within this study, only 15% of individuals reported using n-3 fatty acid 
supplements (195).  In summary, consistent positive associations between total PUFA, 
LA, total n-6, and total n-3 and site-specific BMD have been observed in several 
observational (prospective and cross-sectional) studies.  Less consistent findings support 
the positive association between the n-6, AA and the n-3 PUFA, ALA. 
Ratio of Fatty Acid Intake 
 
 As discussed earlier, LA and ALA and their longer chain derivatives share 
common enzymes for elongation and desaturation however, the metabolically active 
products have roles as pro- and anti-inflammatory mediators in the body (Figure 2-4).  
These two contrasting roles of pro- and anti-inflammatory mediators suggest the 
importance of the PUFA ratio in the diet.   
Risk of Fracture: 
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 The NHS and WHI considered the PUFA ratio in their analyses.  Results from 
these two large cohorts show no significant relationships associated with the dietary 
ratio of total n-6 to n-3 fatty acids and hip fracture risk.  In the NHS, the ratio varied 
from less than 6.7 in the lowest quintile to greater than 8.9 in the highest (201).  This 
range may have been too narrow to detect any differences in fragility fracture risk in the 
population.  From the WHI, dietary PUFA ratios spanned from 0.49 to 39.01 with an 
average ratio of 7.6 (198).  A 7% reduction in relative risk of total fractures was 
discovered in this population of postmenopausal women when the total n-6 to n-3 PUFA 
ratio was above 6.4 compared to those with a PUFA intake ratio below 6.4.  This data 
provides support for the importance of attaining a minimum daily dietary intake of n-6 
PUFA for the proper maintenance of bone health. 
BMD: 
 In a fully adjusted model of analysis of postmenopausal women (not using 
hormone replacement therapy) enrolled in the Rancho-Bernardo study, the ratio of total 
n-6 to total n-3 PUFA was negatively associated with total hip and lumbar spine BMD 
(189).  This population of mid-upper class, white residents of Southern California 
consumed a ratio of total n-6 to n-3 fatty acids (7.9 ± 2.2) made up of 10.2 g/day and 1.3 
g/day n-6 and n-3 PUFAs, respectively.  In contrast, findings from women enrolled in the 
BEST Study (196) or those in the Framingham Osteoporosis Study (200) showed no 
associations between PUFA ratio (average of BEST: 8.27 ±1.74, average of Framingham 
Osteoporosis Study: 8.22 ± 2.89) and BMD.  The dietary PUFA ratio in these studies are 
relatively low compared to the national intake in the USA, estimated between 15 through 
17:1 (155). 
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Fish Consumption 
 
 Although intake of individual fatty acids and their association with fracture 
provide us with specific information regarding the benefits of PUFA consumption on 
fracture risk, it is important to also consider the association with a food source, such as 
fish.  Fatty fish are rich sources of EPA and DHA, although the levels of each vary 
widely among fish species.  Moreover, fatty fish (i.e., swordfish, salmon, mackerel, 
sardines, salmon) are also a good source of vitamin D and protein, critical for bone 
health.   
Risk of Fracture: 
 In the 18-year follow-up study of the NHS, consisting of over 72,000 
postmenopausal women, consumption of a 85-142 g serving of fatty fish more than once 
per week, resulted in a 33% lower risk of hip fracture compared to those who consumed 
fatty fish less than once per month (197).  Separate analysis of the same population of 
white American women, followed for 24 rather than 18 years, showed a significant 
reduction in age-adjusted hip fracture risk among women who consumed more than 5 
servings per week of fish compared to those who consumed less than 1 serving per month 
(201).  
BMD: 
 The observational studies that used BMD as a surrogate measure of risk of 
fracture to investigate the association between fish and bone health have provided 
conflicting results.  A study of 632 postmenopausal Japanese women found no significant 
difference in lumbar spine BMD between women who consumed fish more than 5 times 
per week compared to those who consumed fish less than 5 times per week (190).  The 
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authors of this study did not clarify the type of fish consumed, but do suggest that both 
groups may have exceeded the intake level necessary to provide any further benefit.  
Another large cohort of 5201 men and women found a negative effect of more frequent 
intake of tuna and other fish, citing a slightly lower average femur neck BMD between 
the highest (≥ 3 servings per week, corresponding to 0.59 g/day EPA+DHA) and lowest 
(< 1 serving per month, 0.05 g/day EPA+DHA) quintiles of intake where average intake 
was 1.6 servings per week (199).  There was no association between EPA+DHA intake 
and risk of fracture in this population.  In this study of older (average age 72.8 years), 
community-dwelling participants, although more frequent fish intake was negatively 
associated with femur neck BMD these associations were not paralleled with an increased 
fracture incidence when stratified by intake of EPA+DHA (199). 
 In direct contrast, three prospective studies - two cohorts of Chinese populations 
and the Framingham Osteoporosis cohort - reported a positive association of higher fish 
consumption on BMD (191, 193, 200).  An intake of 250 g/week or greater (roughly 3 
servings per week) of seafood, including fish and shellfish, was associated with a greater 
total body and hip BMD in rural Chinese postmenopausal women (191).  Similarly, a 
dose-dependent linear relation was observed between intakes of sea fish (non freshwater 
or shellfish) and BMD or BMC at the whole body, total hip, femur neck, trochanter, and 
intertrochanter in 685 postmenopausal women (193).  This association corresponded to a 
significantly lower odds ratio of osteoporosis at the whole body, total hip, femur neck, 
and intertrochanter for women consuming the highest (64.7 g/day) compared to those in 
the lowest (0.6 g/day) quintile of intake of sea fish (193).  In the Framingham 
Osteoporosis Study, consumption of ≥ 3 servings of fish per week was associated with 
 67 
the maintenance of femur neck BMD in older women over a 4-year follow-up period 
(200).  This association can be mainly attributed to fatty fish consumption, as women 
with high intakes of fatty fish lost significantly less femur neck BMD than did women 
with moderate or low intakes.  These associations were also observed with total fish 
intake in women, but were not significant.  In the Framingham Osteoporosis Study, the 
type of fish consumed was mainly tuna and white and other fish, while fatty fish 
accounted for 12% of intake (200). 
 The conflicting results in these studies of fish consumption and BMD may be 
attributed to the type of fish consumed.  In the observational studies citing no benefit with 
fish intake, the sub-type of fish was either not classified (190) or was classified as either 
tuna or broiled or baked fish, or fried fish (199).  Benefits were observed in those studies 
quantifying fish and shellfish (191), sea fish (193), or total fish, fatty fish + tuna, fatty 
fish, or tuna intakes (200).  The positive effects of fish consumption in these studies may 
be attributed to their displacement of low-quality food items from the diet, the high 
vitamin D levels, and/or the high content of long chain n-3 PUFAs found within these 
types of fish.  The total PUFA, n-6 PUFA, and n-3 PUFA content of different fish species 
varies substantially.  Table 2-8 summarizes the total fat and PUFA contents of a variety 
of fish species and has been adapted from data published by Strobel and colleagues (203).   
 In summary, findings from observational studies reveal higher intakes of total 
PUFA, total n-6, LA, total n-3 and fatty fish are associated with higher BMD and a lower 
risk of fragility fracture in women.  Less consistent benefits to bone health are associated 
with higher intake of long chain n-3 PUFAs or when the dietary ratio of n-6 to n-3 PUFA 
is considered.  When comparing findings across observational studies, it is important to 
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consider many aspects of the study including the population characteristics, current 
dietary patterns, and primary outcome measures (Table 2-9).
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Table 2-8. Total fat, n-6, n-3, and EPA+DHA contents of various fish species 1 
Fish Species Total Fat 2  Total n-6 Total n-3  EPA+DHA  
Fatty Fish 
Salmon, farmed 12.3 1.32 2.40 1.53 
Salmon, wild 2.07 0.05 0.53 0.44 
Herring 12.7 0.31 1.95 1.45 
Mackerel 20.6 0.59 4.64 3.08 
Anchovies, drained of oil 6.21 2.31 0.93 0.66 
Sardine, drained of oil 10.2 2.45 1.40 1.16 
Non-Fatty Fish 
Tilapia 1.63 0.29 0.12 0.06 
Tuna 2.28 0.14 0.78 0.72 
Perch, fillet 0.80 0.05 0.12 0.08 
Prawn 0.53 0.09 0.11 0.10 
Alaskan pollock, fillet 0.77 0.02 0.39 0.37 
Alaskan pollock, breaded 7.85 4.04 0.30 0.16 
 
1 Data from (203) 
 
2 The amount of fat is expressed as a percentage of fresh fish weight (g/100g). 
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Table 2-9. Aspects to consider when reviewing observational studies assessing the 
effect of PUFA intake on bone health 1 
 
Participant 
Baseline 
Characteristics 
Age, sex, ethnicity, body mass index, physical activity, general health 
status, years since menopause, hormone therapy use, previous fracture 
incidence, medication use, protein intake, vitamin D intake, and 
calcium intake are all variables that modulate bone health 
Dietary 
Patterns 
FFQ: captures habitual dietary patterns; generally less detailed than 
other methods; more likely to overestimate intake; less expensive 
24-h Recall, food diaries: capture a snapshot of dietary patterns; time 
consuming 
Dietary patterns and supplement use: may change over time with 
changing public health recommendations 
Accessibility to fresh food items: changes with season, geographical 
region, and economic burden 
Range of intake: variation of dietary intake among the sample 
population must be wide enough to establish distinct subgroups of 
intake 
Follow-up time: wide range of average follow-up times among studies 
(3 to 24yrs) 
Ability of the diet assessment tool to accurately estimate intake of fatty 
acid chain length and saturation index, i.e., n-3 PUFAs from plant or 
marine sources 
Sensitivity of the diet assessment tool to differentiation between fatty 
acid sources, i.e., fatty fish vs. fried fish vs. canned fish, etc. 
Primary 
Outcome 
Measure 
Fracture risk: clinically relevant measure; results may be masked by a 
short follow-up period, error in self-reporting fractures, or changes to 
fall incidence with dietary patterns 
BMD by DXA: measures skeletal site-specific effects; changes may be 
observed without concomitant changes in fracture incidence 
High-resolution pQCT: nondestructive imaging techniques that allow 
for the 3D quantification of bone structure; not used in any human 
studies reviewed in this thesis 
 
1 BMD; bone mineral density, DXA; dual energy X-ray absorptiometry, FFQ; food 
frequency questionnaire, pQCT; peripheral quantitative computed tomography, PUFA; 
polyunsaturated fatty acid. 
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Findings from RCTs 
 
 While observational studies of the population identify associations between 
dietary habits and bone health, they do not allow for causal relationships to be 
investigated.  RCTs have been conducted to determine whether a cause and effect 
relationship exists between dietary PUFA intake and markers of bone health in 
postmenopausal women.  Most studies have shown either a benefit or a null effect of 
PUFA supplementation to bone health (Table 2-10).
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Table 2-10. Summary of findings from RCTs concerning PUFA intake and bone health 1 
 
Reference Population 
Characteristics 
Intervention Duration Bone-Related Outcome 
Studies of Flaxseed or ALA 
Lucas, 2002 
(204) 
n=36 PM 
women 
40 g/d wheat germ, 
40 g/d whole flaxseed 
12 weeks • No effect of supplementation on serum or urinary 
markers of bone metabolism 
Brooks, 2004 
(205) 
n=46 PM 
women 
Placebo, 
25 g/d whole flaxseed, 
25 g/d soy flour 
16 weeks • No effect of supplementation on serum or urinary 
markers of bone metabolism 
Dodin, 2005 
(206) 
n=179 PM 
women 
40 g/d wheat germ, 
40 g/d whole flaxseed 
12 months • No effect of supplementation on lumbar spine or 
femur neck BMD 
Griel, 2007 
(207) 
n=23 men and 
women (n=3 
PM women) 
LA: ALA (9.5:1), 
LA: ALA (3.5:1), 
LA: ALA (1.6:1) 
6 weeks, 3 
week 
wash-out 
• Lower PUFA ratio decreased serum NTX and TNFα 
concentrations 
Cornish, 2009 
(208) 
n=23 PM 
women 
30 mL/d corn oil, 
30 mL/d flaxseed oil 
(both undergoing 
resistance exercise) 
12 weeks • No effect of supplementation on lumbar spine or hip 
BMD  
Studies of Fish oil, EPA, DHA or EPA+DHA 
Vanpapendorp, 
1995 (209) 
n=40 women 
with confirmed 
osteoporosis 
4 g/d Olive Oil, 
4 g/d EPO, 
4 g/d Fish oil, 
4 g/d EPO + Fish oil 
16 weeks • Fish oil supplementation increased serum 
osteocalcin compared to EPO 
• Olive oil, fish oil, EPO + Fish oil increased pro-
collagen concentrations from baseline 
Kruger, 1998 
(210) 
n=60 PM 
women with 
confirmed 
osteoporosis 
6 g/d coconut oil (97% 
SFA), 
6 g/d EPO + fish oil (60% 
LA, 8% GLA, 4% EPA, 
3% DHA 
18 months 
(phase I) + 
18 months 
(phase II) 
• Both interventions increased procollagen, BALP, 
osteocalcin, and deoxypyridinoline 
• EPO + fish oil supplementation preserved lumbar 
spine and femur neck BMD in phase I and phase II 
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Bassey, 2000 
(211) 
n=45 PM 
women 
1 g/d calcium, 
1 g/d calcium + 4 g/d 
EPO + 440 mg/d fish oil 
12 months • No effect of supplementation on total body BMD or 
urinary markers of bone metabolism 
Appleton, 
2011 (212) 
n=190 men and 
women 
1.48 g/d Olive oil, 
0.63 g/d EPA + 0.85 g/d 
DHA 
12 weeks • No effect of supplementation on serum CTX 
concentrations 
Hutchins-
Weise, 2014 
(213) 
n=34 women 
on aromatase 
inhibitors 
4 g/d Safflower oil 
2.52 g/d EPA + 1.68 g/d 
DHA 
12 weeks • EPA+DHA supplementation decreased serum CTX 
compared to control 
• Serum CTX concentrations were positively 
correlated with serum AA and with serum n-6 to n-3 
ratio and negatively correlated with serum 
EPA+DHA concentrations 
 
1 AA; arachidonic acid, BALP; bone specific alkaline phosphatase, BMD; bone mineral density, CTX; C-terminal telopeptide, DHA; 
docosahexaenoic acid, EPA; eicosapentaenoic acid, EPO; evening primrose oil, GLA; γ-linoleic acid, LA; linoleic acid, NTX; N-
terminal telopeptide, PM; postmenopausal, PUFA; polyunsaturated fatty acid, SFA; saturated fatty acid, TNFα; tumor necrosis factor 
alpha. 
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 One of the first trials investigated the effects of evening primrose oil, a natural 
source of the n-6 PUFA γ-linoleic acid, fish oil, or the combination of oils on serum 
biochemical markers of elderly women with osteoporosis (209).  In this study, 4 g/day of 
fish oil for 16 weeks showed a beneficial effect via an increase in serum osteocalcin and 
procollagen concentrations, biochemical markers of bone turnover and formation 
respectively (209).  More recent support of long chain n-3 PUFAs on bone health comes 
from a study investigating the effect of 2.52 g EPA and 1.68 g DHA/day compared to 4 g 
safflower oil control/day in postmenopausal women receiving aromatase inhibitors for 
the treatment of estrogen-positive breast cancer (213).  Following 12 weeks of treatment, 
women in the EPA+DHA supplementation group experienced a significant decrease in 
serum C-terminal telopeptide (CTX), and this marker of bone resorption was positively 
correlated with serum AA and with serum long chain n-6 to n-3 fatty acid ratios and 
negatively correlated with serum EPA+DHA concentrations (213).  Of importance to 
note, all women received a 1000 mg calcium supplement and 800 IU vitamin D/day and 
not all women experienced a similar response, suggesting that these women were ‘non-
responders’ and were retroactively removed from the analyses.  This study did not 
evaluate baseline serum calcium and vitamin D concentrations, but it is possible that 
supplementation of all women upon entrance into the study may have masked some of 
the effects of EPA+DHA supplementation. 
 Conversely, ancillary analysis of a large RCT consisting of 190 men and women 
consuming either 1.48 g EPA+DHA/day or olive oil placebo found no change in CTX 
(212).  Although average fasting plasma concentrations of n-3 PUFAs increased over the 
12-week study, no association was found with this marker of bone resorption.  This 
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finding could be due to the variability in participant characteristics, which included both 
men and women of a wide age-range, of which only 75% were over 50 years and most 
likely not experiencing menopause. 
 There is insufficient evidence to suggest a positive effect of ALA on 
postmenopausal bone health.  In one study of 179 women with at least 6 months of 
amenorrhea, neither 40 g of flaxseed (roughly 9.2 g ALA/day) or wheat germ placebo 
incorporated into the diet prevented the progressive bone loss observed over 12 months in 
early menopausal women (206).  Although this study saw no change in lumbar spine or 
femur neck BMD by DXA between the two groups, this could be attributed to the early 
stage of menopause women were classified in and the overall good health status of the 
participants, inferred by the recruitment criteria of the study.  Bone loss at the hip and 
lumbar spine over the menopausal transition is most dramatic during late peri-menopause 
(3 to 11 months amenorrhea) and post-menopause (> 12 months amenorrhea) (214), 
which coincides with the relatively early stage of the menopausal transition women from 
this study were classified in (206).  Similarly, no change in lumbar or hip BMD was 
observed after 12 weeks of resistance training with and without the supplementation of 30 
mL flaxseed oil/day (approximately 14 g ALA/day) (208).  The design of this trial could 
not distinguish the effect of diet alone on bone health as all 51 Canadian men and women, 
23 of whom were postmenopausal females, underwent resistance training.  Flaxseed 
supplementation trials of 40 g/day of whole ground flaxseed for 3 months (roughly 9.2 g 
ALA/day) (204) and 25 g/day for 4 months (roughly 5.8 g ALA/day) (205) in 
postmenopausal women resulted in no effect on biomarkers of bone metabolism when 
compared to their wheat placebo or wheat and soy supplementation controls, respectively. 
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 To establish the long-term effect of a complex combination of PUFAs in an 
elderly population of women with osteoporosis, supplementation with 6 g evening 
primrose oil and fish oil was compared with 6 g of coconut oil/day over 18 months (210).  
The PUFA supplement consisted of approximately 68% n-6 fatty acid and 7% long chain 
n-3 fatty acid, while the coconut oil treatment was rich in saturated fatty acids.  Both 
interventions resulted in significant increases in markers of bone formation (procollagen, 
bone alkaline phosphatase), and decreases in markers of bone turnover (osteocalcin) and 
resorption (deoxypyridinoline).  The similar findings observed with both treatments may 
be attributed to the calcium supplement (600 mg) provided to all women enrolled in the 
study.  Upon entrance into the study, the average daily calcium intake was 653 ± 249 mg, 
below the 1998 recommended dietary allowance of 800 mg and the current dietary 
recommended intake (US, Canada) of 1200 mg for women over 70 years of age.  Thus, 
their bone health likely benefited from this calcium supplementation, rather than the fatty 
acid intervention.  Interestingly, PUFA supplementation with evening primrose and fish 
oil was able to preserve lumbar spine BMD and increase femur neck BMD over the 18-
month treatment period, while coconut oil caused a 3.2% and 2.1% decrease in lumbar 
spine and femur neck BMD, respectively.  Because of the beneficial effects observed 
with PUFA supplementation, 21 women remained in the study for a total of 36 months, 
and those in the coconut oil group were reallocated to receive evening primrose and fish 
oil.  After 36 months, lumbar spine and femur neck BMD was preserved in those women 
who had consistently been supplemented with the PUFA combination and was increased 
in the women switched to the PUFA supplement (210).  In contrast, a study of 45 
postmenopausal women consuming either 1 g calcium with 4 g evening primrose and 440 
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mg fish oil, or calcium alone found a decrease in total body BMD by 1% in both groups 
over 12 months and no between group differences in urinary markers of bone turnover 
(211).  The women recruited in this study already had an average baseline calcium intake 
of approximately 900 mg/day, which may have masked any effect attributed to the fatty 
acid supplementation. 
 To our knowledge, the only randomized crossover control trial to assess the effect 
of the ratio of n-6 to n-3 PUFAs on bone health comes as ancillary data from a larger 
study designed to evaluate the effect of PUFAs in the diet on cardiovascular disease 
(207).  Three diets were used, lasting a period of 6 weeks and separated by a 3-week 
washout period.  All diets consisted of 35% fat as energy based on 2400 kcal/day and 
differed by PUFA ratio.  As a control, created to mimic the average American diet, a ratio 
of 9.5 for LA to ALA was consumed.  Two experimental diets consisted of ratios of 3.5 
and 1.6, respectively.  At study endpoint, the lowest ratio of dietary n-6 to n-3 yielded a 
significantly lower serum N-terminal telopeptide (NTX) concentration.  This treatment 
diet also reduced serum concentrations of the inflammatory marker, tumor necrosis factor 
alpha (TNFα), and a positive correlation was observed between NTX levels and TNFα 
concentrations across all diets.  Although bone resorption rates seem to be positively 
affected by PUFA ratio, serum bone alkaline phosphatase levels were not changed with 
this diet.  Although the crossover design is powerful, this study included 23 participants, 
of which only 3 were postmenopausal women and the remainder were men, and all were 
at high risk for cardiovascular disease.  These results suggest the need for more controlled 
feeding studies with crossover design, particularly studies including postmenopausal 
women, to evaluate how the level and ratio of n-6 to n-3 PUFAs modulates bone health. 
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 In summary, findings from RCTs have suggested some benefit to bone health with 
supplementation with fish oil (with or without evening primrose oil) and the long chain n-
3 PUFAs, EPA and DHA in the diet (209, 210, 213) but a null effect of the plant source, 
ALA (204-206, 208).  When reviewing RCTs assessing the effect of PUFA intake on bone 
health, aspects to consider include participant inclusion criteria, baseline dietary patterns, 
intervention type and length, and the primary outcome measure (Table 2-11). 
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Table 2-11. Aspects to Consider When Reviewing RCTs Assessing the Effect of 
PUFA Intake and Bone Health 1 
 
Inclusion Criteria Participant characteristics: age, sex, ethnicity, body mass index, 
physical activity, general health status, and previous fracture 
incidence are all variables that modulate bone health 
Baseline Dietary 
Patterns 
Habitual PUFA intake and supplement use: lifelong exposure to 
certain PUFAs may impact the ability of an intervention to alter 
bone health above a threshold 
Baseline calcium and vitamin D intake: most RCTs provide all 
groups with calcium and vitamin D supplements, which may mask 
any additional effect of an intervention if baseline values are lower 
than recommended 
Intervention PUFA intervention: PUFA type and source (food or supplement), 
PUFA amount, PUFA ratio 
Primary Outcome 
Measure 
Imaging technique used: BMD by DXA, 3-D quantification of bone 
structure by high-resolution pQCT 
Site-specific effects: regions of the skeleton may not respond 
uniformly to an intervention (e.g., hip, lumbar spine, appendicular 
limbs) 
Biochemical markers of bone turnover: circadian variation of 
markers, sampling in a fed or fasted-state, intra-individual 
variability.  To reduce variability, it is useful to measure multiple 
markers as well as the longitudinal change in markers over time 
 
1 BMD; bone mineral density, DXA; dual energy X-ray absorptiometry, pQCT; 
peripheral quantitative computed tomography, PUFA; polyunsaturated fatty acid, RCT; 
randomized controlled trial
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Summary of Findings in Human Studies 
 
 Findings from human studies largely show that a greater intake of total PUFA, 
total n-6 PUFA, total n-3 PUFA, and fish is associated with higher BMD or a lower risk 
of fragility fracture in adult women (Table 2-12).  Less consistent benefits to bone health 
are associated with higher intake of long chain n-3 PUFA or when the dietary ratio of n-6 
to n-3 PUFA is considered.  The strongest evidence for benefits to bone is from studies of 
fish intake.  Regular consumption of fish and seafood not only provides high quantities of 
PUFA but can also be rich sources of protein, vitamin D, calcium, and other vitamins and 
minerals, all of which are necessary for the maintenance of strong, fracture-resistant 
bones. 
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Table 2-12. Summary of the findings concerning PUFA intakes and bone-related outcomes in humans 4 
PUFA DRI1 Quantity Bone-Related Outcome Study 
Type 
Reference 
Total 
PUFA 
12.1 g/d Quartile 1 (0.71-5.16% energy) vs. 
Quartile 4 (7.90-31.84% energy) 
• Decrease total fracture risk P Orchard 
2010 (198) 
Quintile 1 (7.9 g/d) vs. Quintile 5 
(13.9 g/d) 
• Decrease hip fracture risk P Virtanen 
2012 (201) 
Quartile 1 (≤7.11 g/d) vs. Quartile 4 
(>10.24 g/d) 
• Increase lumbar spine BMD2 P Jarvinen 
2012 (202) 
11.26 g/d • No association with lumbar spine and 
total body BMD2 
CS Harris 2015 
(196) 
Total n-6 
PUFA 
11 g/d Quartile 1 (0.61 g/d) vs. Quartile 4 
(6.94 g/d) 
• Decrease total fracture risk P Orchard 
2010 (198) 
Quintile 1 (6.9 g/d) vs. Quintile 5 
(12.4 g/d) 
• Decrease hip fracture risk P Virtanen 
2012 (201) 
Quartile 1 (4.89 g/d) vs. Quartile 4 
(6.89 g/d) 
• Increase lumbar spine and total body 
BMD2 
P Jarvenin 
2012 (202) 
Tertile 1 (<8.51 g/d) vs. Tertile 
3(>11.46 g/d) 
• Decrease total body BMD2 CS Harris 2015 
(196) 
LA 11 g/d Quintile 1 (6.8 g/d) vs. Quintile 5 
(12.1 g/d)  
• Decrease hip fracture risk P Virtanen 
2012 (201) 
Quartile 1 (4.8 g/d) vs. Quartile 4 
(6.77 g/d)  
• Increase lumbar spine and total body 
BMD2 
P Jarvinen 
2012 (202) 
9.78 g/d • No association with lumbar spine and 
total body BMD2 
CS Harris 2015 
(196) 
Total n-3 
PUFA 
1.1 g/d >1.27 g/d • Increase femur neck and total femur 
BMD 
CS Rousseau 
2009 (192) 
Quintile 1 (0.9 g/d) vs. Quintile 5 • Decrease hip fracture risk P Virtanen 
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(1.6 g/d) 2012 (201) 
Quartile 1 (1.31 g/d) vs. Quartile 4 
(2.21 g/d) 
• Increase total body BMD2 P Jarvenin 
2012 (202) 
Mean: 2.7 g/d • Increase lumbar spine BMD CS Nawata 
2013 (194) 
Tertile 1 (<0.99 g/d) vs. Tertile 3 
(>1.40 g/d) 
• Decrease total body BMD2 CS Harris 2015 
(196) 
ALA  1.1 g/d 40 g whole flaxseed/d (12 wk) • No change in serum or urinary markers 
of bone metabolism 
RCT Lucas 2002 
(204) 
25 g whole flaxseed/d (16 wk) • No change in serum or urinary markers 
of bone metabolism 
RCT Brooks 
2004 (205) 
40 g flaxseed/d (12 mo) • No benefit to bone loss at lumbar spine 
or femur neck 
RCT Dodin 2005 
(206) 
30 mL flaxseed oil/d (12 wk) • No change in lumbar spine or hip BMD RCT Cornish 
2009 (208) 
Quartile 1 (0.08 g/d) vs. Quartile 4 
(0.84 g/d)  
• Decrease total fracture risk P Orchard 
2010 (198) 
Quintile 1 (0.7 g/d) vs. Quintile 5 
(1.2 g/d)  
• No change in fracture risk P Virtanen 
2012 (201) 
Quartile 1 (1.02 g/d) vs. Quartile 4 
(1.73 g/d)  
• Increase lumbar spine BMD2 P Jarvenin 
2012 (202) 
1.11 g/d • No association with LS and total body 
BMD2 
CS Harris 2015 
(196) 
EPA+ 
DHA 
Up to 10% 
of AMDR 
consumed 
as EPA 
and/or 
DHA 
4 g fish oil/d compared with 4 g 
EPO/d (16 wk) 
• Increase levels of serum osteocalcin and 
procollagen 
• Decrease levels of serum BALP 
RCT Van 
Papendorp 
1995 (209) 
Quintile 1 (0.145 g/d) vs. Quintile 5 
(0.519 g/d) from fish 
• No effect on BMD 
• No effect on hip fracture risk 
P Virtanen 
2010 (199) 
Quartile 1 (0 g/d) vs. Quartile 4 • Decrease hip fracture risk P Orchard 
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(0.09 g/d)  • Increase total fracture risk3 2010 (198) 
1.0 g/d (24 wk) • Decrease levels of TNFα and IL-6 RCT Tartiban 
2010 (215) 
1.48 g/d (12 wk) • No change in levels of CTX RCT Appleton 
2011(212) 
Quintile 1 (0.07 g/d) vs. Quintile 5 
(0.37 g/d) 
• Decrease hip fracture risk3 P Virtanen 
2012 (201) 
0.15 g/d from supplements • Increase lumbar spine BMD CS Mangano 
2014 (195) 
0.18 g/d • No association with lumbar spine and 
total BMD2 
CS Harris 2015 
(196) 
Ratio of 
n-6 to n-3 
PUFA  
10 6 g EPO + fish oil combination/d 
(18 mo) 
• Increase levels of serum procollagen and 
BALP 
• Decrease levels of serum osteocalcin and 
urinary deoxypyridinoline 
• Preservation of lumbar spine BMD 
• Increase femur neck BMD 
RCT Kruger 
1998 (210) 
4 g EPO + 0.44 g fish oil/d (12 mo) • No benefit to total body BMD loss RCT Bassey 
2000 (211) 
Mean ratio of n-6 to n-3 PUFA: 7.9 
Mean ratio of LA to ALA: 8.4 
• Inverse association with total hip (LA to 
ALA only) and lumbar spine BMD2 
CS Weiss 2005 
(189) 
Ratio of LA to ALA: 9.5 vs. 3.5 vs. 
1.6 (6 wk) 
• Decrease levels of NTX and TNFα RCT Griel 2007 
(207) 
Ratio of n-6 to n-3 PUFA > 6.43 • Decrease total fracture risk P Orchard 
2010 (198) 
Greater AA intake when 
EPA+DHA intake is above 0.14 g/d 
• Increase femur neck BMD P Farina 2011 
(200) 
Ratio of LA to ALA: 3.61 to >5.13 • Inverse association (NS) with lumbar 
spine BMD2 
P Jarvenin 
2012 (202) 
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1 DRI, Females 51-70 y (154). 
 
2 Women not receiving HRT only. 
3 Significant associations were lost after full multivariate adjustment of the model. 
4 ALA; alpha-linolenic acid, AMDR; acceptable macronutrient distribution range, BALP; bone specific alkaline phosphatase, BMC; 
bone mineral content, BMD; bone mineral density, CC; case-control, CS; cross-sectional, CTX; C-terminal telopeptide, DHA; 
Mean ratio of n-6 to n-3 PUFA: 
8.27 
Mean ratio of LA to ALA: 9.15 
• Negative association with total body 
BMD2 
CS Harris 2015 
(196) 
Fish Two 
servings of 
fish/wk 
 
3-4 servings/wk • Decrease hip fracture risk CC Suzuki 
1997 (216) 
Quartile 1 (<1 serving/mo) vs. 
Quartile 4 (>1 serving/wk) 
• Decrease hip fracture risk P Feskanich 
2003 (197) 
≤5 servings/wk vs. >5 servings/wk • No difference in lumbar spine BMD CS Muraki 
2007 (190) 
>250 g seafood/wk • Increase hip and total body BMD CS Zalloua 
2007 (191) 
Quintile 1 (0.6 g/d) vs. Quintile 5 
(64.7 g/d) from sea fish 
• Positive dose-dependent relationship 
with hip, spine, and whole body BMD 
and BMC 
• Decrease hip and total fracture risk 
CS Chen 2010 
(193) 
Quartile 1 (<1 serving/mo) vs. 
Quartile 4 (≥3 serving/wk) 
• Decrease femur neck BMD P Virtanen 
2010 (199) 
≥3 servings/wk • Maintenance of femur neck BMD P Farina 2011 
(200) 
Quintile 1 (<1 serving/mo) vs. 
Quintile 5 (≥5 servings/wk) 
• Decrease hip fracture risk3 P Virtanen 
2012 (201) 
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docosahexaenoic acid, DRI; dietary recommended intake, EPA; eicosapentaenoic acid, EPO; evening primrose oil, LA; linoleic acid, 
NS; non significant, NTX; N-terminal telopeptide, P; prospective, PUFA; polyunsaturated fatty acid, RCT, randomized controlled 
trial, TNFα; tumor necrosis factor alpha.
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Strengths and Limitations of Human Studies 
 
 While observational studies and RCTs are clinically relevant, as they directly 
assess the effect of diet on the human population, there are several limitations associated 
with these study designs.  The use of observational studies in research provides 
information regarding associations only, and cannot imply causation.  The findings from 
observational studies are also limited by the baseline characteristics of the population 
studied, the range of intake of a nutrient within the population and the specificity of the 
dietary assessment tool used, the length of the follow-up period, and the primary outcome 
measured.  Findings from RCTs are similarly affected by factors such as the inclusion 
criteria and baseline characteristics of the sample population, and the duration of the 
intervention period and the primary outcome measured.  RCTs also provide details of 
only a snapshot in time in the life of a woman. 
 Although it is generally understood that habitual dietary patterns of an individual 
do not change drastically over time (217), studies of the effect of diet in the human 
population often capture only one specific life stage (i.e., childhood, adulthood, post-
menopause).  Extending follow-up periods through several life stages in a large sample 
size would be very costly, but would provide valuable information on the effect of 
specific lifelong diet patterns to bone health, as bone is a dynamic tissue affected by the 
chronic exposure to nutrients in the diet, including PUFAs.  As an alternative to costly 
and time-intensive studies in humans, rodent models have been used for the study of bone 
health in response to dietary interventions.  The use of rodent models allows for the 
assessment of long term feeding trials that can extend over many stages of the life cycle 
including development, growth, adulthood, aging.  Rodent studies also allow for a 
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researcher to have strict control over factors including diet (type and amount), physical 
activity and hormone status.  Higher resolution imaging and testing of ex vivo tissues can 
also be conducted in a rodent model that cannot be obtained in humans. 
PUFA and Rodent Studies 
 
 To assess the direct effect of PUFA intake on bone health related outcomes, many 
studies have been performed using rodent models.  These pre-clinical models are 
beneficial as they provide the unique opportunity to assess the effect of dietary 
interventions over the life course (i.e., growth and development, attainment of peak bone 
mass, protection from aging and hormone-related bone loss).  Alterations to bone and to 
bone health is a lifelong process and so early and prolonged exposure to nutrients, such as 
PUFAs, may provide protection from the hormone-related bone loss experienced later in 
life, although this hypothesis has never been tested in a rodent model. 
Feeding Intervention Trials in Growing Rats 
 
 Studies performed on growing rats are summarized in Table 2-13 and discussed 
below. 
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Table 2-13. Summary of findings from PUFA feeding intervention trials in growing rats 1 
 
Reference Strain 
(Sex), 
Age 
Dietary 
Content 
(by weight) 
Intervention Diets Duration Bone-Related Outcomes 
Claasen, 
1995 (156) 
SD (M), 
4 weeks 
8% total fat Ratio of LA: ALA (3:1) 
(Control), 
GLA: EPA+DHA (3:1), 
GLA: EPA+DHA (1:1), 
GLA: EPA+DHA (1:3) 
6 wk • GLA: EPA+DHA (3:1) increased 
calcium balance compared to control 
(absorption, bone mineral calcium 
content, excretion) 
Yamada, 
1995 (218) 
Wistar 
(M), 6 
weeks 
6% total fat Soybean oil (6g/kg) 
(Control), 
Soybean + EPA (5.4 + 
0.6g/kg), 
Soybean + DHA (5.4 + 
0.6g/kg) 
7 wk • No effect on femur peak strength 
• EPA-supplementation increased 
calcium excretion, decreased plasma 
phosphorous and PTH compared to 
DHA-supplementation 
Li, 1999 
(219) 
SD (M), 
21 days 
7% total fat Soybean oil (Control), 
Ratio of SFO: menhaden 
oil (44:56) 
42 d • No effect on tibia histomorphometry, or 
bone calcium, phosphorous, or 
magnesium content 
Watkins, 
2000 (169) 
SD (M), 
21 days 
7% total fat Ratio of SFO: menhaden 
oil (90:10), 
SFO: menhaden oil 
(80:20), 
SFO: menhaden oil 
(50:50), 
SFO: menhaden oil 
(30:70) 
42 d • Decreasing PUFA ratio associated with 
increased BALP concentration 
• SFO: menhaden oil (30:70) diet 
increased bone formation rate 
compared to (90:10) diet 
Sirois, 2003 
(220) 
SD (F), 
21 days 
7% total fat Soybean oil (7g/kg), 
Soybean + menhaden oil 
(1 g/kg soybean + 6 g/kg 
menhaden oil) 
5 wk • No effect on femur BMD, BMC, or 
biomechanical strength properties 
• Menhaden oil diet decreased LV5 peak 
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load 
Reinwald, 
2004 (221) 
Long-
Evans, 49 
days 
7.8% total 
fat 
Modified AIN-93G with 
coconut and SFO, 
Modified AIN-93 G 
with 4.8g/kg flaxseed oil 
+ 3.0g/kg DHA 
8 wk • High n-6 to n-3 ratios in the tibia 
decreased bone growth, peak load and 
bending moment 
• No changes to femur mechanical 
properties 
Kruger, 
2005 (222) 
SD (M), 
5 weeks 
5% total fat Corn oil (Control), 
EPO, 
Fish oil (4% fish oil, 1% 
corn oil), 
Tuna oil (4% tuna oil, 
1% corn oil) 
6 wk • Tuna oil increased calcium balance 
compared to control (absorption, bone 
mineral calcium content, excretion)  
• Tuna oil increased lumbar spine and 
femur BMD compared to control 
• No changes to femur mechanical 
properties 
• RBC DHA-content associated with 
lumbar spine and femur BMD and 
BMC 
Lau, 2010 
(163) 
SD (M), 
40 days 
20% total 
fat 
SFA diet (18% coconut 
oil, 2% soybean oil), 
n-3 diet (20% flaxseed 
oil), 
n-6 diet (20% SFO)  
65 d • No difference in femur mechanical 
properties at the midpoint or BMC 
Li, 2010 
(165) 
Long-
Evans 
(M), 
PND 2 
10% total 
fat 
3.1% of total lipid as 
ALA (Control), 
15% of total lipid as LA, 
LA diet + 1% of total 
lipid as DHA,  
LA diet + 1% of total 
lipid as DPA, 
LA diet + 1% of total 
lipid as DHA + 0.4% as 
15 wk • All diets reduced distal femur BMC 
compared to control 
• DPA-supplementation decreased 
proximal femur BMC compared to 
control 
• No changes to femur midpoint or tibia 
bone mass or density 
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DPA 
Lukas, 2011 
(159) 
SD (F), 
28 days 
12% total 
fat 
Corn oil (73:1) 
(Control), 
Flaxseed oil (1:3), 
Krill oil (1:33), 
Menhaden oil (1:48), 
Salmon oil (1:23), 
Tuna oil (1:12) 
8 wk • Tuna oil increased tibia BMD 
compared to control 
• Flaxseed oil and menhaden oil 
increased femur BV/TV, Tb.N., and 
connectivity and decreased Tb.Sp. 
compared to control 
• Flaxseed increased tibia BV/TV 
compared to control 
• Flaxseed oil and menhaden oil 
increased Tb.N. and connectivity and 
decreased Tb.Sp. compared to control 
• No changes to femur or tibia cortical 
microarchitecture or mechanical 
properties 
• Flaxseed oil increased osteocalcin 
compared to salmon and tuna oil 
 
1 ALA; alpha-linolenic acid, BALP; bone specific alkaline phosphatase, BMC; bone mineral content, BMD; bone mineral density, 
BV/TV; percent bone volume, d; day, DHA; docosahexaenoic acid, DPA; docosapentaenoic acid, EPA; eicosapentaenoic acid, EPO; 
evening primrose oil, F; female, GLA; γ-linoleic acid, LA; linoleic acid, M; male, PND; post-natal day, PTH; parathyroid hormone, 
PUFA, polyunsaturated fatty acid, RBC; red blood cell, SD; Sprague-Dawley, SFA; saturated fatty acid, SFO; safflower oil, wk; 
week.
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Effect of Varying PUFA Source on Bone During Growth 
 
 While this thesis focuses on females, many of the studies investigating effects of 
PUFA source on bone growth have studied male rodents.  One of the first studies to 
determine the effect of different n-6 to n-3 ratios and the impact of essential fatty acids 
compared to their longer chain derivatives was conducted in 5-week old, male, SD rats 
(156).  Following randomization to a diet consisting of either LA to ALA in a 3:1 ratio or 
its derivatives γ-linoleic acid to EPA and DHA in a 3:1 ratio (both diets made up of 8% 
total fat) for 6 weeks, the longer chain PUFA diet caused an increase in intestinal calcium 
absorption and bone calcium content and a decrease in urinary calcium excretion.  These 
early findings suggest that derivatives of the essential fatty acids may be more effective 
in modulating calcium balance than their precursors (156).  A follow-up study conducted 
by the same authors also suggested that diets supplemented with γ-linoleic acid and EPA 
inhibited bone resorption, as measured by urinary collagen cross-link markers, compared 
to diets supplemented with LA and ALA (160).  
 To understand the importance of n-3 PUFA in the diet, one study of the offspring 
of n-3 deficient female Long-Evans rats found that even after n-3 repletion through diet 
(4.8 + 3.0 g/kg diet of flaxseed oil + DHA), the mechanical properties of the tibia were 
altered compared to the n-3 adequate controls (221).  This suggests that high n-6 to n-3 
PUFA ratios fed during the bone modeling process early in life in rapidly growing rats 
can cause structural changes that ultimately alter bone strength.  Another study of young, 
male rats investigating the effect of the different long chain n-3 PUFA found no effect of 
feeding diets made up of 6% fat by weight of soybean oil control, soybean oil + EPA, or 
soybean oil + DHA on femur peak strength (218).  EPA-supplementation over 7 weeks 
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did however increase urinary calcium excretion and decrease plasma phosphorous and 
parathyroid hormone concentrations compared to rats not receiving EPA.  DHA-
supplementation did not cause a similar trend in results, suggesting a difference in the 
effect of the long chain n-3 PUFA on bone related outcomes. 
 In support of these findings of a benefit of DHA to bone health, supplementation 
of 5-week, male SD rats for 6 weeks with diets consisting of corn oil, evening primrose 
oil (high n-6 γ-linoleic acid content), fish oil (high n-3 EPA content), or tuna oil (high n-3 
DHA content) suggested diets high in DHA are more effective than EPA in preserving 
bone mass and increasing calcium bioavailability (222).  Tuna oil caused significant 
increases in calcium absorption, total bone calcium content, lumbar spine and femur 
BMD compared to corn oil-fed controls.  The concentration of DHA in the red blood cell 
membranes was also significantly correlated with femur and lumbar spine BMD and 
BMC (222).  Together, these results support the effectiveness of DHA over EPA, γ-
linoleic acid, and corn oil for bone health related outcomes in young, growing, male rats. 
 Studies comparing the essential n-3 fatty acid, ALA, and its longer chain 
derivatives are limited.  Weanling female SD rats fed either 7% by weight soybean oil 
(rich in ALA) or soybean and menhaden oil (1 g soybean oil/kg + 6 g menhaden oil/kg) 
for 5 weeks did not experience differences in femur BMD, BMC, or biomechanical 
strength properties, although LV5 peak load was decreased in soybean oil + menhaden oil 
fed rats (220).  Another comprehensive, comparative study determined the effect of 
feeding n-3 from varying dietary sources to the bone mass, microarchitecture, strength, 
and markers of formation and resorption in young, growing female rats (159).  Twenty-
eight day old female SD rats were fed a higher fat diet (12% total fat) composed of corn 
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oil, flaxseed oil, krill oil, menhaden oil, salmon oil, or tuna oil for 8 weeks.  These diets 
differed in the ALA, EPA, and DHA content and ratio.  Only feeding krill oil (highest 
EPA to DHA ratio of the oil sources) failed to improve any aspect of bone health.  
Feeding flaxseed (highest ALA content) and menhaden oil (lowest n-6 to n-3 ratio of the 
oil sources) had positive effects to trabecular microarchitecture of the femur and tibia 
compared to control, while no diet had an effect on cortical outcomes of the long bones 
(159).  Of the diets tested, flaxseed oil and menhaden oil had the highest ALA content, 
suggesting that ALA improves the microarchitecture of the long bones in growing female 
rats.  No differences were observed between flaxseed oil and menhaden oil fed groups, 
possibly due to the large discrepancy in n-6 to n-3 PUFA ratio between these diets 
(flaxseed oil, 1:3 PUFA ratio versus menhaden oil, 1:48 PUFA ratio).  Furthermore, this 
is the only study to quantify the microarchitecture of the long bones of young rats by µCT 
in response to PUFA-supplementation.  These microarchitecture changes did not 
correspond to improvements in femur or tibia strength or to calcium or phosphorous 
balance compared to control.  No diet improved both bone mass and bone 
microarchitecture, highlighting a differential effect of each of the n-3 PUFAs, which may 
be influenced by the ratio in which they exist in the diet.  Studies in this thesis further 
elucidated the effects of feeding flaxseed oil versus menhaden oil at similar 
experimentally controlled PUFA ratios on the microarchitecture of the tibia during 
periods of rapid growth by incorporating these oils in the diets of 28-day old female SD 
rats and after following their development to young adulthood (1 through 3 months) and 
for 3 months following OVX-induced bone loss.  As discussed previously, exposure to 
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nutrients over the life course, such as PUFA, may provide protection from the hormone-
related bone loss experienced following OVX, although this has never been tested. 
 To differentiate between the effects of DHA and its n-6 series equivalent, 
docosapentaenoic acid (DPA, 22:6n-6), Long-Evans rats at postnatal day 2 were either 
dam-reared by mothers fed a diet consisting of 3.1% of total lipids as ALA or artificially 
reared with rat milk containing 15% of total lipids as LA (n-3 deficient), LA diet + 1% of 
total lipids as DHA, LA diet +1% of total lipids DPA, or LA diet + 1% of total lipids as 
DHA + 0.4% DPA (165).  At postnatal day 21, rats were weaned onto pelleted diets of 
the same treatment type and following 15 weeks of feeding, a trend towards lower BMD 
and BMC of the femur, tibia, and LV from rats fed DPA was observed, although these 
results were not statistically significant.  Of importance to note in this study, no 
differences were observed in outcomes measured by DXA between rats randomized to a 
diet of ALA (3.1% of total lipids) or a diet of DHA (1% of total lipids), although those 
receiving ALA had three-fold greater n-3 PUFA by weight in the diet (165).  These 
results suggest that the tibia, femur, and LV are able to adapt to the PUFA source 
incorporated in the diet at very early life and regardless of diet, the bones are able to 
develop similarly.  The effect of PUFA source on bone structure by µCT was not 
examined in this study. 
Effect of Varying PUFA Ratio on Bone During Growth 
 
 While feeding intervention trials in animals allow for the strict manipulation of 
specific dietary components to understand the impact of a single PUFA source, what may 
be more reflective of the human diet is the study of the n-6 to n-3 PUFA ratio on bone 
health.  To elucidate the effect of varying ratio of n-6 to n-3 PUFA on the bone health, 
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two studies have used young, growing, 21-day old male SD rats randomized to receive 
diets of varying n-6 to n-3 ratios for 42-days (169, 219).  Fat from these diets made up 70 
g/kg of total diet and the ratio of PUFA were altered with the addition of LA and 
EPA/DHA from safflower oil and menhaden oil, respectively.  In the first of these 
studies, soybean oil control (n-6 to n-3 PUFA ratio of approximately 6.5:1) caused an 
increase in ex vivo PGE2 production from tibia and femur bone culture compared to 
safflower oil and menhaden in a 44:56 ratio by weight but no changes in the 
histomorphometry of the tibia were observed (219).  In a follow-up study from the same 
authors, rats were randomized to receive 1 of 4 diets made up of safflower oil and 
menhaden oil ratios by weight in the following proportions: (90:10), (80:20), (50:50), 
(30:70) (169).  These proportions resulted in dietary n-6 to n-3 PUFA ratios of 23.8, 9.8, 
2.6, and 1.2 to 1, respectively.  The commonly used control diet, AIN-93G, provides 7% 
fat by weight from soybean oil, and provides a PUFA ratio of 6.5:1.  Of importance to 
note, the total PUFA of each diet was decreased with the decreasing ratio, which may 
have impacted the results of this study.  With a decreasing n-6 to n-3 ratio in the diet, an 
increase in the bone formation marker bone alkaline phosphatase was observed.  
Histomorphometric analysis of the proximal tibia resulted in significant increase in bone 
formation rate between diets of the highest and lowest PUFA ratio.  Ex vivo PGE2 
production from the rat tibia was negatively correlated with bone formation rates, which 
supports a positive effect of low n-6 to n-3 PUFA ratios in the diet of young, growing 
male rats for improved bone outcomes by decreasing PGE2 signaling (169, 219).  
Changes to bone structure with altered dietary PUFA ratio was not measured in either of 
these studies and remains unknown. 
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Effect of High-Fat PUFA Diet on Bone During Growth 
 
 While most studies of young, growing rats involve the impact of low to moderate 
fat diets, one study has investigated the impact of high-fat diets (20% fat by weight) with 
fats from coconut oil (saturated fat), flaxseed oil (n-3 PUFA in the form of ALA), or 
safflower oil (n-6 PUFA in the form of LA) compared to chow-fed rats (5.2% fat by 
weight) on bone related outcomes in 40-day old male SD rats (163).  Following 65 days 
of feeding, the fatty acid composition of the femur reflected the fatty acid composition of 
the diet but these changes did not alter femur BMD or biomechanical strength properties 
of the femur midpoint between rats fed the high-fat diets (163).  High-fat diet feeding 
caused significant increases in the unadjusted biomechanical strength properties: yield 
load, resilience, stiffness, peak load, toughness and the BMD and BMC of the femur 
compared to normal chow-fed rats.  After adjustment for body weight, all differences 
were lost except, rats fed n-3 PUFA or n-6 PUFA rich diets experienced greater peak load 
at the femur midpoint, suggesting some benefit to these high-fat PUFA rich diets in this 
cortical bone site. 
Summary of Findings in Growing Rats 
 
 Most studies of feeding intervention trials in young, growing rats have shown 
some benefit to bone health related outcomes during this period of rapid growth and bone 
modeling, although only one study has been conducted in female rats.  Growing female 
rats reach sexual maturity at 6 weeks of age (223), and so there may be potential sex 
differences between males and females and the effect of feeding interventions on bone-
related outcomes by this age.  Several studies have suggested a benefit with consumption 
of a lower n-6 to n-3 PUFA ratio (159, 169, 221), but the source of n-3 PUFA seems to 
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have an effect.  Generally, a benefit to bone has been observed with DHA-
supplementation (159, 165, 222) and a detriment with EPA-supplementation (159, 218) 
suggesting that the long chain n-3 PUFA have different effects when fed to growing rats. 
 Only two studies have directly compared the effect of feeding ALA from flaxseed 
to other fat sources in young rats (159, 163).  Feeding diets with 20% and 12% fat from 
flaxseed does not affect bone strength compared to coconut oil or safflower oil or 
compared to marine sources of long chain n-3 PUFAs, respectively (159, 163), but the 
latter diet supplemented for 8 weeks did result in changes to bone microarchitecture 
(159).  Only one study to date has investigated the effect of ALA-supplementation from 
flaxseed compared to similar amounts of the long chain n-3 PUFA, EPA and DHA, from 
fish oil sources.  Although this study furthers our understanding of PUFA and bone 
health, the quantities and ratios implemented in this feeding trial are supra-physiological 
and do not represent typical human consumption patterns (159).  The average Western 
diet provides n-6 to n-3 PUFA ratios of roughly 15 through 17:1 (155), but the studies 
reviewed above provide a range of PUFA ratios from 73:1 to as low as 1:38 (159). 
 While several studies have investigated the impact of feeding intervention trials 
on the growth and development of bone tissue, the effect of similar nutritional 
interventions to provide potential protection against OVX-induced bone loss have also 
been studied.  To date, no studies have followed the same rat longitudinally to examine 
the effect of lifelong exposure to PUFA interventions through growth, young adulthood, 
and following OVX.  Therefore, this was a primary objective of Study 4 of this thesis. 
Feeding Intervention Trials in OVX Rats 
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 Several animal studies have been conducted using the OVX rat as a pre-clinical 
model of postmenopausal osteoporosis to determine the effect of dietary PUFA intake on 
bone health related outcomes.  Studies performed on OVX rats are summarized in Table 
2-14 and discussed below. 
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Table 2-14. Summary of findings from PUFA feeding intervention trials in OVX rats 1 
 
Reference Age at 
OVX 
(Strain) 
Dietary 
Content 
(by weight) 
Intervention Diets Duration Bone-Related Outcomes 
Sakaguchi, 
1994 (224) 
17 wk 
(SD) 
3.4% from 
fat 
Corn oil (control), 
Corn oil low calcium, 
3.1% Corn oil + 0.3% EPA, 
3.1% Corn oil + 0.3% EPA 
low calcium 
35 days • EPA-supplementation increased femur 
midpoint strength when calcium is deficient 
Kruger, 1997 
(225) 
11 wk 
(SD) 
8% from fat LA: ALA (3:1) (control), 
GLA: EPA+DHA (9:1), 
GLA: EPA+DHA (3:1), 
GLA: EPA+DHA (1:3), 
GLA: EPA+DHA (1:9) 
6 weeks 
(initiated 1 
week post-
OVX) 
• RBC DGLA concentrations negative 
correlated with urinary deoxypyridinoline 
• RBC EPA, DGLA, and DHA 
concentrations positively correlated with 
femur calcium content 
Schlemmer, 
1999 (226) 
11 wk 
(SD) 
1% from fat 1% Sunflower oil (control), 
1% Sunflower oil + 1g/kg 
GLA+EPA 
3 weeks • No effect on femur length or calcium 
content of the femur 
• No effect on deoxypyridinoline or 
osteocalcin concentrations 
Watkins, 
2005 (170) 
2 mo 
(SD) 
11% from 
fat 
100% from SFO (344:1), 
72.6% from SFO + 27.4% 
from menhaden oil (5.6:1) 
12 weeks 
(initiated 1 
week post-
OVX) 
• Lower PUFA ratio increased tibia BMC in 
vivo and ex vivo 
• Lower PUFA ratio increased femur and 
tibia length 
• No effect on serum biomarkers or 
histomorphometry of the tibia 
Poulsen, 
2006 (227) 
8 mo 
(SD) 
4% from fat Corn oil (control), 
3.8% Corn oil + 0.2% EPA 
(0.1 mg/kg body weight), 
2.2% Corn oil + 1.8% EPA 
(1.0 mg/kg body weight) 
10 weeks • High dose EPA-supplementation reduced 
femur BMC and BMD compared to control 
• No change in LV BMC or BMD 
• High dose EPA-supplementation increased 
CTX-1 concentrations compared to Sham 
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Watkins, 
2006 (141) 
3 mo 
(SD) 
11% from 
fat 
76% from SFO + 24% from 
DHA (5:1), 
87% from SFO + 13% from 
DHA (10:1), 
87% from high-oleate SFO 
+ 13% from DHA (5:1), 
93% from high-oleate SFO 
+ 7% from DHA (10:1) 
12 weeks • Lower PUFA ratio increased femur BMC 
• Higher PUFA content in the diet increased 
serum pyridinoline and deoxypyridinoline 
and decreased osteocalcin concentrations 
compared to low PUFA diets 
Poulsen, 
2007 (166) 
7 mo 
(SD) 
4% from fat Corn oil (control), 
3.3% Corn oil + 0.7% GLA, 
3.3% Corn oil + 0.7% EPA, 
3.3% Corn oil + 0.7% DHA, 
3.3% Corn oil + 0.2% GLA 
+ 0.1% EPA + 0.4% DHA 
16 weeks • No change in LV or femur BMC or BMD 
compared to control 
• DHA-supplementation decreased LV BMC 
percent change from baseline and increased 
tibia endosteal circumference compared to 
control 
• GLA-supplementation increased femur 
BMC percent change from baseline and 
tibia trabecular bone area and decreased 
break stress compared to control 
Poulsen, 
2008 (228) 
7 mo 
(SD) 
4% from fat Corn oil (control), 
3.3% Corn oil + 0.7% DHA 
18 weeks • DHA-supplementation increased femur 
BMC and BMD compared to control 
(DXA) 
• No effect on biomechanical properties of 
the femur 
• No effect on LV BMC and BMD 
• DHA-supplementation increased trabecular 
BMC of the tibia (high-resolution pQCT) 
Boulbaroud, 
2008 (229) 
3 mo 
(Wistar) 
7 or 10% 
from fat 
Corn oil (control), 
Sesame oil, 
Flaxseed oil 
4 weeks • 10% sesame oil and flaxseed oil 
supplementation reduced serum BALP and 
TRAP activity 
Matsushita, 12 mo, 4% from fat Soybean oil (control), 10 weeks • Menhaden oil increased whole femur BMC 
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2008 (230) retired 
breeder 
(SD) 
Menhaden oil and BMD (distal femur) and percent 
mineralizing surface and mineral apposition 
rate on endocortical surfaces of the femur in 
OVX rats only 
• No effect on serum CTX concentrations 
Sacco, 2009 
(139) 
3 mo 
(SD) 
4% from fat 
(Control) 
Soybean oil (4%) (control), 
4% Soybean oil + 10% 
Flaxseed 
12 weeks • No change in BMC, BMD, or 
biomechanical properties of the femur, 
tibia, or LV 
Sacco, 2014 
(231) 
3 mo 
(SD) 
4% from fat 
(Control) 
Soybean oil (4%) (control), 
4% Soybean oil + 10% 
Flaxseed 
2 weeks, 
12 weeks 
• Flaxseed-supplementation increased OPG 
concentrations (2 weeks) 
• Flaxseed increased osterix-positive cells 
compared to control (12 weeks) 
• No change in LV trabecular 
microarchitecture (µCT) (12 weeks) 
 
1 ALA; alpha-linolenic acid, BALP; bone specific alkaline phosphatase, BMC; bone mineral content, BMD; bone mineral density, 
CTX; C-terminal telopeptide, DGLA; dihomo- γ-linoleic acid, DHA; docosahexaenoic acid, DXA; dual energy X-ray absorptiometry, 
EPA; eicosapentaenoic acid, GLA; γ-linoleic acid, LA; linoleic acid, LV; lumbar vertebrae, mo; month, OPG; osteoprotegerin, OVX; 
ovariectomy, pQCT; peripheral quantitative computed tomography, PUFA; polyunsaturated fatty acid, RBC; red blood cell, SD; 
Sprague-Dawley, SFO; safflower oil, TRAP; tartrate-resistant acid phosphatase, µCT; micro-computed tomography, wk; week. 
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Effect of Varying PUFA Source on Bone in OVX Rats 
 
 To examine the specific effects of PUFA source on bone health, one short-term 
study of 11-week OVX SD rats supplemented either 1% sunflower oil (high LA content) 
or 1% sunflower oil + 1g/kg γ-linoleic acid +EPA diester (226).  In this study, γ-linoleic 
acid +EPA supplementation did not alter serum markers of bone turnover or urinary 
markers of collagen breakdown and had no effect on femur calcium content or femur 
length.  The lack of effects may be due to the short duration of feeding following OVX, 
as rats were only supplemented with their respective diet for 3-weeks post-OVX.  The 
lack of effects may also be due to the low fat content in the diets. 
 One of the first studies conducted to compare the effect of EPA with and without 
adequate amounts of calcium in the diet to a corn oil diet control suggests a benefit to 
EPA-supplementation (224).  EPA levels as low as 0.3% of total energy intake (with 
3.1% total energy from corn oil) were sufficient to rescue femur midpoint peak strength 
and femur wet weight in female SD rats over 35 days when calcium intake was deficient 
(0.01% calcium) but did not provide added benefit when dietary calcium was adequate 
(1.26% calcium) (224).  In contrast, a study evaluating the effect of 10-week 
supplementation with a low (3.8% corn oil + 0.2% EPA) or high (2.2% corn oil + 1.8% 
EPA) EPA diet on 8-month OVX SD rats reported a detrimental effect of high dose EPA 
(227).  To limit any baseline variations between groups, the authors of this study 
provided all groups with 0.5% calcium in the diet, and 4-weeks prior to OVX or Sham-
surgery, all groups were fed the 4% corn oil control diet.  With a higher EPA-
supplemented diet, a decrease in femur BMD and BMC was observed compared to OVX 
control-fed rats (4% fat from corn oil) at study endpoint.  High-dose EPA groups 
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experienced the greatest reduction in percent BMD and BMC of the femur and LV, 
suggesting a diet of 2.2% corn oil with 1.8% EPA exacerbates the deleterious effects 
following OVX compared to corn oil control (227).  A follow-up study of 7-month OVX 
SD rats fed either control diet with 4% corn oil or 3.3% corn oil + 0.7% from either γ-
linoleic acid, EPA, DHA, or a combination for 16-weeks found γ-linoleic acid-
supplementation reduced break stress (N/mm2) of the femur but increased trabecular area 
of the tibia compared to control-fed OVX rats (166).  γ-linoleic acid-supplementation in 
the diet exacerbated the percent change of femur BMD from baseline to endpoint, while 
DHA-supplementation reduced the percent change in LV BMC compared to control rats.  
These diets differed not only in their PUFA source, but also the PUFA ratio.  γ-linoleic 
acid diets provided rats with a 31:1 ratio of n-6 to n-3 PUFA, while DHA diets provided a 
4.5:1 PUFA ratio.  DHA and EPA-supplementation each increased endosteal 
circumference of the tibia, suggesting a benefit to cortical bone with long chain n-3 
PUFA feeding.  Further investigation of the effect of DHA-supplementation in 7-month 
OVX SD rats found increased femur BMC and BMD as measured by DXA and increased 
tibia trabecular BMC as measured by high-resolution pQCT compared to control-fed 
OVX rats (4% corn oil compared to 3.3% corn oil + 0.7% DHA for 18 weeks) (228).  
These changes did not however result in changes to mechanical properties of the femur.  
Together, these findings highlight a benefit of DHA incorporation in the diet to the 
trabecular bone following OVX.   
 Much work has focused on the effect of the long chain n-3 PUFA on bone health, 
but only three studies in the OVX rat have investigated the effect of the essential n-3 
PUFA, ALA (139, 229, 231).  Following a 4-week supplementation period in 3-month 
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Wistar rats fed 10% fat by weight from corn oil control, flaxseed oil, or sesame oil, both 
intervention diets reduced serum bone alkaline phosphatase levels and tartrate-resistant 
acid phosphatase activity, suggesting an overall effect of PUFA on bone cell activity 
(229).  Interestingly, similar results were not observed when these fats were incorporated 
as 7% by weight (229).  Both as part of larger studies, 3-month SD rats provided with 
diets supplemented with 10% flaxseed were compared to their AIN-93M fed controls 
(4% fat from soybean oil).  Following 2-weeks of supplementation, a sufficient time 
point for monitoring changes to bone metabolism, rats receiving flaxseed experienced 
higher serum OPG concentrations compared to control, but no changes in other 
biomarkers of bone turnover were observed (231).  Twelve-week feeding of 10% 
flaxseed diets did not alter BMD of biomechanical strength properties of the lumbar 
spine, femur, or tibia (139), or µCT-related trabecular outcomes of LV (231).  Flaxseed 
supplementation did however increase the number of osterix-positive cells compared to 
control, suggesting a higher osteoblast number (231).  These results were part of a larger 
study, which found that flaxseed supplementation acts synergistically with low dose 
estrogen to provide metabolic and structural benefits to bone following OVX-induced 
bone loss. 
Effect of Varying PUFA Ratio on Bone in OVX Rats 
 
 To assess the effect of dietary PUFA ratio, a 12-week study of 3-month OVX SD 
rats was undertaken (141).  In this study, OVX rats were randomized to 1 of 5 diets with 
25% of energy derived from fat (11% total fat by weight).  The diets had either a high 
PUFA content (68% of total fat from PUFA) or low PUFA content (37% of total fat from 
PUFA) and a PUFA ratio of either 10:1 or 5:1, with almost all of the n-3 PUFA derived 
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from DHA.  Feeding a 5:1 PUFA ratio resulted in greater femur BMC compared to rats 
fed a 10:1 ratio when measured both in vivo and ex vivo and the ratio of tissue LA to total 
n-3 was negatively correlated with femur BMC, suggesting that lowering the PUFA ratio 
of the diet may play a significant role in minimizing bone mineral loss in the femur 
following OVX when n-3 PUFA is provided as DHA (141).  Total PUFA intake did not 
have an effect on femur bone mineral, but high PUFA intake caused a significant 
decrease in osteocalcin and an increase in serum pyridinoline and deoxypyridinoline 
compared to low total PUFA intake.  This suggests that diets lower in total PUFA content 
promote bone formation and reduce markers of resorption (141).  With the design of this 
study, the authors were able to investigate the effect of both total PUFA and PUFA ratio 
in the OVX model and found beneficial effects to feeding lower total PUFA and to 
feeding lower PUFA ratios.  Although total fat was matched, total saturated fatty acid 
(SFA) and total monounsaturated fatty acids (MUFA) varied across all diets. 
 Other studies investigating the role of PUFA ratio and bone health have yielded 
similar results supporting the benefit of a low PUFA ratio and the preservation of bone 
health (170, 225), although very few studies have investigated the effect on 
microarchitecture by µCT.  In one study of 12-week OVX SD rats randomized to receive 
a control diet consisting of LA: ALA in a 3:1 ratio, or γ-linoleic acid: EPA+DHA in a 
9:1, 3:1, 1:3, or 1:9 ratio with all fat contributing to 8% of the diet by weight, red blood 
cell concentrations of dihomo-γ-linoleic acid (the downstream derivative of γ-linoleic 
acid), EPA, and DHA were significantly correlated with calcium content of the femur 
(225).  Only dihomo-γ-linoleic acid concentrations were negatively correlated with 
urinary deoxypyridinoline concentrations, however.  Comparison of 2-month OVX SD 
 106 
rats supplemented for 12 weeks with a PUFA ratio of 344:1 (with 100% of fat from 
safflower oil) or 5.6:1 ratio (with 72% fat from safflower oil and 27% fat from menhaden 
oil) resulted in benefits to the femur and tibia with lower PUFA ratios (170).  While these 
results support a benefit to bone health following OVX with feeding lower dietary PUFA 
ratios, these studies utilize PUFA ratios that are not representative of a typical human 
dietary pattern.  For this thesis, the dietary ratio of PUFA was altered to more closely 
mimic human PUFA intakes (10:1 versus 5:1) and fed to female SD rats to further 
elucidate the effect of varying PUFA ratio on the trabecular and cortical 
microarchitecture of bone (Study 4). 
PUFA Effects in Sham and OVX Rats Differ 
 
 In most studies of the OVX rat model, the effect of PUFA intervention diets are 
only assessed in OVX animals and all results are compared to one group of Sham-
operated and OVX rats receiving control diet.  This strategy is used to minimize groups 
and overall animal numbers, but there is evidence that bone from Sham-operated/control 
rats and from OVX rats does not respond to feeding trials of PUFA similarly (230, 232).  
Study 4 of this thesis determined the differential effects of PUFA exposure over the life 
course in Sham and OVX rats to bone microarchitecture outcomes of the proximal tibia. 
 To assess the effect of soybean oil compared to menhaden oil, 12-month retired 
breeder SD rats were fed diets with 4% of energy derived from soybean or from 
menhaden oil for 10-weeks following Sham-control or OVX (230).  Menhaden oil 
supplementation caused increases in femur BMC and BMD (distal femur only) measured 
by DXA compared to their soybean-fed OVX controls.  Menhaden oil supplementation in 
OVX rats also caused increased rates of mineral apposition and percent mineralized 
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surface on the endocortical surfaces of the femur midpoint compared to OVX controls.  
No differences in serum CTX concentrations, a marker of bone resorption was observed 
(230), suggesting menhaden oil causes an increased rate of bone formation but not 
resorption in OVX rats. These results were not observed when menhaden oil was 
supplemented in Sham-operated rats compared to soybean oil control, suggesting a 
beneficial role for long chain n-3 PUFAs only in circumstances of estrogen deficiency 
induced bone loss. 
 Similarly, supplementation with 15% soybean oil or 10% sesame oil for 8-weeks 
in OVX SD rats caused changes to serum calcium, phosphorus, magnesium, estrogen, 
parathyroid hormone, osteocalcin, and bone alkaline phosphatase but no effect of diet 
was observed in normal control rats fed similar diets (232).  A similar pattern of an effect 
of soybean and sesame oil supplementation in OVX rats only was found for femur BMD, 
calcium, phosphorous, and magnesium concentrations, and bone alkaline phosphatase 
activity.  Although findings from this study are interesting, the differences between 
normal and OVX rats cannot be directly compared as two species of rats were used 
(normal control Wistar rats compared to OVX SD rats) and the quantity of fat in the diet 
was not controlled across experimental groups (232).  These studies did not quantify the 
effects of dietary PUFA intake on bone microarchitecture outcomes, and so whether a 
differential effect of PUFA intake on Sham/control and OVX rats exists is unknown. 
Summary of Findings in OVX Rats 
 
 Similar to findings in growing rats, feeding intervention trials of the OVX rat 
have found a benefit with DHA-supplementation (141, 166) and a detriment with EPA-
supplementation (227) to bone health.  Limited studies of the essential n-3 fatty acid, 
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ALA have been conducted in OVX rats (139, 229, 231).  Moreover, no study has directly 
compared the effect of sources rich in ALA (i.e., flaxseed oil) with oils rich in its long 
chain derivatives, EPA and DHA, in the OVX rat.  Lowering the n-6 to n-3 PUFA ratio in 
the diet provides benefits to bone health related outcomes in OVX rats (141, 170, 225), 
although some studies provide PUFA ratios in the diet that are supra-physiological and 
do not represent dietary patterns that can be sustained in humans (170, 225). 
 To limit any differences at baseline, which may confound some of the changes 
induced by diet, many studies have incorporated a period of feeding a control diet prior to 
randomization (139, 156, 166, 226, 227, 231).  This period of pre-feeding ranges from 1 
to 4 weeks in the literature and provides an added level of control in these studies of 
OVX rats.  While this strategy limits any baseline variations between groups, this thesis 
is the first to investigate the potential protective effect of a pre-diet of varying PUFA 
source and ratio on bone health following OVX. 
Summary of Findings of Feeding Intervention Trials in Rats 
 
 Many studies have been conducted in rats to assess the effect of feeding various 
quantities and sources of PUFA, and generally, a benefit to bone health outcomes has 
been observed when compared to control diets, although very few studies have assessed 
changes to bone microarchitecture through µCT.  These studies can be categorized based 
on the life stage of the rat when the intervention is applied: during growth and bone 
modeling or following OVX and bone remodeling.  But, no study to date has combined 
these life stages and followed the response of a rat to a PUFA-feeding intervention 
throughout growth and in response to Sham or OVX surgery.  As benefits to bone health 
with PUFA-incorporation in the diet have been observed in growing rats, it can be 
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hypothesized that lifelong PUFA-supplementation may provide a protection to the age- 
and hormone-associated decline in bone health in older, OVX rats.   
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Chapter 3: Objectives and Hypotheses
 111 
Objectives 
 
The overall objective of this thesis is to characterize the µCT scanning method used to 
evaluate the changes to bone structure following OVX and exposure to a PUFA 
intervention over the life course in a rat model of postmenopausal osteoporosis. 
The specific objectives of this thesis are four-fold and uses a female rat model: 
1. To characterize the longitudinal changes in the proximal tibia microarchitecture 
over a 3-month period, following Sham or OVX-surgery at 3-months of age 
(Study 1). 
2. To determine if monthly repeated radiation exposure of the hind limb in Sham and 
OVX rats over a 3-month period alters the trabecular or cortical microarchitecture 
of the proximal tibia (Study 2). 
3. In rat proximal tibia, i) to determine the differences in bone structure from in vivo 
compared to ex vivo scans; ii) to determine how voxel size (9µm versus 18µm) of 
ex vivo scans modulated the quantification of bone structure; iii) to determine if 
the well characterized differences between Sham and OVX groups can be 
similarly detected with each scan protocol (Study 3). 
4. To determine how the dietary source of n-3 PUFA (ALA from flaxseed oil versus 
EPA and DHA from menhaden oil) and dietary ratio of n-6 to n-3 PUFA (10:1 
versus 5:1) modulate outcomes of bone health when fed from 1 month of age 
through to 6 months of age, following Sham or OVX surgery at 3 months of age 
(Study 4). 
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Hypotheses 
 
1. OVX rats but not Sham rats, will experience characteristic changes to trabecular 
and cortical microarchitecture of the proximal tibia including decreased BV/TV, 
Tb.N., Tb.Th., Ct.Th., Ec.Pm., Ct.Ar./Tt.Ar., and increased Tb.Sp., Ma.Ar., 
Ps.Pm. over a 3-month period (Study 1). 
2. Monthly repeated radiation exposure to Sham and OVX rats over a 3-month 
period will not alter the trabecular or cortical microarchitecture of the proximal 
tibia (Study 2). 
3. i) Scanning of the proximal tibia in vivo and ex vivo will not alter the 
quantification of trabecular of cortical microarchitecture in Sham or OVX rats  
ii) Scanning of the proximal tibia at a different voxel size (18µm versus 9µm) will 
alter the absolute quantification of trabecular and cortical microarchitecture 
parameters. 
iii) The expected difference between Sham and OVX groups will be detected 
similarly, regardless of scan protocol (Study 3). 
4. i) Feeding menhaden oil from 1 through 3 months of age will cause changes, 
generally considered to be beneficial, to microarchitecture outcomes of the 
proximal tibia compared to rats fed flaxseed oil. 
ii) Feeding menhaden oil from 1 through 6 months of age will cause changes, 
generally considered to be beneficial, to microarchitecture outcomes of the 
proximal tibia following Sham or OVX surgery at 3 months of age compared to 
rats fed flaxseed oil. 
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iii) Feeding a PUFA ratio of 5:1 from 1 through 3 months of age will cause 
changes, generally considered to be beneficial, to microarchitecture outcomes of 
the proximal tibia compared to rats fed a PUFA ratio of 10:1. 
iv) Feeding a PUFA ratio of 5:1 from 1 through 6 months of age will cause 
changes, generally considered to be beneficial, to microarchitecture outcomes of 
the proximal tibia following Sham or OVX surgery at 3 months of age compared 
to rats fed a PUFA ratio of 10:1 (Study 4). 
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Chapter 4: Experimental Approach 
 
 
 115 
Experimental Approach 
For this thesis, female rats were fed a diet of varying PUFA ratio and n-3 PUFA 
source from early life and following randomization to Sham- or OVX-surgery.  By 
measuring the changes to the trabecular and cortical microarchitecture and BMD of the 
rat at various stages of life and bone development the potential protective effect of PUFA 
incorporation in the diet, at levels representative of human dietary patterns was assessed. 
 As outlined in Chapter 2, several knowledge gaps exist in the literature 
surrounding the changes to the trabecular and the cortical microarchitecture of the long 
bones, as measured by µCT, in response to endogenous estrogen deficiency and to 
varying PUFA quantity and source within the diet at levels attainable through common 
dietary practice (i.e., not through supplementation).  This thesis fills these knowledge 
gaps through characterization and experimentation with the female SD rat either Sham-
operated or having undergone OVX at 3 months, coinciding with periods of bone 
modeling and remodeling (Figure 4-1).
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Figure 4-1. Summary of the experimental approach used to characterize the changes 
to bone microarchitecture in the rat model of postmenopausal osteoporosis by µCT 
and the investigation of lifelong PUFA-supplementation and bone health 
 
Study 1, 2, and 3 characterized the OVX rat model of postmenopausal osteoporosis 
through µCT.  Study 1 characterized the longitudinal changes to trabecular and cortical 
bone microarchitecture following Sham or OVX-surgery at 3 months of age in the rat.  
Study 2 and 3 evaluated the effects of scanning protocols (i.e., repeated irradiation, in 
vivo, ex vivo, pixel size) on the bone microarchitecture.  Study 4 investigated the effect of 
lifelong exposure to varying n-6 to n-3 PUFA ratio and n-3 PUFA source to bone 
microarchitecture, serum markers of bone formation and bone resorption, and to body 
composition.
Use of μCT for the characterization of OVX rat model of PM osteoporosis
Study 1 Study 2 Study 3
•  Sham versus OVX at 3 mo
•  Longitudinal in vivo μCT 
assessment at 3, 4, 5, 6 
months
•  Trabecular and cortical 
microarchitecture of the 
proximal tibia 
•  Sham versus OVX at 3 mo
•  Repeated in vivo μCT 
radiation exposure  
at 3, 4, 5, 6 months (right) 
versus single radiation  
exposure at 6 months (left)
•  Trabecular and cortical 
microarchitecture  
of the proximal tibia
•  Sham versus OVX at 3 mo
•  in vivo versus ex vivo μCT 
assessment at 18μm 
resolution
•  9μm versus 18μm resolution 
(ex vivo)
•  Trabecular and cortical 
microarchitecture  
of the proximal tibia
Use of μCT for the evaluation of life long PUFA-supplementation 
Study 4
•  Varying PUFA Source: ALA from flaxseed versus 
EPA+DHA from menhaden oil
•  Varying PUFA Ratio: 10:1 versus 5:1
•  PUFA-supplementation from 1 mo (growth, 
modeling) to 6 mo (adulthood, remodeling)  
 
•  Sham versus OVX at 3 mo
•  Trabecular and cortical microarchitecture of the 
proximal tibia at 3 and 6 mo, and LV at 6 mo
•  OPG and RANKL serum concentrations
•  In vivo body composition by μCT at 6 mo
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Study 1: Time-course of the changes to bone microarchitecture in the 3-month OVX 
rat model of postmenopausal osteoporosis 
 
 To characterize the longitudinal changes to bone microarchitecture during periods 
of modeling and remodeling, Study 1 assessed bone microarchitecture at monthly 
intervals over a period of 3 months in the female SD rat having undergone OVX or 
Sham-surgery at 3-months of age.  Although much work has been done in older SD rats, 
this study further characterizes the changes to the trabecular microarchitecture of younger 
rats, often used in nutritional and/or drug intervention studies for practical reasons 
discussed in Chapter 2.  Results from Study 1 added to the limited knowledge of 
longitudinal changes to in vivo cortical microarchitecture of the tibia. 
Study 2: Characterization of the effect of repeated radiation exposure by in vivo 
µCT scanning in rat tibia 
 
 With the development of the µCT and the ability to repeatedly image an animal in 
vivo, the potential effect of repeated X-ray radiation exposure to the very skeletal site 
under investigation must be elucidated.  Study 2 determined the effect of monthly 
repeated radiation exposure by µCT using the SkyScan 1176 scanner in 3-month old 
Sham and OVX SD rats to their contralateral hind limb, irradiated at study endpoint only.  
Findings from this study provided insight into whether changes observed over time are 
due to the intervention and not due to repeated radiation-induced effects. 
Study 3: Comparison of ex vivo and in vivo µCT of rat tibia at different scanning 
settings 
 
 Multiple considerations must be made during the experimental design of in vivo 
studies of animal models including primary outcome, time, cost, and animal welfare.  To 
reduce the cost and the time-sensitive nature of endpoint in vivo µCT scanning, Study 3 
investigated the difference between in vivo and ex vivo scanning of the tibia.  Secondary 
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to this, the effect of ex vivo scanning of the tibia with voxel sizes of 18µm and 9µm were 
compared to determine the effect of voxel size on trabecular and cortical outcomes of the 
proximal tibia in Sham and OVX rats. 
Study 4: Lifelong intake of flaxseed or menhaden oil to provide varying n-6 to n-3 
PUFA ratios modulate bone microarchitecture during growth, but not after OVX 
 
 Following characterization of the OVX model and the µCT method for 
quantification of trabecular and cortical microarchitecture of the proximal tibia, the effect 
of PUFA-supplementation in the diet was assessed.  Young (28-day old) female SD rats 
were randomized to receive diets with varying PUFA ratio (10:1 versus 5:1) and with 
varying n-3 PUFA source (ALA from flaxseed oil versus EPA and DHA from menhaden 
oil).  Prior to randomization to Sham or OVX-surgery at 3 months of age, rats underwent 
an in vivo µCT scan of the right proximal tibia.  To assess the effect of varying PUFA 
diets in response to Sham or OVX surgery, rats were maintained on their respective diet 
and underwent an in vivo µCT scan of the proximal tibia and of the body cavity 
surrounding LV3 at 6 months of age, coinciding with study endpoint.  Ex vivo µCT 
scanning of LV4 was done to assess an effect of diet at a second, non load-bearing 
skeletal site.  Trabecular and cortical microarchitecture were quantified from the in vivo 
and ex vivo µCT scans and in vivo body composition of the abdominal region surrounding 
LV3 was quantified.  At study endpoint, a serum marker of bone formation and bone 
resorption was quantified by multiplex enzyme assay. 
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Materials and Methods 
 
 All studies were approved by the Animal Care Committee of Brock University 
and conducted in accordance with the guidelines established by the Canadian Council on 
Animal Care (Study 1 and 2, AUP 13-11-01; Study 3 and 4, AUP 14-09-02). 
Animals, Food Intake, Body Weight, Diet 
 
 For Study 1 and 2, female virgin SD rats underwent Sham-control or OVX 
surgery at 12-weeks of age (n=12/group) and were obtained and entered into the studies 
following a 7-day recovery and acclimatization period from Charles River Canada (QC, 
Canada).  Rats were doubly housed with cage-mates of similar surgery type in a 
controlled environment (12-h light/dark cycle; 20ºC).  Rats were given ad libitum access 
to a control diet (AIN-93M, Harlan Teklad, Mississauga, Ont) and water.  Food intake 
was measured twice per week and body weight was measured weekly for the duration of 
the study.  Rats were sacrificed at 6 months of age.  Success of OVX was confirmed at 
necropsy by the visual determination of atrophy of the uterine horns. 
 For Study 3 and 4, 21-day old female virgin SD rats (n=120) were obtained from 
Charles River Canada (QC, Canada) and given ad libitum access to a control diet (AIN-
93G, Harlan Teklad, Mississauga, Ont) and water.  Rats were doubly housed in a 
controlled environment (12-h light/dark cycle; 20ºC).  Following a 7-day acclimatization 
period, rats were randomized to 1 of 4 dietary treatments modified from AIN-93G to 
contain 18% kcal from protein, 57% kcal from carbohydrate, and 25% kcal from fat.  
Diets were modified to contain an n-6 to n-3 ratio of 10:1 or 5:1 with LA provided 
primarily from safflower oil as the n-6 source and ALA provided from flaxseed oil or 
EPA and DHA provided from menhaden oil as the n-3 source.  Total SFA, MUFA, and 
 120 
PUFA were matched in all diets (Table 4-1).  Rats were given ad libitum access to food 
and water from 1 through 6 months of age.  At 3-months of age, rats were randomized to 
receive Sham-control or OVX surgery (n=12-13/group/diet) or to be sacrificed for 
baseline tissue collection (n=4-6/diet).  Body weight was measured weekly and food 
intake was measured three-times weekly.  To avoid oxidation, all diet was stored in 
vacuum-sealed bags at -20ºC until use and were changed twice per week.  Rats were 
sacrificed at 6 months of age (n=96).  Success of OVX was confirmed at necropsy by 
comparison of uterine weight between Sham and OVX groups. 
 Sham (n=8) and OVX (n=8) rats receiving a diet modified to contain an n-6 to n-3 
ratio of 10:1 with safflower oil as the primary n-6 source and EPA and DHA from 
menhaden oil as the primary n-3 source were used for Study 3.
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Table 4-1. Dietary composition of four experimental diets used in Study 4 1,2 
 
Component (g/kg) Flaxseed oil Menhaden oil 10:1  5:1 10:1 5:1 
Casein + L-Cysteine 203 203 203 203 
Corn Starch 357 357 357 357 
Maltodextrin 132 132 132 132 
Sucrose 100 100 100 100 
Cellulose 50 50 50 50 
Mineral Mix  35 35 35 35 
Vitamin Mix  10 10 10 10 
Choline Bitartrate 2.5 2.5 2.5 2.5 
TBHQ 0.022 0.022 0.022 0.022 
Safflower Oil 53 45 64.5 70 
Cottonseed Oil 45 43 26 4 
Flaxseed Oil 12 22 - - 
Menhaden Oil - - 19.5 36 
SFA 18.52 18.25 18.50 17.47 
MUFA 17.58 18.16 17.63 18.07 
PUFA 73.86 73.55 72.42 72.42 
n-6 67.13 61.32 64.97 58.21 
% kcal from n-6 14.8% 13.5% 14.3% 12.8% 
n-3 6.74 12.23 6.42 11.71 
% kcal from n-3 1.5% 2.7% 1.4% 2.6% 
n-6 to n-3 9.97 5.01 10.13 4.97 
Product ID TD.140812 TD.140813 TD.140814 TD.140815 
 
1 All diets were developed by Longo AB, Flowers J, and Ward WE (unpublished) and 
matched for macronutrient content (17.7% protein, 56.5% carbohydrate, 11.2% fat by 
weight) (17.8% protein, 56.8% carbohydrate, 25.4% fat kcal) and provided 4.0 kcal/g.  
Total SFA, MUFA, and PUFA were matched across all diets. 
 
2 ALA; alpha-linolenic acid, DHA; docosahexaenoic acid, EPA; eicosapentaenoic acid, 
MUFA; monounsaturated fatty acid, PUFA; polyunsaturated fatty acid, SFA; saturated 
fatty acid, TBQH; T-butylhydroquinone. 
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Sham and OVX Surgery 
 
 For Study 3 and 4, rats were randomized to receive Sham and OVX surgery at 3 
months of age on-site (Comparative Biosciences Facility, Principal Surgeon: Longo AB).  
Rats were anesthetized in an induction chamber using isoflurane (rate of delivery 
between 2-5%) and transitioned to a nose cone for maintenance of the anesthesia (2-5% 
delivery rate, as needed) and placed on a sterile surgery surface.  Metacam (analgesic) 
and Baytril (antibiotic) were injected subcutaneously prior to surgery.  A single dorsal 
skin incision and bilateral muscle incisions were made and the ovaries were exposed and 
removed of as much adipose tissue as possible, and removed (OVX).  Ovaries were 
exposed but not removed in the rats randomized to Sham-control surgery.  The muscle 
incisions were closed with dissolvable sutures and the dorsal skin incisions were closed 
with surgical staples.  After surgery, prior to recovery from anesthesia, Buprenorphine 
(analgesic) and isotonic saline (fluid replacement) were injected subcutaneously.  After 
recovery from anesthesia, rats were returned to a recovery cage and monitored for any 
complication for four hours post-surgery.  Cage-mates had similar surgery-type on the 
same day and were reunited two days post-op.  Rats were weighed and carefully 
examined for five days after surgery – with additional oral Metacam, injectable Baytril or 
injectable Buprenorphine being administered daily for up to three days when necessary 
(one case).  Surgical skin staples were removed under light isoflurane anesthesia 7-10 
days post-op. 
µCT Scanning 
 
 For all studies, Sham and OVX rats were initially anesthetized with isoflurane in 
an induction chamber with a 3-4% flow rate and later transferred to a nose cone with a 1-
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2% flow rate for maintenance of general anesthesia.  When scanning the hind limb, the 
leg was held secure with a customizable apparatus (Figure 4-2).  In the SkyScan 1176 
scanner, the X-ray beam is collimated, restricting radiation to the scan field of view only.  
Only the scanned leg, held in a polystyrene tube, was included in the field of view and 
therefore only that leg received exposure to radiation.  Rats were maintained under 
general anesthesia for approximately 25 minutes, which included the time for the 
induction of anesthesia and the acquisition of the scan.  When scanning the proximal tibia 
in vivo, the field of view began at the knee joint and extended distally 20 mm (Figure 4-
3).
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Figure 4-2. Representative image of the scan set-up for imaging of the rat hind limb 
 
Studies 1 through 4 used the above set-up for imaging of the rat hind limb in vivo.  Study 
2 involved scanning of the right and left hind limb. 
 
(Image by Longo AB, published in (233)) 
 
 
 
Figure 4-3. Representative images of the field of view of the rat hind limb 
 
A) Raw image and B) reconstructed image of the field of view of the in vivo rat hind limb 
with representative boxes of the region of interest analyzed.  Blue box represents ROI 
analyzed in Study 1 and Study 2.  Red box represents region of interest analyzed in Study 
3 and Study 4. C) Representative cross-section at which the growth cartilage begins to 
transition into the proximal tibia. 
 
(Image by Longo AB, unpublished, 2016). 
Scanner
Plastic tube
Foam Right knee extended Wrapped torso  
for temperature  
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 For Study 1 and 2, Sham and OVX rats underwent in vivo µCT scanning 
(SkyScan 1176, Bruker micro-CT, Kontich, Belgium) of the right hind limb at 13, 17, 21, 
and 25 weeks of age, coinciding with 1, 5, 9, and 13 weeks post-surgery at a voxel size of 
18µm.  For Study 2, the contralateral hind limb was scanned at 25 weeks of age (13 
weeks post-surgery) only, to serve as a non-irradiated internal control at a voxel size of 
18µm. 
 For Study 3, Sham and OVX rats underwent in vivo µCT scanning of the right 
hind limb at 24 weeks of age (12 weeks post-surgery).  Within one-week following in 
vivo scanning, rats were euthanized and the right tibia was excised, cleaned of soft tissue, 
wrapped in saline soaked gauze and stored at -80°C until subsequent scanning.  For ex 
vivo scanning of the right proximal tibia, bones were hydrated in phosphate buffered 
saline (Sigma, St. Louis, MO, USA) at room temperate for two hours and subsequently 
wrapped in parafilm wax.  Parafilm-wrapped tibias were held secure in foam in a plastic 
tube secured to the scan bed to limit movement.  Ex vivo tibias were scanned at both 
18µm and 9µm voxel sizes. 
 For Study 4, all rats underwent in vivo µCT scanning of the right hind limb at 3 
months of age, prior to Sham and OVX surgery at a voxel size of 18µm.  At 6 months of 
age, all rats underwent in vivo scanning of the right hind limb and of the abdomen at 
voxel sizes of 18µm and 35µm, respectively.  For ex vivo scanning of LV4, bones were 
hydrated in phosphate buffered saline at room temperature for two hours and 
subsequently wrapped in parafilm wax.  Parafilm-wrapped LV4 were held secure in foam 
in a plastic tube secured to the scan bed to limit movement.  Ex vivo LV4 were scanned at 
9µm voxel size. 
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 For all studies, scanning parameters were set to limit the scan duration while 
attaining a high quality image.  In vivo and ex vivo scan parameters used for image 
acquisition and reconstruction settings (NRecon, v. 1.6.9.10, Bruker micro-CT, Kontich, 
Belgium) of the proximal tibia, LV, and abdomen (for body composition) are 
summarized in Table 4-2.  The region of interest (ROI) of the tibia to be analyzed began 
2.64 mm (Study 1 and 2) or 1.76 mm (Study 3 and 4) distal from the point at which the 
growth cartilage begins to transition into the proximal tibia metaphysis and extended 3.52 
mm toward the ankle (Figure 4-3).  The ROI differed between Studies 1 and 2 and 
Studies 3 and 4 because of the drastic loss of trabecular bone that occurred 3-months 
post-OVX.  The ROI of the abdomen to be analyzed for body composition extended the 
length of one vertebral body (LV3). 
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Table 4-2. Scan, reconstruction, and analysis parameters by µCT 1 
 
 Tibia and/or LV4 Abdomen 
Scanning 
Parameters 18µm in vivo 18µm ex vivo 9µm ex vivo 35µm in vivo 
Voxel Size (µm) 18 18 9 35 
Voltage (kV) 60 60 68 60 
Amperage (µA) 200 200 385 385 
Filter 1mm Al 1mm Al 1mm Al 1mm Al 
Exposure Time 
(ms) 700 700 1140 90 
Rotation Step  
(over 360º) 0.5 0.5 0.2 0.7 
Approximate Scan 
Time (min) 12 12 44 9 
Reconstruction  
Parameters 
Filter Gaussian Gaussian Gaussian Gaussian 
Smoothing Kernel 3 1 1 8 
Ring Artifact 
Reduction 8 8 8 10 
Beam Hardening 
Correction (%) 30 30 30 30 
Attenuation 
Coefficient 0.000-0.058 0.000-0.058 0.000-0.054 0.000-0.070 
Analysis  
Parameters  
Thresholding Global, 102 Global, 102 Global, 102 
Non-lean, 1-34 
Lean, 35-93 
Bone, 94-255 
Trabecular 
Thresholding Adaptive, 76 Adaptive, 76 Adaptive, 76 N/A 
 
1 All µCT scans were obtained using the SkyScan 1176 model, Bruker micro-CT, 
Kontich, Belgium. 
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 The distinction between trabecular and cortical bone within the ROI of scans of 
the proximal tibia were defined and separated by automatic processes (created by Longo 
AB) and analyzed separately (CT Analyzer, v. 1.14.4.1 + (64-bit), SkyScan, Bruker 
micro-CT, Kontich, Belgium) (Figure 4-4).  In brief, bone tissue was identified by a 
global thresholding procedure followed by a series of morphological operations to 
separate the trabecular processes from the cortical shell.  Once segmented, trabecular and 
cortical regions were defined and saved as distinct ROIs.  Trabecular and cortical bone 
were binarized using an adaptive and global thresholding procedure, respectively.  The 
resulting ROIs were subsequently analyzed.  The trabecular microarchitecture 
measurements, including BMD, BV/TV, connectivity density (Conn.D), degree of 
anisotropy (DA), Tb.Th., Tb.N. and Tb.Sp. were quantified by 3D analysis of the defined 
ROI.  The cortical microarchitecture measurements, including BMD, cross-sectional area 
inside the periosteal envelope (Tt.Ar.), Ct.Ar., Ct.Ar./Tt.Ar., Ct.Th., Ps.Pm., Ec.Pm., 
Ma.Ar., and mean eccentricity (Ecc.) were performed using 2D analysis of the defined 
ROI.  A summary of the microarchitecture measurements assessed is outlined in Table 4-
3.  A summary and general description of the primary and secondary trabecular and 
cortical microarchitectural outcomes are reported in Table 4-4. 
 Non-lean mass, lean mass, and bone mass within the ROI of scans of the abdomen 
were defined and separated by global thresholding.  Thresholding values of 1-34, 35-93, 
and 94-255 were set for non-lean mass, lean mass, and bone mass, respectively.  The 
percent object volume (Obj.V/TV) was assessed by 2D analysis of the defined ROI (CT 
Analyzer, v. 1.14.4.1 + (64-bit), SkyScan, Bruker micro-CT, Kontich, Belgium) and 
made relative to the ROI length. 
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Figure 4-4. Representative (A) cross-section of proximal tibia with (B) cortical and 
(C) trabecular bone defined and separated by automatic processes 
 
Through a series of thresholding and morphological operations, the binarized B) cortical 
and C) trabecular bone can be defined, separated and analyzed.  The same process can be 
applied to all samples to automatically segment bone compartments without bias. 
 
(Image by Longo AB, published in (234))
Cross-sec(on	 Cor(cal	Only	 Trabecular	Only	
Sham	
OVX	
A	 B	 C	
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Table 4-3. Summary of microarchitecture measurements 1,2,3 
 
Trabecular Outcomes 
General Implication 
of a Higher Value 
for Bone Health 
BMD (g/cm3) • Volumetric mineral density per unit volume Positive 
BV/TV (%) • Percentage of area within the ROI occupied by bone Positive 
Conn.D  
(mm-3) 
• Number of redundant connections between 
trabecular structures per unit volume Positive 
DA (no unit) 
• Orientation of the trabecular network, 
1=isotropic (lacking orientation), 
>1=anisotropic (highly oriented) 
Positive 
Tb.Th. (mm) • Average thickness of the trabeculae Positive 
Tb.N. (mm-1) • Average number of trabeculae per unit length Positive 
Tb.Sp. (mm) • Average distance between trabeculae assessed by ‘3D sphere-fitting’ Negative 
Cortical Outcomes  
Tt.Ar. (mm2) • Cross-sectional area within the outer perimeter of bone (periosteum) Positive 
Ct.Ar. (mm2) • Area of the cortical bone only Positive 
Ct.Ar./Tt.Ar. 
(%) 
• Percentage of area within the ROI occupied 
by bone Positive 
Ct.Th. (mm) • Average thickness of the cortical bone Positive 
Ps.Pm. (mm) • Perimeter of the outer bone (periosteum) For interpretation of 
these 3 outcomes, 
factors such as age 
and hormonal status 
of the rat must be 
considered together 
Ec.Pm. (mm) • Perimeter of the inner bone (endosteum) 
Ma.Ar. (mm2) • Area of the medullary cavity 
Ecc. 
• Circular shape of bone, 0=circle, 
>0=toward ellipsoid 
Body Composition Outcome  
Obj.V/TV (%) • Percentage of area within the ROI occupied by binarized object 
(predefined by thresholding values) 
 1 BMD; bone mineral density, BV/TV, percent bone volume, Conn.D; connectivity 
density, Ct.Ar.; cortical area, Ct.Ar./Tt.Ar.; cortical area fraction, Ct.Th.; cortical 
thickness, DA; degree of anisotropy, Ec.Pm.; endocortical perimeter, Ecc.; mean 
eccentricity, Ma.Ar.; medullary area, Obj.V./TV; object area fraction, Ps.Pm.; periosteal 
perimeter, Tb.N.; trabecular number, Tb.Sp.; trabecular separation, Tb.Th.; trabecular 
thickness, Tt.Ar.; total bone area. 
 
2 Standardized nomenclature and units are derived from (61, 235). 
 
3 Bolded outcomes are primary outcomes.  Non-bolded outcomes are secondary 
outcomes.
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Serum Biochemical Markers 
 
 To assess serum markers of bone cell activity, serum OPG and RANKL were 
quantified using a Milliplex Rat OPG-Single Plex (RBN1MAG-31K-01, Millipore 
Canada, Toronto, Ont) and a Milliplex Rat RANKL-Single Plex (RRNKLMAG-31K-01, 
Millipore Canada, Toronto, Ont) according to the manufacturer’s instructions.  Data was 
collected using the MagPix (Luminex xMAP, Toronto, Ont).  The standard curve ranges 
from 10-40,000 pg/mL for OPG and 3.7-15,000 pg/mL for RANKL.  The minimum 
detection limit is 4.4 pg/mL for OPG and 2.6 pg/mL for RANKL.  All values were 
quantified in triplicate and determined by comparison to a standard curve prepared by the 
supplier.  
Statistical Analyses 
 
 Study 1: The effects of hormone status (with two levels: Sham and OVX), and 
time, and their interaction for each dependent variable (body weight, food intake) was 
investigated using a two-way repeated measures ANOVA.  Time was assessed on 13 
levels for analysis of weekly body weights and on 26 levels for analysis of twice weekly 
food intakes.  Where a significant interaction was found, a Bonferroni post hoc test was 
used to test the main effects between Sham and OVX rats at each time point. 
 A two-way repeated measures ANOVA was used to determine an effect of time 
post-surgery (13, 17, 21, and 25 weeks) and hormone status (Sham versus OVX) on 
longitudinal microarchitecture measures of the right proximal tibia.  Where a significant 
interaction was found, a Bonferroni post hoc test was used to test the main effects 
between Sham and OVX rats at each time point.  In the event of missing values, the series 
mean was used to replace those missing values.  Missing values resulted from rat 
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movement during the scan that caused poor image quality, not allowing for adequate 
analysis. 
 
 Study 2: To determine an effect of irradiation, a two-way ANOVA was used to 
compare the repeatedly irradiated right tibia to the non-irradiated left tibia with hormone 
status (Sham versus OVX) and irradiation frequency (right hind limb versus left hind 
limb) as independent factors at 25 weeks of age. 
 Study 3: A two-tailed independent t-test was used to determine differences in 
final body weights, final food intake, wet uterine weights, and microarchitecture 
outcomes between Sham and OVX rats.  The effect of scanning protocols (9µm ex vivo, 
18µm ex vivo, 18µm in vivo) for all trabecular and cortical morphological outcomes was 
assessed using a one-way ANOVA.  A Bonferroni post hoc test was used to compare 
differences between groups.  A Pearson’s correlation will be used to assess correlations 
between the microarchitecture outcomes calculated by 9µm ex vivo (independent 
variable) and 18µm ex vivo and 18µm in vivo (dependent variables) scanning protocols.  
It is well established that OVX has a drastic and deleterious effect to bone morphology at 
the proximal tibia.  For this reason, bone outcomes for Sham and OVX rats were further 
analyzed separately, so that the effect or interaction of hormone status did not 
overshadow any more subtle effects of scanning parameters.  A power analysis of each 
scanning protocol was performed retrospectively to determine the number of animals 
needed to identify differences in the primary microarchitecture outcomes between Sham 
and OVX groups.  Power was set at 0.80 and type I error rate was set at 0.05 for all power 
analyses. 
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 Study 4: A one-way repeated measures ANOVA was used to determine the effect 
of diet on body weight and food intake from 1 through 3 months of age.  A two-way 
repeated measures ANOVA was used to determine the effect of diet, hormone status and 
their interaction on body weight and food intake from 3 through 6 months of age.  A 
Bonferroni post hoc test was used to test the main effects of diet at each time point when 
a significant interaction was found. 
 A one-way ANOVA was used to determine the effect of diet on bone 
microarchitecture outcomes (proximal tibia and LV4) from 1 through 3 months of age.  A 
two-way ANOVA was used to determine the effect of diet, hormone status, and their 
interaction on uterine weights and bone outcomes at 6 months of age (proximal tibia, 
LV4, serum biomarkers).  Because changes in bone structure of the proximal tibia 
occurred between 1 through 3 months of age and because the same rat was followed 
longitudinally, the absolute difference in microarchitecture outcomes of the proximal 
tibia from 3 through 6 months of age was assessed using a two-way ANOVA.  This 
secondary analysis allowed for an investigation into the contribution of diet on the bone 
microarchitecture of the proximal tibia following Sham or OVX surgery.  
 Because of the strong effect of hormone status, bone microarchitecture outcomes 
for Sham and OVX groups at 6 months of age and the longitudinal change were analyzed 
independently within each hormone status group (Sham, OVX) by one-way ANOVA.  
This analysis was done to remove the large influence of hormone status and to allow any 
subtle effects of diet to be observed within each hormone status group.  A Bonferroni 
post hoc test was used to test the main effects of diet and/or hormone status when a 
significant interaction was found.   
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 All statistical analyses were performed using SPSS Statistics (v. 22, IBM).  The 
level of significance was set at p<0.05 for all analyses.  All food intake and body weight 
data are presented as Mean ± SEM.  All uterine weights, µCT data and serum biomarker 
data are presented as Mean ± SD. 
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Abstract 
 
In vivo µCT provides the ability to measure longitudinal changes to tibia 
microarchitecture, but the effect of this radiation is not well understood.  The right 
proximal tibia of SD rats (n=12/group) randomized to Sham-control or OVX surgery at 
12 weeks of age was scanned using µCT at 13, 17, 21, and 25 weeks of age, at a 
resolution of 18µm and a radiation dose of 603 mGy.  The left proximal tibia was 
scanned only at 25 weeks of age to serve as an internal non-irradiated control.  Repeated 
irradiation did not affect tibia microarchitecture in Sham or OVX groups, although there 
was an increase in cortical Ecc. (P<0.05).  All trabecular outcomes and cortical BMD 
were different (P<0.05) between groups after only 1 week post-surgery and differences 
persisted to study endpoint.  Characteristic changes to trabecular bone were observed in 
OVX rats over time.  Interactions of time and hormone status were found for cortical 
BMD (P<0.001), Ps.Pm., and Ec.Pm. (P<0.05).  Repeated irradiation of the tibia at 13, 
17, 21, and 25 weeks of age does not cause adverse effects to microarchitecture, 
regardless of hormone status.  This radiation dose can be applied over a typical 3-month 
study period to comprehensively understand how an intervention alters tibia 
microarchitecture without confounding effects of radiation. 
Introduction 
 
 µCT imaging is the gold standard for the direct 3-dimensional modeling and 
assessment of the trabecular and cortical microarchitecture in pre-clinical animal studies 
(2-4).  Of more recent interest is the ability to measure changes in vivo to bone 
microarchitecture at multiple time points throughout the lifespan in response to an 
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intervention.  Because µCT imaging is a non-destructive method, its use may 
substantively reduce the number of animals required for longitudinal testing of an 
outcome and allows for repeated measurement of the same animal, which may minimize 
the impact of inter-animal variability that may arise with a cross-sectional study design. 
 Although the data obtained from repeated µCT scanning may provide powerful 
evidence for a change in bone health in response to an intervention within the same 
animal, the effect of exposure to radiation may be detrimental to the very region under 
investigation (5-7).  Some studies investigating the effect of radiation exposure by µCT to 
the hind limb or rats suggest a resilience to 500 or 900 mGy radiation, respectively (6, 8), 
although one study of adult rats found a difference between irradiated and non-irradiated 
limbs after exposure to 400 mGy of radiation, repeated 5 times (5).  In a male mouse 
model, three repeated radiation doses of 776 mGy caused significant reductions in 
trabecular bone volume and Tb.N., while a similar scanning protocol applying 434 mGy 
caused no damage to the irradiated tibia (7).  High-radiation dose scans produce high-
quality images, but a balance must be struck between radiation exposure and images of 
sufficient quality to be analyzed.  While the skeletal site-specific loss of bone mineral and 
microarchitectural integrity after OVX is well characterized (9), whether hormone status 
modulates the skeleton’s susceptibility to radiation-induced damage is less well 
understood. 
 Because the OVX rat model is the most widely used pre-clinical model of 
osteoporosis and has been used extensively for developing prevention and treatment 
strategies (10, 11), the primary objective of this study was to investigate the effect of 
repeated irradiation to bone structure over a typical 12-week protocol by comparing the 
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irradiated and non-irradiated limb.  Although previous studies have investigated the 
effects of irradiation dose between 400 and 900 mGy per scan at intervals between 1 and 
20 weeks (5-8), this study used specific parameters that resulted in a low signal-to-noise 
ratio and high-quality images with a total absorbed dose of 2400 mGy delivered locally 
over 12 weeks.  Twelve weeks is a typical time period in which the response of an 
intervention is studied using the OVX rat model.  The average remodeling period in the 
rat and human is roughly 40 and 200 days, respectively (12, 13).  Therefore, a 12-week 
trial in the OVX rat results in approximately two complete remodeling cycles; this is 
roughly equivalent to a one to one-and-a-half year clinical trial in humans.  Also, the 
early increase in bone turnover favouring bone resorption as reported in postmenopausal 
women is mimicked in the first 14 days post-OVX in the rat model (12, 14).  Because no 
study to date has followed the same rat over a 12-week study period following OVX at 12 
weeks of age, to determine changes in both the trabecular and cortical bone using µCT, a 
secondary aim is to investigate the longitudinal effect of hormonal status on trabecular 
and cortical bone of the proximal tibia to further characterize this pre-clinical model of 
postmenopausal osteoporosis. 
Materials and Methods 
 
*See Chapter Four – Experimental Approach for methodologies regarding Animals and 
Diet, µCT, and Statistical Analyses 
 
Radiation Dose 
 
 Radiation dose was calculated using a portable dosimeter on high bias setting 
scanned in air (TN-502RD-H, Best Medical Canada, Ottawa, Canada).  The probe was 
secured in the center of the field of view and was scanned under the same parameters as 
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the rat hind limbs.  Radiation dose was calculated as an average of five scans over the 
five days that scanning occurred.  Since the rats were scanned in vivo, the layer of soft 
tissue surrounding the bone would have attenuated some of the radiation.  Thus, the 
calculated radiation dose may slightly overestimate the actual X-ray exposure to bone. 
 
Results 
 
Body Weight and Food Intake 
 
 A significant interaction (P<0.05) and a significant main effect of hormone status 
and age (P<0.001) were observed for body weight.  One week post-surgery, OVX rats 
had a greater body weight than Sham rats and this persisted until study endpoint, age 25 
weeks (P<0.05).  At study endpoint, average body weight of Sham and OVX rats was 
343.1 ±28.7 g and 387.5 ± 38.1 g, respectively (Figure 5-1).  A significant interaction 
(P<0.05) and a significant main effect of hormone status and age (P<0.001) were 
observed for food intake.  Food intake did not differ between Sham and OVX rats 
between 1 and 2 weeks post-surgery.  Food intake was greater (P<0.05) in OVX rats 
compared to Sham rats from week 2.5 through week 6 post-surgery.  Food intake did not 
differ between treatment groups from 6.5 weeks post-surgery to study endpoint, age 25 
weeks (Figure 5-2). 
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Figure 5-1. Weekly body weight of Sham and OVX rats from 1 to 13 weeks post-
surgery.   
 
Values are Mean ± SEM, n=12/group.  Differences from Sham at a time point are 
denoted by * (P<0.05) and † (P<0.001).
* 
* * 
* 
* 
ƚ ƚ ƚ ƚ ƚ ƚ ƚ ƚ 
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Figure 5-2. Weekly food intake of Sham and OVX rats from 1 to 13 weeks post-
surgery.   
 
Values are Mean ± SEM, n=12/group.  Differences from Sham at a time point are 
denoted by * (P<0.05). 
* * * * * * * * 
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Radiation Dose 
 
The average radiation dose for one scan in air was 603 ± 8.3 mGy. 
 
Radiation Effect on Bone Microarchitecture 
 
 The effect of radiation exposure was determined by comparing the repeatedly 
irradiated right proximal tibia to the singly irradiated left proximal tibia at 25 weeks of 
age (13 weeks post-surgery).  No interactions were observed between irradiation and 
hormone status for any of the trabecular outcomes measured when the right and left 
proximal tibia were compared (Table 5-1).  No independent effect of irradiation was 
observed for any trabecular outcome.  As expected, OVX resulted in a decrease in BMD, 
BV/TV, and Tb.N. and an increase in Tb.Sp. and DA (P<0.001) compared to Sham rats at 
study endpoint.  No difference in Tb.Th. was observed between groups. 
 No interactions were observed between irradiation and hormone status for any 
cortical outcomes examined (Table 5-2).  Radiation exposure resulted in an increased 
cortical Ecc. of the proximal tibia (P<0.05).  OVX caused a decrease in cortical BMD and 
Ec.Pm. (P<0.001) and an increase in Ps.Pm. (P<0.05) compared to Sham rats at study 
endpoint. 
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Table 5-1. Effect of irradiation to trabecular microarchitecture of the proximal tibia in 25-week old Sham and OVX rats 1,2 
 
 Sham OVX P values 
Trabecular 
Outcomes 
Non-
irradiated,  
Left proximal 
tibia 
Irradiated,  
Right proximal 
tibia a 
Non-
irradiated,  
Left proximal 
tibia a 
Irradiated,  
Right proximal 
tibia 
Irradiation   
X 
Hormone 
Status 
Irradiation  Hormone Status 
BMD (g/cm3) 0.258 ± 0.091 0.255 ± 0.098 0.033 ± 0.018 0.026 ± 0.018 0.920 0.796 <0.001 
BV/TV (%) 24.87 ± 5.01 24.69 ± 5.38 2.58 ± 1.24 2.08 ± 1.16 0.886 0.761 <0.001 
Tb.Th. (mm) 0.083 ± 0.005 0.083 ± 0.008 0.083 ± 0.011 0.079 ± 0.008 0.363 0.370 0.546 
Tb.N. (mm-1) 2.992 ± 0.521 2.994 ± 0.690 0.317 ± 0.166 0.260 ± 0.157 0.835 0.849 <0.001 
Tb.Sp. (mm) 0.229 ± 0.048 0.253 ± 0.081 1.394 ± 0.240 1.465 ± 0.266 0.663 0.372 <0.001 
DA 2.065 ± 0.160 2.063 ± 0.140 2.450 ± 0.470 2.198 ± 0.477 0.467 0.446 <0.001 
 
1 Values are expressed as Mean ± SD of rats at 25 weeks of age (13 weeks post-surgery) after having undergone no irradiation (left 
proximal tibia) compared to repeated irradiation (right proximal tibia), n=12/group 
 
a Where one missing value occurred, the values were replaced by the series mean.  Due to animal movement during scanning, 
trabecular microarchitecture could not be obtained for this sample. 
 
2 BMD; bone mineral density, BV/TV; percent bone volume, DA; degree of anisotropy, Tb.N.; trabecular number, Tb.Sp.; trabecular 
separation, Tb.Th.; trabecular thickness.
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Table 5-2. Effect of irradiation to cortical microarchitecture of the proximal tibia in 25-week old Sham and OVX rats1,2 
 Sham OVX P values 
Cortical  
Outcomes 
Non-
irradiated,  
Left proximal 
tibia 
Irradiated,  
Right proximal 
tibia a 
Non-
irradiated,  
Left proximal 
tibia a 
Irradiated,  
Right proximal 
tibia 
Irradiation  
X 
Hormone 
Status 
Irradiation Hormone Status 
BMD (g/cm3) 1.388 ± 0.006 1.389 ± 0.005 1.372 ± 0.003 1.372 ± 0.003 0.822 0.807 <0.001 
Tt.Ar. (mm2) 12.164 ± 0.978 11.833 ± 0.936 12.076 ± 0.662 12.095 ± 0.877 0.492 0.540 0.731 
Ct.Ar. (mm2) 6.375 ± 0.557 6.530 ± 0.511 6.410 ± 0.231 6.442 ± 0.240 0.608 0.440 0.824 
Ct.Ar./Tt.Ar. (%) 52.53 ± 4.06 52.53 ± 4.06 53.44 ± 3.24 53.17 ± 2.24 0.388 0.259 0.818 
Ct.Th. (mm) 0.465 ± 0.038 0.484 ± 0.026 0.467 ± 0.015 0.475 ± 0.018 0.464 0.069 0.633 
Ps.Pm. (mm) 26.195 ± 1.228 25.715 ± 1.087 26.851 ± 0.896 26.548 ± 0.820 0.766 0.191 0.015 
Ec.Pm. (mm) 1.257 ± 0.303 1.254 ± 0.379 0.630 ± 0.136 0.581 ± 0.114 0.760 0.732 <0.001 
Ma.Ar. (mm2) 5.788 ± 0.775 5.304 ± 0.595 5.666 ± 0.535 5.653 ± 0.793 0.238 0.215 0.567 
Ecc. 0.461 ± 0.051 0.522 ± 0.045 0.473 ± 0.078 0.525 ± 0.074 0.798 0.004 0.676 
 
1 Values are expressed as Mean ± SD of rats at 25 weeks of age (13 weeks post-surgery) after having undergone no irradiation (left 
proximal tibia) compared to repeated irradiation (right proximal tibia), n=12/group.   
 
a Where one missing value occurred, the values were replaced by the series mean.  Due to animal movement during scanning, cortical 
microarchitecture could not be obtained for these samples. 
 
2 BMD; bone mineral density, Ct.Ar.; cortical bone area, Ct.Ar./Tt.Ar.; cortical area fraction, Ct.Th.; cortical thickness, Ec.Pm.; 
endocortical perimeter, Ecc.; mean eccentricity, Ma.Ar.; medullary area, OVX; ovariectomized, Ps.Pm.; periosteum perimeter, Tt.Ar.; 
cross sectional area inside the periosteal envelope.
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Longitudinal Effect on Trabecular Bone Microarchitecture 
 
 One week post-surgery, coinciding with 13 weeks of age, all trabecular outcomes 
except DA were significantly different between Sham and OVX, and these differences 
were maintained throughout the study period in all but Tb.Th., which returned to similar 
values by 21 weeks of age (Table 5-3).  When the right proximal tibia of Sham or OVX 
rats was scanned at 4-monthly intervals between ages of 13 and 25 weeks, an interaction 
was observed between age and the hormone status for BV/TV (P<0.05), Tb.N. (P<0.001), 
and Tb.Sp. (P<0.001).  No interaction was observed for BMD (P=0.11), DA (P=0.079), 
or Tb.Th. (P=0.19).  An effect of age was observed for BMD, DA, and Tb.Th. (P<0.05), 
and an effect of hormone status was observed for BMD (P<0.001). 
 Sham rats showed no significant changes to trabecular BMD, BV/TV, or Tb.Sp. 
with time.  A decline in Tb.Th. (P<0.05) from 13 to 17 weeks of age and increase 
(P<0.05) from 17 to 25 weeks of age coincided with a decrease (P<0.05) from 17 to 21 
weeks of age for Tb.N. in Sham rats.  Trabecular BMD, BV/TV, Tb.N., and Tb.Sp. all 
showed a similar pattern over time in OVX rats where significant differences were 
observed among all time points except for between 21 and 25 weeks of age.  OVX rats 
experienced a decline (P<0.05) in Tb.Th. between ages of 13 and 17 weeks followed by 
an increase (P<0.001) in Tb.Th. from age 21 to 25 weeks.  Both Sham and OVX rats 
experienced a significant reduction in DA between 13 and 17 weeks of age (P<0.05). 
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Table 5-3. Longitudinal changes to trabecular microarchitecture of the right proximal tibia in Sham and OVX rats at 13, 17, 
21, and 25 weeks of age 1,2 
  
 Sham OVX P values 
Age (week) 13 17 e 21 25 d 13 17 e 21 25 Age X 
Hormone 
Status 
Age Hormone Status 
Time Post-
Surgery 
(week) 
1 5 9 13 1 5 9 13 
Trabecular Outcomes 
BMD  
(g/cm3) 
0.279 ± 
0.100 
0.269 ±  
0.095 
0.244 ± 
0.107 
0.255 ± 
0.098 
0.155 ± 
0.097a* 
0.082 ± 
0.046b† 
0.035 ± 
0.025c† 
0.026 ± 
0.017c† 0.110 0.001 <0.001 
BV/TV  
(%) 
26.00 ± 
5.50 
25.43 ± 
5.22 
24.07 ± 
5.91 
24.69 ± 
5.38 
17.70 ± 
6.64a* 
5.88 ±  
3.21b† 
2.66 ±  
1.70c† 
2.08 ±  
1.17c† 0.002 <0.001 <0.001 
Tb.Th.  
(mm) 
0.080 ± 
0.004a 
0.076 ± 
0.004b 
0.081 ± 
0.007ab 
0.083 ± 
0.008a 
0.076 ± 
0.004a* 
0.072 ± 
0.005b* 
0.083 ± 
0.006c 
0.079 ± 
0.008c 0.190 0.007 0.093 
Tb.N.  
(mm-1) 
3.254 ± 
0.713abc 
3.330 ± 
0.640b 
2.991 ± 
0.693ac 
2.994 ± 
0.690ac 
2.319 ± 
0.853a* 
0.810 ± 
0.401b† 
0.325 ± 
0.215c† 
0.266 ± 
0.156c† <0.001 <0.001 <0.001 
Tb.Sp.  
(mm) 
0.230 ± 
0.074 
0.245 ± 
0.077 
0.264 ± 
0.095 
0.253 ± 
0.081 
0.360 ± 
0.167a* 
1.099 ± 
0.339b† 
1.420 ± 
0.306c† 
1.465 ± 
0.266c† <0.001 <0.001 <0.001 
DA 2.397 ± 0.196a 
2.093 ± 
0.151b 
1.997 ± 
0.199b 
2.063 ± 
0.140b 
2.358 ± 
0.121a 
2.098 ± 
0.209b 
2.289 ± 
0.244a 
2.198 ± 
0.477ab 0.079 0.003 0.093 
 
1 Values are expressed as Mean ± SD, n=12/group.  Different letters denote a significant difference within treatment over time 
(P<0.05).  Significant differences from Sham within a time point are shown by * P (<0.05) or † (P<0.001). 
 
Where one d or two e missing values occurred, the values were replaced with the series mean.  Due to animal movement during 
scanning, trabecular microarchitecture could not be obtained for these samples. 
 
2 BMD; bone mineral density, BV/TV; percent bone volume, DA; degree of anisotropy, Tb.N.; trabecular number, Tb.Sp.; trabecular 
separation, Tb.Th.; trabecular thickness.
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Table 5-4. Longitudinal changes to cortical microarchitecture of the right proximal tibia in Sham and OVX rats at 13, 17, 21, 
and 25 weeks of age 1,2 
 
 Sham OVX P values 
Age (week) 13 17e 21 25d 13 17e 21 25 Age X 
Hormone 
Status 
Age Hormone Status 
Time Post-
Surgery 
(week) 
1 5 9 13 1 5 9 13 
Cortical Outcomes 
BMD  
(g/cm3) 
1.385 ± 
0.004 
1.390 ± 
0.003 
1.389 ± 
0.004 
1.390 ± 
0.005 
1.378 ± 
0.004a† 
1.373 ± 
0.004b† 
1.372 ± 
0.004b† 
1.372 ± 
0.003b† <0.001 0.514 <0.001 
Tt.Ar.  
(mm2) 
11.953± 
0.909ac 
12.412± 
0.879a 
12.021± 
0.971bc 
11.834± 
0.936bc 
12.162± 
1.222ac 
12.976± 
1.062b 
12.362± 
0.895a 
12.195± 
0.877c 0.645 0.020 0.300 
Ct.Ar.  
(mm2) 
5.643 ± 
0.369a 
6.350 ± 
0.263b 
6.540 ± 
0.361c 
6.530 ± 
0.511bc 
5.559 ± 
0.236a 
6.216 ± 
0.259b 
6.362 ± 
0.245bc 
6.442 ± 
0.240c 0.784 <0.001 0.286 
Ct.Ar./ 
Tt.Ar. (%) 
47.34 ± 
3.02a 
51.32 ± 
2.50b 
54.58 ± 
2.81c 
54.55 ± 
4.08c 
46.06 ± 
4.32a 
48.20 ± 
3.92b* 
51.66 ± 
3.52c* 
53.44 ± 
3.24c 0.296 <0.001 0.070 
Ct.Th.  
(mm) 
0.403 ± 
0.028a 
0.453 ± 
0.018b 
0.476 ± 
0.021c 
0.484 ± 
0.026c 
0.396 ± 
0.020a 
0.431 ± 
0.026b* 
0.462 ± 
0.025c 
0.475 ± 
0.018d 0.094 <0.001 0.103 
Ps.Pm. 
(mm) 
26.580 
± 1.167a 
26.607± 
1.205a 
26.032± 
1.182b 
25.715± 
1.087c 
26.859± 
1.183ac 
27.956± 
1.183b* 
26.914± 
1.047a 
26.548± 
0.820c* 0.046 <0.001 0.072 
Ec.Pm.  
(mm) 
1.431 ± 
0.233ab 
1.590 ± 
0.418a 
1.466 ± 
0.695ab 
1.245 ± 
0.379b 
1.251 ± 
0.223a 
0.925 ± 
0.203b† 
0.659 ± 
0.123c* 
0.581 ± 
0.114c† 0.036 0.001 <0.001 
Ma.Ar.  
(mm2) 
6.310 ± 
0.747a 
6.062 ± 
0.702a 
5.480 ± 
0.727b 
5.304 ± 
0.595b 
6.630 ± 
1.132a 
6.760 ± 
1.000a 
6.000 ± 
0.839b 
5.653 ± 
0.793c 0.473 <0.001 0.102 
Ecc. 0.547 ± 0.033a 
0.528 ± 
0.036ab 
0.521 ± 
0.042b 
0.522 ± 
0.045ab 
0.528 ± 
0.070a 
0.477 ± 
0.078b 
0.506 ± 
0.088ab 
0.525 ± 
0.074ab 0.250 0.013 0.375 
 
1 Values are expressed as Mean ± SD, n=12/group.  Different letters denote a significant difference within treatment over time 
(P<0.05).  Significant differences from Sham within a time point are shown by * P (<0.05) or † (P<0.001). 
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Where one d or two e missing values occurred, the values were replaced with the series mean.  Due to animal movement during 
scanning, trabecular microarchitecture could not be obtained for these samples. 
 
2 BMD; bone mineral density, Ct.Ar.; cortical bone area, Ct.Ar./Tt.Ar.; cortical area fraction, Ct.Th.; cortical thickness, Ec.Pm.; 
endocortical perimeter, Ecc.; mean eccentricity, Ma.Ar.; medullary area, OVX; ovariectomized, Ps.Pm.; periosteum perimeter, Tt.Ar.; 
cross sectional area inside the periosteal envelope. 
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Discussion 
 
 Our findings show that µCT scanning of the proximal tibia at monthly intervals 
over a standard 3-month time period following surgery, Sham or OVX, does not alter the 
main parameters of microarchitecture of the tibia.  Lack of differences between any of the 
major 3D outcomes of either trabecular or cortical bone for the right leg (underwent 4 
scans) or left leg (only scanned at study endpoint) suggests that researchers can apply this 
radiation dose at monthly intervals over a typical 3-month study period to 
comprehensively understand how a diet or other intervention impacts both trabecular and 
cortical bones of the rat tibia without the confounding effects of radiation.  This evidence 
supports the resilience of the long bones of the rat to repeated irradiation at an absorbed 
dose of 600 mGy, and that this resilience is independent of hormone status. 
 The only main effect of radiation exposure was a decrease in mean Ecc., an 
outcome that quantifies the deviation of a bone’s shape from circular toward elliptical.  
Ecc. describes the asymmetric distribution of a bone and is associated with aging and 
OVX in mice and rats, respectively (15, 16).  Changes to cortical eccentricity have often 
been thought to occur in response to the loads applied to bones, but since the current 
study found differences between contralateral limbs, altered weight bearing cannot be the 
cause.  It is possible that this finding is a false positive due to chance, which becomes 
more likely as the number of multiple statistical comparisons being made increases. 
 Our findings are supportive of previous work, which found no effect of either 
weekly or bi-weekly scanning at radiation doses of approximately 900 or 600 mGy, 
respectively (6, 8).  In these studies, the rats used were roughly 8-month retired breeder 
Wistar, older than those used in the current study.  With increasing age, the rate of bone 
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turnover changes in favour of bone resorption (9-11, 14, 17-24).  Therefore, it is possible 
that radiation exposure may have less of an impact to bone tissue with increasing age, as 
bone modeling rates slow.  In fact, the only study citing radiation-induced changes to 
skeletally mature (10 month + 54 week study period) ovary-intact Wistar rats having 
undergone five scans of 400 mGy compared to their age-matched non-irradiated controls 
found a decrease in structure model index and an increase in Tb.Th. (5).  In this study, the 
non-irradiated controls were scanned only at study endpoint, which introduces a source of 
variation that the current study was able to eliminate by comparing contralateral limbs.  
Similar studies have been conducted using an ovary intact mouse model and have found a 
radiation dose response whereby repeated irradiation (776 mGy) caused changes to the 
trabecular microarchitecture of the tibia but lower doses of radiation (166 and 434 mGy) 
did not (7). 
 The time points in our study were chosen to mimic those commonly used in OVX 
rat studies of a nutritional intervention (25-32) so that the data may be applicable for the 
effective design of future experiments.  OVX has been shown to cause skeletal site-
specific effects to bone health (9, 14, 15, 33).  Overall, the proximal tibia is considered to 
show the earliest and the greatest changes to trabecular bone mineral and 
microarchitecture (9), and so this is often the primary site of investigation in studies of 
surgically induced compromised bone health (5, 23, 34-37). 
 There was a significant interaction between hormone status and the age of the rats 
for the trabecular outcomes BV/TV, Tb.N., and Tb.Sp.  This interaction suggests that the 
effect of time on microarchitecture outcomes was different between Sham and OVX 
groups.  Although both Sham and OVX groups experienced statistically significant 
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differences between some of the microarchitecture outcomes within interim time points, 
these findings are likely due to random variation associated with bone remodeling at 
these ages.  As expected, over the 12-week study period, the OVX group experienced the 
greatest reduction in BV/TV (-88.25 %) and Tb.N. (-88.26 %) and the greatest increase in 
Tb.Sp. (+308.33 %) compared to their Sham counterparts.  While Sham rats experienced 
the same pattern, the magnitude of change was much smaller.  Although comparable to 
some studies (38, 39), the current findings suggest more dramatic trabecular bone loss 
than what has been found in studies of older Wistar rats (40, 41).  Our findings are 
supportive of a disruption of normal bone modeling with OVX at 3 months of age 
causing a premature switch to remodeling and loss of trabecular BV/TV. 
 The finding that Tb.Th. was unaffected by hormone status suggests that the 
decrease in BV/TV observed with time in the OVX group is due to a decrease in the total 
number of trabeculae and greater separation of those remaining trabeculae, rather than the 
overall reduction and thinning of the entire trabecular framework.  Waarsing and 
colleagues (5) have speculated that the trabecular structures neighbouring individual 
trabeculae that are resorbed in the remodeling process are preserved and even experience 
an increase in thickness resulting in a net zero chance in average thickness.  This theory is 
supported by the current findings and also by the larger decrease in Tb.N. and only small 
change in thickness in long bones in similar OVX model characterization studies (12, 37, 
40-42).  OVX had a significant effect on DA, a morphological parameter, which 
describes the preferential alignment of the bone of the trabecular structure.  An increasing 
value suggests preference for a more anisotropic structure, with a preferred orientation.  
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Our data are supportive of previous findings of an increase in DA following OVX in rat 
models of osteoporosis (43-45). 
 Over the 12-week study period, an interaction of hormone status and age of the rat 
was found for the cortical indices, BMD, Ps.Pm., and Ec.Pm.  Interestingly, average 
Ps.Pm. and Ec.Pm. decreased over time, in such a way that Sham rats experienced the 
greatest decline in Ps.Pm. (3 %) and OVX rats the greatest decline in Ec.Pm. (54 %).  It is 
generally understood that OVX causes bone loss on the endocortical surfaces (trabecular 
and endosteum) by causing an imbalance between bone formation and resorption (14, 17-
19, 23).  At first glance, our findings in OVX rats would imply that a decrease in Ec.Pm. 
was due to formation at this site.  A more plausible mechanism could be that inner 
cortical bone perimeter may be decreasing with time because of a change in shape and, 
ultimately, an increased surface area.  Bone at the endocortical surfaces may be resorbed 
into a more smooth and uniform shape, which is supported by the finding of an increase 
in Ct.Th. and Ct.Ar./Tt.Ar., and a decrease in Ma.Ar. and Ecc. over time.  With the 
hormonal changes observed with age and with OVX, the marrow cavity expands and the 
cortical bone thins (17) in an effort to increase its resistance to bending by spreading its 
mass further away from the centroid, thereby increasing its moment of inertia.  In this 
study, the cortical bone of the proximal tibia was analyzed.  Although the cortical bone of 
the diaphysis of the rat experiences changes that are more consistent with the changes 
seen in the long bones of humans (46, 47), the diaphysis was not included in the single 
scan field, which was primarily aimed at the trabecular-rich proximal tibia region.  To 
limit the length of time that the rat was anesthetized and the dose of radiation it was being 
exposed to, two scan fields were not practical in this study. 
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 Of particular importance to note, trabecular BMD, BV/TV, Tb.Th., Tb.N., Tb.Sp., 
and cortical BMD of the proximal tibia were significantly different between treatment 
groups after only 1 week post-surgery.  In this study, rats were ordered from the supplier 
either Sham-operated or ovariectomized at 12-weeks of age, and received their first scan 
after 1 week of recovery.  Therefore, the earliest deterioration to bone microarchitecture 
was missed in our study.  In the literature, the most rapid and detectable loss of bone was 
reported as early as 14 days post-OVX at the proximal tibia (23, 41) and more recent 
work using µCT at 26µm pixel size has found differences in trabecular outcomes 12 days 
post-OVX (36).  Our findings that the trabecular bone microarchitecture and BMD show 
detectable differences between OVX and Sham rats after only 7 days post-surgery 
highlight the importance of timing in studies utilizing such sensitive, high-resolution 
imaging equipment.  Efforts should be made to perform these surgeries on-site, and to 
acquire baseline values before any hormonal insult. 
 In conclusions, monthly irradiation over a 12-week period did not impact any of 
the microarchitectural properties of the proximal tibia, and this finding is consistent in 
both Sham and OVX rats.  Radiation exposure affected only the 3D morphological 
parameter, cortical Ecc.  Therefore, the rat tibia can be considered robust and resistant to 
radiation-induced damage under this scanning protocol.  These findings can be used as 
proof of concept for the resilience of the rat tibia in intermittent in vivo radiation exposure 
of 600 mGy.  This study also advances the characterization of the rat model of 
postmenopausal osteoporosis by providing a monthly time course of trabecular and 
cortical microarchitectural changes at the proximal tibia in rats.  Future research should 
be done to elucidate any effect of repeated radiation exposure to the activity of bone 
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modeling/remodeling, as these processes may have been impacted without having had an 
effect on microarchitectural properties as measured by µCT.  Also, the use of this 
scanning protocol should be reanalyzed using an experimental model of malignant bone 
disease as this dose of radiation may have varying effects on different disease states. 
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Abstract 
 
The parameters of a µCT scan, including whether a bone is imaged in vivo or ex vivo, 
determine the quality of the resulting image. In turn, this impacts the accuracy of the 
trabecular and cortical outcomes.  The absolute impact of µCT scanning at different voxel 
sizes and whether the sample is imaged in vivo or ex vivo on the morphological outcomes 
of the proximal tibia in the rat is unknown.  The right proximal tibia of 6-month old 
Sham-control and OVX rats (n=8/group) was scanned using µCT (SkyScan 1176, Bruker 
micro-CT, Kontich, Belgium) using three sets of parameters (9µm ex vivo, 18µm ex vivo, 
18µm in vivo) to compare the trabecular and cortical outcomes.  Regardless of scan 
protocols, differences between Sham and OVX groups were observed as expected.  At a 
voxel size of 18µm, scanning in vivo or ex vivo had no effect on any of the outcomes 
measured. However, compared to a 9µm voxel size scan (ex vivo), imaging at 18µm ex 
vivo resulted in significant underestimation of the Conn.D (P<0.05) of the trabecular bone 
and a significant overestimation (P<0.05) of the trabecular indices (Tb.Th., DA) and of 
the cortical indices (Ct.Ar., Ct.Ar./Tt.Ar., Ct.Th.) in both Sham and OVX rats.  These 
results suggest the benefit to scanning the proximal tibia of rats at a voxel size as low as 
9µm, although considerations must be made for the increased acquisition time, 
anesthesia, animal welfare, and radiation exposure associated with lower voxel size in 
vivo scanning. 
Introduction 
 
The use of 3D µCT has become the gold standard for the quantitative assessment of 
bone microarchitecture (2).  In vivo scanning allows for the repeated imaging and 
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analysis of the same animal over time in a longitudinal study.  We have previously shown 
that repeated exposure of the rat hind limb to monthly radiation doses of 600 mGy does 
not cause differences in bone morphology, suggesting the resilience of the proximal tibia 
to repeated in vivo µCT scanning (3).  Isolated bones however can be stored and scanned 
ex vivo without consideration of scan duration, subsequent data file size, ionizing 
radiation, animal welfare, or artifacts caused by movement.   
In vivo imaging of the tibia involves scanning of the whole hind limb, including fur, 
skin, and soft tissue surrounding the bone, which may affect the image quality and 
subsequent outcomes.  A greater volume of water surrounding an aluminum tube, used to 
represent bone, resulted in a reduction of beam hardening artifacts due to peripheral 
filtration of the X-rays away from the bone (4).  By changing the scanning scenario from 
one material (aluminum) to two materials (aluminum surrounded by water), the need for 
beam hardening correction was reduced or eliminated (4, 5).  Also, different thickness of 
surrounding medium can change the reconstructed attenuation so that the same bone in 
different parts of an animal can be assigned different density values, artificially.  In 
general, the surrounding medium complicates the task of correcting beam hardening 
artifacts, which is necessary for the accurate quantification of bone densitometry and 
morphology.  Furthermore, extra noise is added to reconstructed µCT images by 
surrounding media. 
 In mice, scanning of the tibia ex vivo with a 5µm voxel size resulted in significant 
differences in some trabecular and cortical outcomes compared to in vivo scanning with a 
9µm voxel size (6).  The authors attribute these differences to the image quality and 
scanning resolution, but the effect of in vivo and ex vivo scanning cannot be discounted.  
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One study of female Wistar rats found all trabecular morphological outcomes of the tibia, 
as measured by µCT at a 26µm voxel size, were correlated between in vivo and ex vivo 
scanning protocols (7), but no study has directly compared these scan protocols at a 
smaller voxel size and in an OVX rat model, where a significant loss of trabecular bone 
volume and structure has occurred.   
A 5µm voxel size is sufficient for the visualization and quantification of 
trabecular bone of the tibia of mice with only a minor benefit at higher resolutions (8).  
Trabeculae from ovary-intact rats are considerably thicker than mouse trabeculae, and 
scanning rat trabeculae at a 10-20µm voxel size is generally considered to be sufficient 
for imaging ex vivo (8), although no studies have directly compared the trabecular and 
cortical outcomes of the rat tibia scanned both in vivo and ex vivo at voxel sizes within 
this range.  The OVX of 12-week SD rats causes an immediate and drastic deterioration 
in the morphology of the proximal tibia, including decreased trabecular bone volume, 
Tb.Th., Tb.N., and increased Tb.Sp. compared to their Sham-counterparts after only 7-
days post-surgery (3).  While the changes to bone as a result of OVX are drastic, it is 
important to determine whether these changes have an impact on the scan settings 
necessary for the accurate measurement and image quality.  For this reason, both Sham- 
and OVX-operated rats were used to compare the right proximal tibia of rats scanned at 
voxel sizes of 9µm ex vivo, 18µm ex vivo and 18µm in vivo.  The purpose of this study 
was to a) determine the effect of scanning the tibia of the rat in vivo compared to ex vivo 
b) further understand the implication of voxel size (9 versus 18µm) on the ex vivo 
scanning of the rat proximal tibia and to c) establish if the well characterized differences 
between Sham and OVX groups can be similarly detected with each scan protocol.  
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Findings from this study will guide the experimental design and determination of µCT 
scan parameters of future pre-clinical studies using the OVX rat model of 
postmenopausal osteoporosis. 
Materials and Methods 
 
*See Chapter Four – Experimental Approach for methodologies regarding Animals and 
Diet, µCT, and Statistical Analyses 
 
Results 
 
 Final body weights did not differ between Sham (390.8 ± 75.8 g) and OVX (422.2 
± 47.1 g) rats (P=0.237).  Final food intake did not differ between Sham (14.7 ± 2.7 g/d) 
and OVX (14.0 ± 2.1 g/d) rats (P=0.607).  Sham rats had significantly greater uterine wet 
weight at necropsy (660 ± 189.3 mg) compared to OVX rats (226.5 ± 26.7 mg) 
(P<0.001), confirming successful removal of the ovaries at 3 months of age.   
 In Sham rats, scanning of the right proximal tibia at a voxel size of 9µm ex vivo 
resulted in significantly lower values for the 3D trabecular morphometric indices Tb.Th. 
(P<0.001) and DA (P=0.001), and a greater Conn.D (P=0.009) and significantly lower 
values for the cortical parameter Ct.Ar. (P<0.001) compared to in vivo and ex vivo 
scanning protocols at the 18µm voxel size (Table 6-1).  9µm ex vivo scanning also 
resulted in lower Ct.Ar./Tt.Ar. (P=0.006) compared to 18µm in vivo scanning and lower 
Ct.Th. (P=0.007) compared to 18µm ex vivo scanning.  No other trabecular or cortical 
morphometric outcomes were different among groups.   
In OVX rats, scanning of the right proximal tibia at a voxel size of 9µm ex vivo 
resulted in significantly lower values for the trabecular morphometric indices Tb.Th. 
(P<0.001) and DA (P=0.002), and a greater Conn.D (P<0.001) and lower values for the 
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cortical indices Ct.Ar., Ct.Ar./Tt.Ar. (P<0.001) and Ct.Th. (P=0.001) compared to all 
other groups (Table 6-2).  No other trabecular or cortical morphometric outcomes were 
different among groups.   
R values for the correlations between 9µm and 18µm in vivo and 18µm ex vivo 
scan settings are reported in Table 6-3.  Strong correlations were observed for most 
trabecular and cortical outcomes when Sham and OVX groups were analyzed together 
and many of these correlations were maintained when Sham and OVX groups were 
analyzed separately.  Values for Tb.Th., DA, and Ct.Ar. when scanned at 18µm (in vivo 
or ex vivo) were not correlated with scans of 9µm. 
Significant differences between Sham and OVX groups were observed for the 
outcomes BV/TV, Tb.N., Tb.Sp., Conn.D, Ct.Ar., Ct.Ar./Tt.Ar., Ct.Th., and Ec.Pm. when 
measured using all scanning protocols (Table 6-4).  Scanning the proximal tibia at 18µm 
voxel size in vivo resulted in a significant difference between Sham and OVX rats for the 
trabecular outcome, Tb.Th. (P=0.012), but differences were not observed using other 
scanning protocols.  Retrospective power analyses revealed the number of animals 
needed to identify differences between Sham and OVX groups for each of the primary 
outcome measures (Table 6-5). 
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Table 6-1.  Trabecular and cortical outcomes of right proximal tibia of Sham-
operated rats scanned using three sets of scanning parameters 
Trabecular Outcomes 
Scanning Parameters 
ANOVA 9µm ex vivo 18µm ex vivo 18µm in vivo 
BV/TV (%) 18.2466 
(6.6254) 
22.2441 
(7.9488) 
24.8317 
(3.0535) 
0.128 
Tb.Th. (mm) 0.0454 
(0.0067)a 
0.0786 
(0.0065)b 
0.0726 
(0.0048)b 
<0.001 
Tb.N. (mm-1) 4.0727 
(1.7458) 
2.7586 
(1.0096) 
3.4235 
(0.3815) 
0.110 
Tb.Sp. (mm) 0.3594 
(0.3578) 
0.4116 
(0.3926) 
0.2449 
(0.0525) 
0.552 
Conn.D (mm-3) 925.808 
(822.021)a 
134.593 
(84.078)b 
222.546 
(66.257)b 
0.009 
DA 
1.5901 
(0.1280)a 
1.9502 
(0.2935)b 
1.9801 
(0.0883)b 
0.001 
Cortical Outcomes 
Tt.Ar. (mm2) 15.4514 
(1.6288) 
15.7596 
(1.6911) 
15.7149 
(1.8830) 
0.929 
Ct.Ar. (mm2) 5.1653 
(0.6401)a 
6.3697 
(0.3262)b 
6.8426 
(0.3986)b 
<0.001 
Ct.Ar./Tt.Ar. (%) 33.972 
(6.775)a 
40.894 
(5.505)ab 
43.934 
(4.201)b 
0.006 
Ct.Th. (mm) 0.3923 
(0.0302)a 
0.4407 
(0.0245)b 
0.4233 
(0.0280)ab 
0.007 
Ps.Pm. (mm) 33.0689 
(3.1843) 
30.8204 
(2.0532) 
30.7821 
(2.1949) 
0.142 
Ec.Pm. (mm) 1.6106 
(0.4224) 
1.4303 
(0.3872) 
1.6339 
(0.2176) 
0.465 
Ma.Ar. (mm2) 30.2553 
(4.9133) 
30.0481 
(5.3022) 
30.8031 
(5.8257) 
0.959 
Ecc. 0.3905 
(0.0524) 
0.4172 
(0.0723) 
0.4437 
(0.0588) 
0.249 
 
Values are expressed as Mean (SD), n=8/group.  Significant differences (P<0.05) are 
shown in bold type.  a,b Different letters across a row denote significant differences 
between all scanning parameters.   
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Table 6-2.  Trabecular and cortical outcomes of right proximal tibia of OVX rats 
scanned using three sets of scanning parameters 
Trabecular Outcomes 
Scanning Parameters 
ANOVA 9µm ex vivo 18µm ex vivo 18µm in vivo 
BV/TV (%) 
4.7031 
(1.6105) 
5.7631 
(2.0738) 
6.5859 
(1.9987) 
0.165 
Tb.Th. (mm) 
0.0507 
(0.0039)a 
0.0848 
(0.0072)b 
0.0791 
(0.0042)b 
<0.001 
Tb.N. (mm-1) 
0.9091 
(0.3379) 
0.6521 
(0.2232) 
0.8302 
(0.2330) 
0.174 
Tb.Sp. (mm) 
1.1565 
(0.2488) 
1.2536 
(0.2397) 
1.1496 
(0.2554) 
0.650 
Conn.D (mm-3) 
145.445 
(45.819)a 
17.867 
(12.450)b 
46.880 
(16.046)b 
<0.001 
DA 
1.6450 
(0.1747)a 
2.1948 
(0.4091)b 
2.0159 
(0.1757)b 
0.002 
Cortical Outcomes 
Tt.Ar. (mm2) 
14.6701 
(0.8249) 
15.0922 
(1.0823) 
15.4852 
(1.0950) 
0.292 
Ct.Ar. (mm2) 
6.0520 
(0.6379)a 
6.9295 
(0.4164)b 
7.4813 
(0.4577)b 
<0.001 
Ct.Ar./Tt.Ar. (%) 
41.245 
(3.383)a 
45.984 
(1.992)b 
48.381 
(2.022)b 
<0.001 
Ct.Th. (mm) 
0.4361 
(0.0218)a 
0.4775 
(0.0146)b 
0.4678 
(0.0204)b 
0.001 
Ps.Pm. (mm) 
31.7131 
(2.4394) 
30.1985 
(1.4249) 
30.8046 
(1.1947) 
0.250 
Ec.Pm. (mm) 
1.1149 
(0.4205) 
0.9199 
(0.2206) 
1.1818 
(0.2073) 
0.215 
Ma.Ar. (mm2) 
26.1494 
(1.8549) 
26.3147 
(3.0409) 
27.5346 
(2.7024) 
0.514 
Ecc. 
0.4376 
(0.0363) 
0.4438 
(0.0595) 
0.4529 
(0.0367) 
0.797 
 
Values are expressed as Mean (SD), n=8/group.  Significant differences (P<0.05) are 
shown in bold type.  a,b Different letters across a row denote significant differences 
between all scanning parameters.  
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Table 6-3. R values for the correlations between morphological outcomes from 
18µm scanning protocols compared to 9µm ex vivo protocols 
 
Trabecular 
Outcomes 
All Sham OVX 
18µm  
ex vivo 
18µm  
in vivo 
18µm  
ex vivo 
18µm  
in vivo 
18µm  
ex vivo 
18µm  
in vivo 
BV/TV 0.994** 0.913** 0.982* 0.780 0.988** 0.981* 
Tb.Th. -0.063 0.316 -0.145 -0.158 -0.660 0.465 
Tb.N. 0.939** 0.860** 0.815* 0.581 0.896* 0.960** 
Tb.Sp. 0.992** 0.967** 0.987** 0.975** 0.932* 0.897* 
Conn.D 0.401 0.567* 0.045 0.148 0.820* 0.344 
DA 0.114 0.396 -0.283 0.141 0.237 0.580 
Cortical Outcomes 
Tt.Ar. 0.950** 0.894** 0.918** 0.970* 0.898* 0.920* 
Ct.Ar. 0.446 0.184 0.298 -0.634 -0.000 -0.000 
Ct.Ar./Tt.Ar. 0.760** 0.696* 0.815* 0.760* -0.257 -0.391 
Ct.Th. 0.767** 0.717* 0.765* 0.750* 0.114 -0.055 
Ps.Pm. 0.846** 0.824** 0.847* 0.840* 0.848* 0.899* 
Ec.Pm. 0.770** 0.750** 0.690 0.751* 0.873* 0.754* 
Ma.Ar. 0.945** 0.954** 0.958** 0.961** 0.919* 0.971** 
Ecc 0.647* 0.430 0.562 0.391 0.777* 0.554 
 
The R values for the correlations between trabecular and cortical morphological 
outcomes from 18µm ex vivo and 18µm in vivo scan protocols compared to 9µm ex vivo 
scan protocols from all groups, Sham or OVX.  Values with an * (P<0.05) or ** 
(P<0.001) are significantly correlated with outcomes obtained using 9µm ex vivo scan 
protocols.  
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Table 6-4.  Statistical difference of trabecular and cortical outcomes between Sham 
and OVX groups for each scanning protocol 
 
Trabecular Outcomes 
Scanning Parameters 
9µm ex vivo 18µm ex vivo 18µm in vivo 
BV/TV  <0.001 <0.001 <0.001 
Tb.Th. 0.078 0.095 0.012 
Tb.N. 0.001 <0.001 <0.001 
Tb.Sp. <0.001 <0.001 <0.001 
Conn.D 0.035 0.011 <0.001 
DA 0.485 0.191 0.614 
Cortical Outcomes 
Tt.Ar. 0.253 0.363 0.771 
Ct.Ar. 0.015 0.010 0.010 
Ct.Ar./Tt.Ar. 0.017 0.028 0.022 
Ct.Th. 0.005 0.003 0.003 
Ps.Pm. 0.355 0.493 0.980 
Ec.Pm. 0.034 0.006 0.001 
Ma.Ar. 0.054 0.106 0.181 
Ecc. 0.056 0.436 0.715 
 
The p values of independent t-test between Sham and OVX groups are expressed, 
n=8/group.  Significant differences (P<0.05) between Sham and OVX groups within each 
scanning protocol are shown in bold type. 
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Table 6-5.  Sample size needed to identify differences in primary trabecular and 
cortical outcomes between Sham and OVX rats 
 
Trabecular Outcomes 
 Scanning Parameters 
Effect Size 9µm ex vivo 18µm ex vivo 18µm in vivo 
BV/TV 13.5433 7 7 4 
Tb.Th. 0.0053 20 22 13 
Tb.N. 3.1636 7 6 4 
Tb.Sp. 0.7971 7 7 5 
Cortical Outcomes   
Tt.Ar. 0.7813 45 71 622 
Ct.Ar. 0.8867 12 11 11 
Ct.Ar./Tt.Ar. 7.273 13 14 13 
Ma.Ar. 4.1059 17 24 33 
 
Estimated number of rats necessary to identify differences between Sham and OVX 
groups for primary trabecular and cortical outcomes.  Sample sizes were calculated with a 
power of 0.80, type I error rate of 0.05, and effect size and standard deviation from raw 
data.   
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Discussion 
 
 The purpose of this study was to better understand the implications of in vivo and 
ex vivo scanning as well as the effect of scan settings, including altered voxel size and 
rotation step, on trabecular and cortical outcomes in a pre-clinical model of 
postmenopausal osteoporosis.  No differences were observed between in vivo and ex vivo 
scans of the proximal tibia at 18µm for any of the trabecular or cortical outcomes 
measured in Sham or OVX rats.  This finding suggests that, despite the potential 
compromises to µCT image quality imposed by in vivo scanning, the quality of the 
resulting bone morphometric data is essentially equivalent to that of scans performed ex 
vivo at the same voxel size.  The reasoning for the lack of observed differences may be 
due to the immeasurable effect of the tissue surrounding the bone in vivo.  Ultimately, 
µCT scanning at the proximal tibia whether performed in vivo or free of all surrounding 
soft tissue does not result in changes to the trabecular or cortical outcomes assessed.  In 
fact, a retrospective power analysis performed for each scan protocol revealed that when 
performing scans in vivo a smaller sample size is necessary to identify differences in 
trabecular outcomes between Sham and OVX groups compared to ex vivo techniques.  
Absolute resolution, the ability of a measure to quantify a theoretically perfect value, 
declines with increasing voxel size (9, 10).  But, relative resolution, which is the ability of 
a scan to detect a difference between group A and B (i.e., Sham and OVX) can be 
unaffected with large increases in voxel size (11).  Therefore, rather than the voxel size 
being the cause of the increase in effect size observed between Sham and OVX groups, 
there may be some unknown advantages of in vivo imaging.  While in vivo scans are 
presumably subject to more artifacts, it is possible that in vivo imaging provides a 
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reduction in the variability, as can be seen with a smaller standard deviation reported for 
most trabecular outcomes compared to ex vivo scans in this study.  The surrounding tissue 
may act to hydrolyze the bone, maintain the bones size and shape, or reduce any potential 
post-mortem demineralization, suggesting a benefit to in vivo scanning of the hind limb 
in rats.  The number of rats necessary to determine differences between Sham and OVX 
groups for the primary cortical outcomes were not affected by the scan parameter used.  
The effect sizes between Sham and OVX groups are larger for trabecular outcomes 
because of the rapid rate of bone loss on the trabecular surfaces compared to cortical (12).  
Therefore, when assessing changes to trabecular outcomes, fewer numbers of animals are 
needed. 
In Sham and OVX rats, 18µm versus 9µm voxel size scanning overestimated Tb.Th., 
Ct.Ar., Ct.Th., and as a result, overestimated DA and Ct.Ar./Tt.Ar. and underestimated 
Conn.D.  To calculate the morphological outcome Tb.Th. using the analysis program, the 
3D image is first ‘skeletonized’ to identify the borders of solid trabecular structures and 
then ‘sphere-fitted’ to determine the average thickness of the largest voxel (3D pixel) that 
can fit within these borders.  Tb.Sp. is quantified similarly, but the theory is applied to the 
space rather than the solid structures within the volume of interest (VOI).  Figure 6-1 
shows a comparison of the distribution of thickness of the trabeculae between scan 
protocols.  Scanning at a lower voxel size causes a left shift in the distribution (thinner 
trabeculae), supporting the hypothesis that when scanning at a larger voxel size, thinner 
trabecular structures are not detected, leading to an artificial increase in the mean 
measured thickness.  Also, with a larger voxel size, the surfaces of the bone tissue are 
blurred and the segmented surface becomes somewhat enlarged resulting in an 
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overestimation of thickness of the binarized surface.  Ct.Th. is quantified in a similar way 
to Tb.Th..  Therefore scanning protocols with a greater voxel size will have the same 
overestimation effect as with the quantification of Tb.Th.. 
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Figure 6-1. Distributions of the Tb.Th. of the proximal tibia between scan protocols 
in (A) Sham and (B) OVX rats 
 
Solid, thick dash, and thin dash lines represent 9µm ex vivo, 18µm ex vivo, and 18µm in 
vivo scan protocols, respectively. 
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 Along with percent bone volume, DA is an important determinant of mechanical 
strength of the trabecular bone (13).  The DA of trabecular bone describes the orientation 
and alignment of the trabecular network within the VOI.  The greater the preferential 
alignment of trabeculae along a principle axis the higher the DA.  The alignment of the 
trabecular structure of the bone is measured in many orientations to determine the 
magnitude of the three principle vectors (Eigen values), from which DA is calculated.  
Scan acquisition with a larger voxel size and larger rotation step would limit the extent to 
which the trabecular network can be visualized and results in an overestimation of the 
DA, as seen in this study.  Limited visualization of the trabecular network at larger voxel 
sizes also resulted in an underestimation of the Conn.D of the trabecular bone, a measure 
of the number of redundant connections between trabecular structures per unit volume.  A 
larger Conn.D value implies a greater number of trabecular connections, which has been 
correlated with greater overall bone strength (14).  Therefore, when comparing absolute 
values, scanning with greater voxel sizes can result in outcomes that are suggestive of a 
weaker bone due to a decreased Conn.D compared to scans done with smaller voxel 
sizes.  Similar to the trabecular outcome DA, Ct.Ar. and Ct.Ar./Tt.Ar. are also 
overestimated with 18µm compared to 9µm voxel size scanning.  Using 18µm, there is a 
smearing effect of the underlying structures (in this case, the edge of the cortical bone) 
and causes an overestimation of Ct.Th. because the boundaries are not as sharp and well 
defined. Part of this is due to increased instances of partial volume effect (15), which 
occurs when a single voxel on the border of a solid structure is made up of part bone and 
part empty space.   
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Overall, findings from this study report that scanning at different settings will result 
in different absolute morphological outcomes, but what may be of greater importance are 
the relative differences observed between scan settings.  Most, but not all cortical and 
trabecular outcomes were correlated between 9µm and 18µm settings.  The significant 
correlations that were observed between 9µm and 18µm scans suggest minimal relative 
changes between scan settings and support the use of 18µm voxel size scanning either in 
vivo or ex vivo when assessing relative changes at the proximal tibia between groups 
within a study.  Depending on whether relationships were assessed between all 9µm and 
18µm scans or within Sham and OVX groups independently, the correlations were 
similar.  Taken together, this suggests that most bone morphological outcomes calculated 
from 9µm and 18µm voxel size scans are correlated regardless of whether they are used 
to assess groups with a high (Sham) or a low (OVX) bone mass. 
The effect of OVX is robust, and as would be expected, caused significant and 
sustained differences in BV/TV, Tb.N., Tb.Sp., Conn.D, Ct.Ar., Ct.Ar./Tt.Ar., Ct.Th., 
and Ec.Pm. compared to Sham rats when assessed by all three scanning protocols at 6 
months of age.  A difference between OVX and Sham for the outcome Tb.Th. was 
observed only with 18µm in vivo scanning, suggesting that these different scan protocols 
alter the ability to differentiate between the absolute values of this trabecular outcome 
between Sham and OVX rats, only.  Therefore, the use of different scanning protocols 
does not alter the ability to detect expected differences between Sham and OVX groups, 
suggesting that any unexpected differences observed are due to an intervention applied 
and not to the scanning protocols used. 
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While the benefits to in vivo µCT scanning are extensive, including the ability to 
follow a single subject longitudinally, there are also limits to this method.  In vivo 
scanning requires the subject to be anesthetized for the duration of the scanning protocol 
which can become costly and depending on the frequency of the anesthesia, may affect 
the welfare of the animal.  Very high-resolution in vivo imaging is also not the most 
optimal option when repeatedly scanning animals due to the extensive scan time and dose 
of ionizing radiation to the animal that is associated with these techniques.  In this study, 
9µm voxel size scans of the tibia required 44 minutes and created a 42GB file, compared 
to a scan time of 12 minutes and a file size of 7GB at a voxel size of 18µm.  Although ex 
vivo scanning of isolated bones can only be analyzed at one time point, this method 
allows for less time-sensitive scanning protocols and for the use of smaller voxel sizes 
and rotation steps in order the acquire the highest quality image.   
A specific limitation of this study was the timing between in vivo and ex vivo 
scanning.  Rats were sacrificed within one-week following the in vivo scan, which may 
have allowed for a short period of remodeling and minor changes to bone structure.  
Although, an effect of growth cannot be fully discounted, only minor changes to the 
microarchitecture of the proximal tibia have been observed between 25 and 30 weeks 
post-OVX (16).  A limitation of ex vivo scanning however, involves the inability to 
accurately and consistently measure BMD.  After storage of isolated bones in saline-
soaked gauze, large air-bubbles can be seen in the marrow space of the bone.  These air-
bubbles affect the calculation of Hounsfield units and ultimately, the determination of 
volumetric BMD.  Finally, a true test of the effect of voxel size could not be conducted 
because 9µm settings used a smaller rotation step.  Reducing the rotation step improves 
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the sharpness of the image and reduces noise, but all settings were chosen to provide a 
high quality image that can be used in future experimental settings. 
In conclusion, the scan settings tested had no effect on the ability to observe expected 
differences between Sham and OVX groups highlighting the robust effect the loss of 
endogenous estrogen has on bone microarchitecture.  In vivo scanning at 18µm voxel size 
in Sham or OVX rats at 6 months of age provides similar values to those obtained by ex 
vivo scanning at the same voxel size and most of these values are correlated with the 
values obtained using 9µm ex vivo scan settings.  Together, these findings suggest no 
relative differences between findings from scan settings.  However, scans performed 
using 18µm voxels, either in vivo or ex vivo, may overestimate or underestimate some 
morphological measurements at the proximal tibia compared to scans of 9µm voxels.
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Chapter 7: Study 4 
 
Lifelong Intake of Flaxseed oil or Menhaden oil to Provide Varying n-6 
to n-3 PUFA Ratios Modulate Bone Microarchitecture During Growth, 
but Not After OVX in SD Rats 
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Abstract 
 
Skeletal health is a lifelong process impacted by environmental factors, including nutrient 
intake.  The n-3 source and PUFA ratio affect bone health in growing rats, or following 
OVX, but no study has investigated the longitudinal effect of PUFA-supplementation 
throughout these periods of bone development.  One month old, SD rats (n=98) were 
randomized to receive 1 of 4 diets from 1 through 6 months of age.  Diets were modified 
from AIN-93G to contain a varying amount and source of n-3 (flaxseed versus menhaden 
oil) to provide an n-6 to n-3 ratio of 10:1 or 5:1.  At 3 (prior to SHAM or OVX) and 6 
months of age, bone microarchitecture of the tibia was quantified using in vivo µCT 
(SkyScan 1176, Bruker microCT).  Providing 5:1 (flaxseed) resulted in lower Tb.Th. and 
Ma.Ar. and greater Ct.Ar./Tt.Ar. during growth compared to diets with a 10:1 PUFA 
ratio, but many of these differences were not apparent following OVX.  PUFA-
supplementation at levels attainable in human diet modulates some bone structure 
outcomes during periods of growth, but is not an adequate strategy for the prevention of 
OVX-induced bone loss in rats. 
Introduction 
 
Coinciding with the transition to menopause, women experience a characteristic 
decrease in bone mass due to the decline in endogenous estrogen production, which 
ultimately increases the risk of fragility fracture and the development of osteoporosis [1].  
The OVX rat model mimics the pathophysiology of bone loss in humans, making this an 
accepted model for the study of potential protective agents and strategies against the 
progression of osteoporosis [2-5]. 
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The n-6 and n-3 series of PUFA have been shown to favourably modulate bone 
health in humans [6-12] and animal models [13-22].  Several feeding intervention trials in 
rats have been conducted to investigate either the source of n-3 PUFA, as ALA-rich or 
EPA and DHA-rich oils, or the ratio of n-6 to n-3 PUFA on bone health outcomes [13-
22], but no study has directly compared these aspects.  Moreover, previous studies of 
either the source or ratio of dietary PUFA can be categorized based on the life stage of 
the rat when the diet is consumed: during growth [13-15, 17] or following OVX [16, 18-
22].  Studies have not examined the impact of varying the source or ratio of dietary 
PUFA in a longitudinal manner, spanning periods of development and aging.  Therefore, 
this study investigated both the n-3 PUFA source and the ratio of n-6 to n-3 PUFA in rats 
from 1 through 6 months of age, to mimic the long-term exposure to these macronutrients 
consumed by humans. 
In young rats undergoing periods of rapid bone growth, most work has been in 
male animal models and has investigated the effect of PUFA-supplementation on bone 
health outcomes including BMD, strength, calcium balance, and serum biomarkers of 
bone turnover [13-15, 23-27].  In general, these studies suggest a benefit to bone 
outcomes with a lower n-6 to n-3 PUFA ratio and differential effects depending on the 
predominant fatty acid found in each of the lipid sources tested.  In females, feeding 
growing rats a diet containing menhaden oil for 5 weeks post-weaning had no effect on 
femoral BMD or biomechanical strength properties compared to control, although bone 
structure was not assessed [28].  Another study that did measure bone structure showed 
that feeding 28 day-old female rats flaxseed or menhaden oil compared to corn oil for 8 
weeks resulted in a positive effect on trabecular microarchitecture of the femur and tibia 
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[17].  This study investigated the effect of lipid source on bone structure with n-6 to n-3 
PUFA ratios ranging from 1:3 through 48, unlike typical human dietary PUFA ratios 
which average 7 through 18:1 [29, 30].  No study has directly compared the effect of 
ALA-rich diets with diets rich in EPA+DHA in the OVX rat to determine their impact 
during periods predominated by bone remodeling. 
 Because n-6 and n-3 compete for the same pool of enzymes for their conversion 
to their longer chain derivatives and subsequent metabolites, the absolute amount of n-3 
and resulting ratio of n-6 to n-3 PUFA is of particular importance.  Studies have 
suggested a benefit to outcomes of bone health with the consumption of a lower n-6 to n-
3 PUFA ratio in both growing [14, 17, 27] and OVX rats [16, 18, 19].  However, some 
studies supplement total PUFA levels that are supra-physiological and do not represent 
typical human consumption patterns [17, 18].  Therefore, the absolute amount of n-3 
provided in the diets used in this study were modified to provide n-6 to n-3 PUFA at a 
10:1 and 5:1 ratio, to test the effects of a dietary PUFA ratio above and below the average 
ratio consumed in Canada of approximately 7:1 [30].  These ratios were achieved by 
including either flaxseed or menhaden oil as the n-3 source.  Diets provided a range of 
total n-6 PUFA and total n-3 PUFA between 12.8-14.8% kcal and 1.4-2.7% kcal, 
respectively (Table 4-1).  The absolute amount of n-6 and n-3 PUFA provided in the 
intervention diets exceeded the average intakes in North American populations [30, 31].  
In the USA, PUFA provide 8% total kcal with LA and ALA providing approximately 5.8 
and 0.61% kcal, respectively [31].  In Canada, the average intake of total PUFA is 5.6% 
kcal, although the total LA or ALA intake has not been determined via nation-wide 
dietary recall survey [30].  Using these intervention diets, the objectives were to 
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determine the effect of varying i) the n-3 PUFA source (flaxseed versus menhaden oil), 
and ii) the absolute amount of n-3 provided to alter the n-6 to n-3 PUFA ratio (10:1 
versus 5:1) on bone microarchitecture and volumetric BMD of the proximal tibia and 
lumbar vertebra 4 (L4) during periods of rapid growth and following Sham or OVX-
surgery. 
Materials and Methods 
 
*See Chapter Four – Experimental Approach for methodologies regarding Animals and 
Diet, µCT, Serum Biomarker Analysis, and Statistical Analyses 
 
Results 
 
Uterine Weight, Body Weight, and Food Intake 
 No significant interaction of diet and hormone status (p=0.354) or main effect of 
diet (p=0.301) was observed for uterine weights (data not shown).  As expected, Sham 
rats had significantly greater (0.66 ± 0.14 g) uterine weight compared to OVX (0.18 ± 
0.23 g) (p<0.001), confirming successful surgery at 3 months.  Although near the level of 
significance, no interaction of diet and hormone status (p=0.054) or main effect of diet 
(p=0.544) was observed for body weight at any time throughout the study (Figure 7-1a).  
OVX rats had significantly greater body weight compared to Sham (p=0.006).  Pairwise 
comparisons within time show that body weight at all time points was significantly 
different from one another (p<0.001) except for one week following surgery (p=0.074), 
suggesting continued growth throughout the study period except during recovery from 
surgery.  No significant interaction (p=0.461), main effect of diet (p=0.666), or main 
effect of hormone status (p=0.079) was observed for food intake (Figure 7-1b).
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Figure 7-1. (A) Weekly body weight and (B) three times weekly food intake from age 
1 month through 6 months 
 
The body weight of all rats was recorded once per week and the average food intake was 
recorded three times per week.  Prior to Sham or OVX surgery (dotted line, open 
symbols), all rats were randomized to receive 1 of 4 intervention diets.  At 3 months of 
age (solid line, closed symbols), rats were randomized to Sham or OVX surgery and were 
maintained on their respective diets until 6 months of age.  Intervention diets and surgery-
type are represented by symbol.  All data are represented as mean (SEM).
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In Vivo Microarchitecture of Tibia 
 At 3 months of age, rats receiving 5:1 (flaxseed) diets had significantly lower 
Tb.Th. and Ma.Ar. compared to rats receiving 10:1 (flaxseed) and greater Ct.Ar./Tt.Ar. of 
the tibia compared to rats receiving either 10:1 diet (Table 7-1).  No significant 
interaction of diet and hormone status or main effect of diet was observed for any 
trabecular outcome of the tibia at 6 months of age (data not shown).  A main effect of diet 
was observed for the cortical indices BMD, Ct.Ar./Tt.Ar. and Ma.Ar. at 6 months of age 
(p<0.05) (data not shown).  Post hoc analysis revealed 10:1 (flaxseed) and 5:1 (flaxseed) 
fed groups experienced lower cortical BMD and Ma.Ar. compared to all other groups, 
respectively (p<0.05).  5:1 (flaxseed) fed groups experienced greater Ct.Ar./Tt.Ar. 
compared to both 10:1 fed groups.  Hormone status significantly affected Ct.Ar./Tt.Ar. 
(p<0.05), trabecular BMD, BV/TV, Tb.N., Tb.Sp. and Ec.Pm. (p<0.001) at 6 months of 
age (data not shown). 
 When the absolute change from 3 to 6 months was examined, no significant 
interaction of diet and hormone status was observed.  Diet had a main effect on cortical 
BMD (p<0.05) with 10:1 (flaxseed) fed groups experiencing the greatest loss compared 
to other groups (data not shown).  Hormone status significantly affected Ct.Ar./Tt.Ar., 
Ec.Pm., Ma.Ar. (p<0.05), trabecular BMD, BV/TV, Tb.N., Tb.Sp. and Ps.Pm. (p<0.001).   
 Sham rats receiving 5:1 (flaxseed) diets experienced lower trabecular BMD, 
BV/TV, Tb.N., and greater Tb.Sp. of the tibia compared to Sham rats receiving 5:1 
(menhaden) diets (Table 7-2a).  These diet-induced effects on trabecular outcomes of the 
tibia were not observed in OVX rats (Table 7-2b).  In rats randomized to OVX surgery, 
those fed diets of 5:1 (flaxseed) experienced lower Ma.Ar. compared to 10:1 (flaxseed) 
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fed rats.  Feeding 5:1 (menhaden) resulted in greater Ct.Th. compared to all other OVX 
groups.  Feeding diets with a 10:1 n-6 to n-3 PUFA ratio resulted in greater Ct.Ar./Tt.Ar. 
compared to 5:1 fed rats.  These effects of diet to the cortical outcomes of the tibia were 
not observed in Sham rats. 
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Table 7-1. In vivo microarchitecture of proximal tibia from 3 month old rats 
 
 10:1  
Flaxseed 
n=25 
5:1  
Flaxseed 
n=25 
10:1 
Menhaden 
n=24 
5:1  
Menhaden 
n=24 
Trabecular Outcomes    
BMD  
(g/cm3) 
0.243 
(.083) 
0.217 
(.095) 
0.230 
(.091) 
0.260 
(.083) 
BV/TV  
(%) 
20.53 
(4.37) 
18.95 
(5.01) 
19.44 
(4.57) 
21.23 
(4.24) 
Tb.Th.  
(mm) 
0.078 
(.004)a 
0.075 
(.004)b 
0.077 
(.004)ab 
0.076 
(.005)ab 
Tb.N.  
(mm-1) 
2.639 
(.495) 
2.540 
(.706) 
2.549 
(.651) 
2.800 
(.528) 
Tb.Sp.  
(mm) 
0.360 
(.132) 
0.442 
(.207) 
0.423 
(.177) 
0.370 
(.158) 
Cortical Outcomes 
BMD  
(g/cm3) 
1.800 
(.006) 
1.795 
(.015) 
1.799 
(.008) 
1.798 
(.013) 
Ct.Ar./Tt.Ar. 
(%) 
37.75 
(3.65)a 
40.09 
(4.47)b 
37.93 
(3.16)a 
38.73 
(2.99)ab 
Ct.Th.  
(mm) 
0.355 
(.026) 
0.354 
(.030) 
0.352 
(.027) 
0.362 
(.024) 
Ps.Pm.  
(mm) 
31.250 
(1.796) 
31.024 
(2.638) 
31.327 
(1.812) 
30.759 
(1.849) 
Ec.Pm.  
(mm) 
1.606 
(.344) 
1.645 
(.839) 
1.579 
(.287) 
1.593 
(.372) 
Ma.Ar.  
(mm2) 
33.821 
(5.925)a 
30.413 
(6.213)b 
33.253 
(5.263)ab 
32.482 
(5.118)ab 
 
Values are expressed as Mean (SD), n=24-25/group.  Different letters in a row denote 
significant differences between diet groups.  Significance was set at p<0.05. 
 
BMD, bone mineral density; BV/TV, percent bone volume; Ct.Ar./Tt.Ar., cortical area 
fraction; Ct.Th., cortical thickness; Ec.Pm., endocortical perimeter; Ma.Ar., medullary 
area; Ps.Pm., periosteal perimeter; Tb.N., trabecular number; Tb.Sp., trabecular 
separation; Tb.Th., trabecular thickness. 
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Table 7-2. In vivo microarchitecture of the proximal tibia from 6 month old (A) 
Sham and (B) OVX rats 
 
(A) Sham 
 
 10:1  
Flaxseed 
n=12 
5:1  
Flaxseed 
n=12 
10:1  
Menhaden 
n=12 
5:1  
Menhaden 
n=12 
Trabecular Outcomes    
BMD  
(g/cm3) 
0.377 
(.080)ab 
0.334 
(.071)a 
0.353 
(.096)ab 
0.413 
(.065)b 
BV/TV  
(%) 
23.91 
(5.45)ab 
21.00 
(4.81)a 
22.26 
(6.47)ab 
26.29 
(4.39)b 
Tb.Th.  
(mm) 
0.077 
(.004) 
0.076 
(.005) 
0.074 
(.005) 
0.073 
(.006) 
Tb.N.  
(mm-1) 
3.100 
(.622)ab 
2.739 
(.552)a 
3.020 
(.976)a 
3.614 
(.645)b 
Tb.Sp.  
(mm) 
0.307 
(.133)ab 
0.374 
(.160)a 
0.346 
(.167)a 
0.230 
(.057)b 
Cortical Outcomes 
BMD  
(g/cm3) 
1.634 
(.185) 
1.750 
(.138) 
1.750 
(.137) 
1.752 
(.138) 
Ct.Ar./Tt.Ar. 
(%) 
44.64 
(5.73) 
46.41 
(3.88) 
44.61 
(4.00) 
43.95 
(3.85) 
Ct.Th.  
(mm) 
0.430 
(.034) 
0.436 
(.022) 
0.433 
(.036) 
0.431 
(.027) 
Ps.Pm.  
(mm) 
30.261 
(2.541) 
29.750 
(2.101) 
30.686 
(1.682) 
31.202 
(2.218) 
Ec.Pm.  
(mm) 
1.543 
(.232) 
1.574 
(.276) 
1.854 
(1.078) 
1.888 
(.680) 
Ma.Ar.  
(mm2) 
30.236 
(7.697) 
27.668 
(5.633) 
30.320 
(3.127) 
32.035 
(6.100) 
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(B) OVX 
 
 10:1  
Flaxseed 
n=13 
5:1  
Flaxseed 
n=13 
10:1  
Menhaden 
n=12 
5:1  
Menhaden 
n=12 
Trabecular Outcomes    
BMD  
(g/cm3) 
0.128 
(.050) 
0.117 
(.050) 
0.132 
(.026) 
0.113 
(.036) 
BV/TV  
(%) 
7.05 
(3.30) 
6.35 
(3.34) 
7.35 
(1.74) 
6.49 
(2.45) 
Tb.Th.  
(mm) 
0.076 
(.009) 
0.075 
(.007) 
0.077 
(.008) 
0.079 
(.005) 
Tb.N.  
(mm-1) 
0.958 
(.490) 
0.868 
(.528) 
0.950 
(.215) 
0.816 
(.282) 
Tb.Sp.  
(mm) 
1.150 
(.365) 
1.180 
(.398) 
1.105 
(.230) 
1.198 
(.301) 
Cortical Outcomes 
BMD  
(g/cm3) 
1.608 
(.180) 
1.688 
(.167) 
1.680 
(.169) 
1.682 
(.171) 
Ct.Ar./Tt.Ar. 
(%) 
44.63 
(3.43)a 
48.68 
(3.77)b 
45.64 
(3.53)a 
48.36 
(2.01)b 
Ct.Th.  
(mm) 
0.435 
(.025)a 
0.432 
(.029)a 
0.437 
(.034)a 
0.465 
(.019)b 
Ps.Pm.  
(mm) 
31.613 
(1.421) 
31.249 
(1.918) 
30.629 
(1.796) 
30.472 
(1.084) 
Ec.Pm.  
(mm) 
1.375 
(.701) 
1.297 
(.473) 
1.177 
(.201) 
1.136 
(.211) 
Ma.Ar.  
(mm2) 
30.915 
(4.442)a 
25.652 
(4.124)b 
28.811 
(4.98)ac 
27.065 
(2.48)bc 
 
Values are expressed as Mean (SD), n=12-13/group.  Different letters in a row denote 
significant differences between diet groups and hormone status.  Significance was set at 
p<0.05. 
 
BMD, bone mineral density; BV/TV, percent bone volume; Ct.Ar./Tt.Ar., cortical area 
fraction; Ct.Th., cortical thickness; Ec.Pm., endocortical perimeter; Ma.Ar., medullary 
area; Ps.Pm., periosteal perimeter; Tb.N., trabecular number; Tb.Sp., trabecular 
separation; Tb.Th., trabecular thickness.
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Ex vivo Microarchitecture of LV4 
 At 3 months of age, rats receiving diets of 10:1 (Menhaden oil) experienced 
reduced DA compared to rats receiving diets with n-3 source from flaxseed (Table 7-3).  
At 6 months of age, there was no interaction of diet and hormone status observed for the 
trabecular outcomes of LV4.  Diet had a main effect on BV/TV and Tb.N. (p<0.05), and 
as expected, hormone status had a main effect on all trabecular outcomes, except Tb.Th. 
(p<0.001) (Table 7-4).  Sham rats randomized to receive diets of 5:1 (menhaden) had a 
greater Tb.N. compared to Sham rats randomized to diets of 10:1 (flaxseed) (Table 7-4a).  
Diet had no significant effect on trabecular outcomes of LV4 in rats randomized to OVX 
(Table 7-4b).
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Table 7-3. Ex vivo microarchitecture of LV4 from 3 month old rats. 
 
 10:1  
(Flaxseed oil) 
n=4 
5:1  
(Flaxseed oil) 
n=4 
10:1  
(Menhaden oil) 
n=6 
5:1  
(Menhaden oil) 
n=6 
Trabecular Outcomes 
BV/TV  
(%) 
20.271 
(3.155) 
20.202 
(2.420) 
24.301 
(5.355) 
26.050 
(3.344) 
Tb.Th.  
(mm) 
0.076 
(0.004) 
0.076 
(0.003) 
0.078 
(0.003) 
0.079 
(0.002) 
Tb.N.  
(mm-1) 
2.658 
(0.293) 
2.668 
(0.265) 
3.094 
(0.576) 
3.316 
(0.423) 
Tb.Sp.  
(mm) 
0.295 
(0.027) 
0.289 
(0.032) 
0.263 
(0.036) 
0.248 
(0.019) 
DA 2.093 (0.055)b 
2.086 
(0.076)b 
1.886 
(0.072)a 
1.905 
(0.140)ab 
Conn.D  
(mm-3) 
85.249 
(9.297) 
95.702 
(11.774) 
87.181 
(9.281) 
90.262 
(10.357) 
 
Values are expressed as Mean (SD), n=4-6/group.  Different letters in a row denote 
significant differences between diet groups.  Significance was set at p<0.05. 
 
BV/TV, percent bone volume; Conn.D; connectivity density, DA; degree of anisotropy, 
Tb.N.; trabecular number, Tb.Sp.; trabecular separation, Tb.Th.; trabecular thickness 
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Table 7-4. Ex vivo microarchitecture of LV4 from 6 month old (A) Sham and (B) 
OVX rats. 
 
(A) Sham 
 
 10:1  
Flaxseed 
n=13 
5:1  
Flaxseed 
n=13 
10:1  
Menhaden 
n=12 
5:1  
Menhaden 
n=12 
Trabecular Outcomes 
BV/TV  
(%) 
25.609 
(4.383) 
22.634 
(2.592) 
23.884 
(3.154) 
26.331 
(4.295) 
Tb.Th.  
(mm) 
0.081 
(.006) 
0.082 
(.005) 
0.081  
(.005) 
0.083  
(.005) 
Tb.N.  
(mm-1) 
3.162 
(.448)ab 
2.765 
(.252)a 
2.932  
(.329)ab 
3.151  
(.375)b 
Tb.Sp.  
(mm) 
0.259 
(.028) 
0.293 
(.025) 
0.276  
(.024) 
0.260  
(.201) 
 
 
(B) OVX 
 
 10:1  
Flaxseed 
n=13 
5:1  
Flaxseed 
n=13 
10:1  
Menhaden 
n=12 
5:1  
Menhaden 
n=12 
Trabecular Outcomes 
BV/TV  
(%) 
15.845 
(4.204) 
14.293 
(3.762) 
16.925 
(2.851) 
16.297 
(3.149) 
Tb.Th.  
(mm) 
0.083 
(.007) 
0.083 
(.007) 
0.084  
(.006) 
0.082  
(.004) 
Tb.N.  
(mm-1) 
1.900 
(.439) 
1.736 
(.489) 
2.008  
(.291) 
1.985  
(.317) 
Tb.Sp.  
(mm) 
0.393 
(.062) 
0.421 
(.086) 
0.384  
(.060) 
0.383  
(.061) 
 
Values are expressed as Mean (SD), n=12-13/group.  Different letters in a row denote 
significant differences between diet groups and hormone status.  Significance was set at 
p<0.05. 
 
BV/TV, percent bone volume; Tb.N., trabecular number; Tb.Sp., trabecular separation; 
Tb.Th., trabecular thickness. 
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Serum OPG and RANKL and the ratio of OPG to RANKL 
 No interaction or main effect of diet was observed for the serum biomarkers OPG 
(Interaction, p=0.243; Diet, p=0.331), RANKL (Interaction, p=0.912; Diet, p=0.922), or 
the ratio of OPG to RANKL (Interaction, p=0.429; Diet, p=0.452) (Figure 7-2).  OVX 
resulted in lower OPG concentrations and a lower ratio of OPG to RANKL and higher 
RANKL concentrations compared to Sham (p<0.001). 
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Figure 7-2. Serum (A) OPG and (B) RANKL concentrations and the (C) ratio of 
OPG to RANKL from 6 month old rats 
 
Values are expressed as Mean (SD).  Light shaded bars represent Sham.  Dark shaded 
bars represent OVX.  *Significantly different from Sham (p<0.05). 
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Body Composition 
 A significant interaction of hormone status and diet was observed for the percent 
lean mass volume, VOI length, and lean volume relative to VOI length (p<0.05) (Table 
7-5).  No main effect of hormone status was observed, but diet had a significant main 
effect on percent lean mass volume and lean volume relative to VOI length (p<0.001).  
Post hoc analysis revealed Sham rats receiving 5:1 (Menhaden oil) diets had significantly 
lower percent lean mass volume compared to all other Sham rats and greater non-lean 
volume relative to VOI length compared to 5:1 (Flaxseed) fed rats (Table 7-5).
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Table 7-5. In vivo body composition of abdominal region surrounding LV3 from 6 month old rats 
 
 SHAM OVX 6 months 
 10:1  
(Flaxseed 
oil) 
5:1  
(Flaxseed 
oil) 
10:1  
(Menhaden 
oil) 
5:1  
(Menhaden 
oil) 
10:1  
(Flaxseed 
oil) 
5:1  
(Flaxseed 
oil) 
10:1  
(Menhaden 
oil) 
5:1  
(Menhaden 
oil) 
X Diet HS 
Body Composition Outcomes 
Percent Non-
Lean Volume 
17.83 
(5.56) 
17.12 
(4.68) 
18.33 
(4.35) 
19.50 
(5.26) 
19.36 
(5.20) 
18.71 
(8.06) 
21.01 
(7.15) 
19.95 
(5.38) 0.910 0.749 0.212 
Percent Lean 
Mass Volume 
59.47 
(8.53)a 
59.15 
(7.97)a 
53.17 
(10.97)a 
39.24 
(12.56)b 
56.56 
(8.90) 
57.16 
(11.21) 
46.68 
(16.42) 
51.62 
(10.36)* 0.035 <0.001 0.979 
Percent Bone 
Volume 
1.46 
(.31) 
1.38 
(.29) 
1.38 
(.26) 
1.44 
(.30) 
1.22 
(.32) 
2.03 
(2.50) 
1.47 
(.20) 
1.173 
(.31) 0.324 0.470 0.711 
VOI Length 
(mm) 
8.408 
(.342)ab 
8.025 
(.352)a 
8.351 
(.320)ab 
8.487 
(.580)b 
8.335 
(.266) 
8.335 
(.412)* 
8.234 
(.490) 
8.204 
(.244) 0.045 0.404 0.646 
Non-Lean 
Volume/VOI 
Length 
2.11 
(.64)a 
2.13 
(.56)a 
2.19 
(.49)ab 
2.29 
(.57)b 
2.32 
(.62) 
2.23 
(.91) 
2.55 
(.86) 
2.42 
(.62)* 0.924 0.771 0.169 
Lean 
Volume/VOI 
Length 
7.10 
(1.15) 
7.40 
(1.13) 
6.36 
(1.29) 
4.59 
(1.33) 
6.80 
(1.15) 
6.90 
(1.51) 
5.66 
(2.01) 
6.30 
(1.32) 0.018 <0.001 0.597 
Bone 
Volume/VOI 
Length 
0.17 
(.04) 
0.17 
(.04) 
0.17 
(.03) 
0.17 
(.04) 
0.15 
(.04) 
0.24 
(.03) 
0.16 
(.06) 
0.14 
(.04) 0.401 0.404 0.767 
 
Values are expressed as Mean (SD), n=10-13/group.  Different letters in a row denote significant differences between diet groups and 
hormone status (HS).  * Significantly different from corresponding SHAM value.  Significance was set at p<0.05.  Non-lean volume 
excludes all lean and bone tissue.
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Discussion 
 This study was the first to investigate the effect of feeding a varying PUFA ratio, 
attained by providing two levels of n-3 PUFA, at physiologically relevant levels, and to 
directly compare the n-3 PUFA sources (ALA-rich flaxseed oil versus EPA+DHA-rich 
menhaden oil) over the life course.  Consistent changes to the primary microarchitectural 
outcomes of trabecular (BV/TV) and cortical (Ct.Ar./Tt.Ar. and Ct.Th.) bone were 
largely not observed among groups.  These primary outcomes of bone structure are most 
closely related to alterations in functional outcomes, including bone strength and 
ultimately to resistance to fracture [34, 35].  Some secondary outcomes, that are unlikely 
to affect bone strength independent of changes to primary outcomes, were altered but 
many of these differences are difficult to interpret or extrapolate without concomitant 
changes to primary outcomes.  However, it is still important to measure the effect of an 
intervention to secondary outcomes to understand the time-course of bone structure 
changes leading to differences in primary outcomes.  Although limited consistency in 
changes to BMD, BV/TV, Ct.Ar./Tt.Ar. and Ct.Th. were observed in this study, 
differences due to diet may have been found with a longer follow-up period post-surgery. 
 Overall, rats experienced small differences, mainly in secondary outcomes, to 
microarchitecture of the tibia following periods of rapid growth (up to 3 months of age) 
and the lower Ma.Ar. and higher Ct.Ar./Tt.Ar observed with 5:1 (flaxseed) feeding 
compared to 10:1 fed groups were sustained to 6 months of age.  At 6 months of age, diet 
influenced cortical BMD, Ct.Ar./Tt.Ar. and Ma.Ar., with the greatest detriments to bone 
health observed in 10:1 (flaxseed) fed groups.  However, when the absolute changes 
between 3 and 6 months of age were assessed, only the detriments of 10:1 (flaxseed) 
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feeding to cortical BMD persisted, suggesting that varying PUFA ratio and n-3 source is 
not an adequate strategy to protect against OVX-induced bone loss. 
 Following a period of rapid bone growth, feeding diets with a lower ratio of n-6 to 
n-3 PUFA with n-3 provided from flaxseed oil resulted in a lower Tb.Th., suggesting an 
overall thinning of the trabecular structures of the tibia.  As there were no differences 
between diet groups for the other trabecular morphology related structures, this finding is 
generally considered to be detrimental to overall bone health.  Flaxseed (5:1) fed rats also 
experienced higher Ct.Ar./Tt.Ar., implying a benefit to the cortical structure, and a lower 
Ma.Ar. compared to diets with a higher PUFA ratio, which persisted to 6 months of age.  
Without concomitant changes to Ps.Pm. or Ec.Pm., it is difficult to interpret how a lower 
Ma.Ar. impacts bone health in this rat model.  At 6 months of age, there was no effect of 
diet on the trabecular bone, however the diet-induced effects of 5:1 (flaxseed) of the 
cortical bone at 3 months of age were sustained to 6 months of age, suggesting that the 
greater volume fraction of cortical bone acquired during periods of rapid growth are 
maintained following Sham or OVX surgery.  The changes to cortical bone 
microarchitecture with diet were not reflected in serum biomarkers of bone formation 
(OPG) or resorption (RANKL) or their ratio at study endpoint.  OVX- and diet-induced 
effects on markers of bone turnover occur rapidly in rat blood and skeletal tissue [36, 37] 
and so the lack of differences observed may be due to the extended length of time of the 
intervention period, which spanned 5 months. 
 Because of the longitudinal design of this study, the absolute change in outcomes 
from 3 through 6 months of age was analyzed.  This secondary analysis allowed us to 
isolate the effect of the intervention diets following surgery without the confounding 
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effect of the diet fed during rapid bone growth (up to 3 months of age) and showed that 
none of the differences observed at 3 months were sustained.  This suggests the proximal 
tibia is sensitive to dietary influence during periods of rapid growth, and some of the 
effects are maintained to 6 months of age, but the bone is no longer as responsive to diet 
after having undergone Sham or OVX surgery.  In fact, the only outcome to be affected 
by diet from 3 to 6 months of age was cortical BMD, with 10:1 (flaxseed) fed rats 
experiencing the greatest decline following surgery. 
 As expected, OVX caused significant detriments to trabecular bone compared to 
Sham rats [5].  For this reason, Sham and OVX rats were analyzed independently so that 
subtle effects of diet were not overshadowed by the dramatic influence of hormone status.  
Similar to previous research, diet was shown to have effects specific to hormone status, 
suggesting that bone from Sham and OVX rats does not respond to PUFA-feeding trials 
similarly [22].  Feeding 5:1 (menhaden) resulted in consistent benefits to most trabecular 
bone outcomes (compared to 5:1 (flaxseed)) and to Ct.Th, (compared to all diets) in 
Sham and OVX rats, respectively.  This suggests some effect of PUFA supplementation 
in circumstances either with or without endogenous hormone production, but not the 
same effects under both conditions.  A possible reason for the opposing diet-induced 
changes to bone microarchitecture may involve the amount of bone tissue that can be 
modulated.  With aging and following OVX, trabecular bone loss proceeds more rapidly 
than cortical bone loss simply because of the accessibility of bone surface area for 
remodeling to initiate [38, 39].  In OVX rats that experience rapid trabecular bone loss, 
PUFA-supplementation may only have the opportunity to influence cortical bone as most 
trabeculae are resorbed within 1 month following surgery [5].  Therefore, feeding a diet 
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with PUFA levels that are attainable through a healthful diet alone, without 
supplementation, may not be adequate to protect against the rapid and substantial 
deterioration of trabecular bone tissue at the proximal tibia or lumbar vertebrae following 
OVX at 3 months of age in the rat. 
 Contrary to our hypothesis, no consistent benefits of either n-3 source were 
observed at either time point.  In general, a benefit to trabecular bone was found with 
diets supplemented with menhaden oil compared to flaxseed oil, but no consistent effect 
of either n-3 source was observed for cortical bone outcomes.  ALA is the predominant n-
3 PUFA found in flaxseed oil and can be converted to EPA and DHA, although this 
process is relatively inefficient [40].  Therefore, results from this study suggest that 
dietary ALA does not produce an equivalent biological response to EPA+DHA-rich lipid 
sources.  In a previous study of young female rats, feeding either flaxseed or menhaden 
oil caused significant increases in femur BV/TV compared to corn oil control, but no 
differences were observed between these two n-3 sources [17]. 
 In general, a benefit to bone health was observed with a lower n-6 to n-3 PUFA 
ratio, although these observed benefits were not consistent.  Previous research in growing 
and OVX rats has suggested benefits of a lower PUFA ratio [14, 16-19, 27]; these ratios 
often do not represent normal dietary intake patterns.  Some controversy surrounding the 
relevancy of the importance of the n-6 to n-3 PUFA ratio has arisen in relation to 
cardiovascular disease risk [41], although limited studies have been aimed at assessing 
bone health outcomes.  Rather, the absolute amount of n-3 PUFA in the diet may be of 
more importance [42, 43].  Although the current study found no consistent implications 
to bone health with varying the absolute amounts of n-3 PUFA, more research should be 
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undertaken to further elucidate the influence of n-6 and n-3 PUFA ratio in the diet and its 
effect on bone microarchitecture changes.  Therefore, the consumption of a low n-6 to n-
3 PUFA ratio with a balance of both ALA and EPA+DHA-rich sources may be the most 
appropriate strategy for the attainment and preservation of bone mass and 
microarchitecture, rather than focusing on a single fatty acid source.  
 In contrast to many findings reported in the literature, hormone status did not have 
an effect on lean, non-lean, or bone mass.  Following OVX, rats experience significant 
increases in fat mass compared to their Sham counterparts [44].  This discrepancy may be 
due to the relatively small ROI under investigation.  Body composition was measured in 
the abdominal region surrounding LV3 only, a much smaller region than would be 
measured using DXA.  Diet did however have an effect on body composition, whereby 
within Sham rats, those receiving diets of 5:1 (menhaden) had lower percent lean mass 
volume compared to all other Sham rats and greater non-lean volume relative to VOI 
length compared to 5:1 (flaxseed) fed Sham rats.  Few studies in the literature have 
directly compared the source of n-3 on body composition of the rat, but supplementation 
of male Wistar rats with EPA has resulted in a decreased total body lean mass compared 
to control feeding [45] when ALA-supplementation did not.  The reduction in non-lean 
volume with flaxseed supplementation observed in this study has been supported in 
studies of young male Wistar rats [46], male rats post-weaning [47], and during lactation 
[48].  Future research should be undertaken to determine the varying effects of n-3 source 
and PUFA ratio on the changes to body composition within a larger VOI throughout the 
lifespan in the rat. 
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 The experimental design of this study has several strengths, including the 
exposure to PUFA supplementation over the life-course, the balanced composition of the 
intervention diets to provide attainable dietary PUFA levels, and the longitudinal 
evaluation of in vivo bone microarchitecture using µCT.  Although commonly used to test 
nutritional interventions [19], a limitation of this study involves the young age (3 months) 
of the rats when randomized to surgery as rats may still be undergoing skeletal growth [5] 
and the relatively small VOI used for the determination of body composition.  A further 
limitation of this study was the inability to interpret some of the cortical bone changes.  
Although the µCT scans were completed at sufficient resolution to attain a high quality 
image [33], a longer follow-up period may have been necessary to observe changes in 
both primary and secondary outcomes. 
 In summary, providing a diet with varying n-6 to n-3 PUFA ratio at levels 
attainable through healthful diet patterns in humans does not cause consistent changes to 
the primary bone structure outcomes most commonly associated with changes to bone 
strength (i.e., BV/TV, Ct.Ar./Tt.Ar., Ct.Th.).  Feeding a lower PUFA ratio (5:1 versus 
10:1) by providing higher absolute amounts of n-3 (as flaxseed oil) does result in benefits 
to cortical bone during growth and these benefits are sustained during periods of bone 
remodeling (following OVX).  However, feeding this diet (5:1 (flaxseed)) resulted in 
significant detriments to trabecular bone compared to 5:1 (menhaden) fed Sham groups.  
In conclusion, altering the source and absolute amount of n-3 PUFA to provide varying n-
6 to n-3 PUFA ratios in the diet caused differences in bone structure between groups at 3 
and 6 months of age but many of these differences are not consistent.  Dietary n-3 PUFA 
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provided at two physiologically relevant levels is not an adequate strategy to protect 
against OVX-induced trabecular bone loss.  
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Chapter 8: General Discussion 
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Major Research Findings 
 
 The studies of this thesis can be grouped into a) those that evaluated the method 
of µCT scanning for its use in characterizing the time course of OVX-induced changes to 
bone microarchitecture of the proximal tibia (Studies 1 through 3), and b) those that 
evaluated the impact of a nutritional intervention on bone health during periods of growth 
and following OVX (Study 4).  The major findings from Studies 1 through 3 are 
summarized in Figure 8-1. 
 The first study presented in this thesis (Study 1, Chapter 5) was performed to 
investigate the time course of structural changes to the trabecular and cortical bone of the 
proximal tibia of female rats having undergone Sham- or OVX-surgery at 3 months of 
age.  Findings from this study showed that rats randomized to receive OVX-surgery 
experienced characteristic declines in trabecular BMD, BV/TV, and Tb.N., and increases 
in Tb.Sp. from surgery at 3 months of age to 5 months of age.  These changes were 
maintained until 6 months of age, suggesting a plateau of trabecular bone loss was 
reached by 5 months of age (2.25 months post-surgery).  In contrast, Sham-control rats 
did not experience changes to trabecular BMD, BV/TV, or Tb.Sp., and Tb.N. only 
slightly declined from 4 to 5 months of age.  Therefore, these results suggest that OVX at 
3 months of age produces a characteristic decline in trabecular bone quantity and 
structure, as measured by µCT, similar to the early events reported in postmenopausal 
women (1).   
 The changes to trabecular bone microarchitecture of the proximal tibia of OVX 
rats can be confidently compared to Sham-operated rats, as trabecular bone 
microarchitecture of Sham rats remained relatively stable, with only minor fluctuations in 
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Tb.Th., Tb.N., and DA throughout the study period.  These findings are in contrast to 
previous studies, which described a reduced osteoporotic response in Wistar rats 
undergoing OVX at 3 months of age compared to Sham (2).  The authors of this study 
suggested that Sham rats were still undergoing growth at this age.  The discrepancy 
between this and the current study may be due to the species of rat under investigation or 
the scanning parameters used.  A major strength of the current thesis involved the 
repeated in vivo imaging of the same rat over time to provide a time course of changes to 
bone with natural aging (Sham) and in response to OVX. 
 OVX at 3 months of age did not produce a change in cortical bone of the proximal 
tibia as expected.  Also, a comparison of the changes to cortical bone from OVX and 
Sham animals is difficult as Sham rats experienced changes that suggest continued 
growth.  Sham-control rats experienced an increase in Ct.Ar./Tt.Ar., Ct.Th., Ct.Ar., and a 
decrease in Ps.Pm. and Ma.Ar.  Therefore, the 3-month SD rat can be considered a good 
preclinical model for the study of therapeutic agents on the trabecular bone of the 
proximal tibia, but not the cortical bone.  Food and Drug Administration guidelines do 
however recommend two different animal species to be tested, the second of which to be 
a larger OVX non-rodent species with more extensive cortical remodeling (3).  Findings 
from Study 1 of this thesis are supportive of this recommendation, as the cortical bone 
outcomes tested experienced a great deal of fluctuation.  This may be due to the age of 
the rat at OVX, but also because of the relatively low amount of intra-cortical remodeling 
experienced compared to human cortical bone (4).  A disadvantage of the rat model 
involves its lack of Haversian systems (5, 6), which limit the surface area on which bone 
multicellular units initiate and complete remodeling cycles.  More research should be 
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undertaken to investigate the changes to the cortical bone of the midpoint of the rat tibia 
from 3 through 6 months of age using in vivo µCT. 
 Current guidelines for the preclinical evaluation of drugs and other therapeutic 
agents for the treatment of osteoporosis provide recommendations for the animal models 
used, but fail to recommend the ages of the rats to be used (3).  Several authors have 
suggested performing OVX at 9 months of age, when the rats near senescence (7-9), but 
ordering, aging, and maintaining laboratory rats for extended periods of time becomes 
costly and time-consuming.  For this reason, many preclinical studies of osteoporosis 
drug therapies have used the younger, 3-month OVX rat model (10-12).  Findings from 
this thesis support the use of this model when assessing trabecular bone structure by 
µCT.   
 A novel finding of Study 1, and arguably the most important, was the significant 
difference observed in BMD, BV/TV, and all other trabecular indices between Sham and 
OVX rats only one week post-surgery.  This is the earliest detectable loss of bone 
reported in the literature.  This finding highlights the importance of attaining a true 
baseline value (before randomization to Sham or OVX), only possible by performing 
surgeries on-site and not by the supplier. 
 Findings from Study 2 (Chapter 5) demonstrated that repeated in vivo µCT 
scanning of the proximal tibia at intervals commonly used for the longitudinal evaluation 
of bone microarchitecture does not affect the trabecular or cortical outcomes examined.  
The only main effect of repeated radiation at 600 mGy was a decrease in Ecc., describing 
the change in the cortical bone shape from circular toward elliptical.  Changes to this 
parameter are often associated with altered load bearing.  Although a strength of this 
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study was the use of contralateral limbs to reduce any inter-animal variability, the loads 
applied to the ankle and distal tibia during repeated scanning were not controlled for and 
may have caused the differences in Ecc. that were observed.  A similar finding of 
decreased Ecc. with repeated irradiation has been found in our lab using a male mouse 
model at a radiation dose of 222 mGy (Sacco et al. 2016, unpublished data), further 
suggesting that this finding was not due to chance, alone.  Results from Study 2 provide 
future researchers with confidence when interpreting results of an intervention without 
the confounding effects of radiation exposure.  This is critical as the use of µCT for the 
assessment of bone quality is the gold standard in preclinical rodent studies (13-15). 
 Following the completion of Study 1 and 2, Study 3 (Chapter 6) was designed to 
determine the relative impact of µCT scanning parameters on the trabecular and cortical 
outcomes of the tibia.  Results from this study demonstrated that in vivo and ex vivo 
scanning of the proximal tibia in Sham or OVX rats did not affect the trabecular or 
cortical outcomes assessed.  This finding is important for the design of future 
experiments.  Considerations must be made when designing experiments with preclinical 
rodent models for the time and cost of many endpoint measures.  While utilizing more 
animals provides a more comprehensive assessment of changes to bone health, the 
feasibility of scheduling these in vivo measurements is not always practical.  With the 
results from Study 3, researchers can confidently exchange the timely and costly endpoint 
in vivo µCT scans with ex vivo scans of harvested and cleaned bone samples, to be 
completed at a later, more convenient time.  And, these ex vivo scans can be compared to 
in vivo scans of baseline and interim time points with confidence.  While this study only 
assessed a single skeletal site, future research should be undertaken to determine if 
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quantification of bone quality at other sites, such as the LV, are also unaffected by scan 
parameters.  Results of this study cannot simply be extrapolated to these other bone sites 
because a thin layer of soft tissue surrounds the proximal tibia only, whereas a thick layer 
of muscle, adipose, skin, and organs surrounds the LV.  This surrounding tissue alters the 
path of the X-ray, and may ultimately have an effect on the outcomes assessed. 
 Scanning of the tibia ex vivo at a voxel size of 18µm over or underestimated 
several of the trabecular and cortical outcomes that are quantified, due to the limited 
extent to which the bone network can be visualized compared to scans of 9µm.  This 
finding is important when interpreting and comparing absolute values among studies (or 
within studies) using different scanning techniques and voxel sizes.  The best evidence of 
this is demonstrated in the shifted distribution of Tb.Th. between 18µm and 9µm scan 
settings (Figure 6-1).  When comparing relative values however, most microarchitecture 
outcomes were correlated between 9µm and 18µm scan settings.  This supports the use of 
a larger voxel size when assessing the relative changes at the proximal tibia between 
groups in a study.  This is applicable to studies of very large sample size as smaller voxel 
size scans require significantly more time and hard drive space when scanning, 
reconstructing, and analyzing.
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Figure 8-1. Summary of the major research findings from Study 1, 2, and 3 
These studies evaluated the method of µCT scanning for its use in characterizing the time course of bone microarchitecture changes of 
the proximal tibia following OVX at 3-months of age.
Use of μCT for the characterization of OVX rat model of postmenopausal osteoporosis
Study 1 Study 2 Study 3
Sham rats experienced:
Trabecular Outcomes
•  No change in BMD, BV/TV, 
Tb.Sp.
•  ê Tb.N., DA
•  Fluctuation in Tb.Th.
Cortical Outcomes
•  é Ct.Ar./Tt.Ar., Ct.Th.
•  ê Ps.Pm., Ma.Ar.
•  Fluctuation in Ec.Pm., Ecc.
OVX rats experienced:
Trabecular Outcomes
•  ê BMD, BV/TV, Tb.N.
•  é Tb.Sp. 
•  Fluctuation in Tb.Th., DA 
Cortical Outcomes 
•  ê Ec.Pm., Ma.Ar.
•  é Ct.Ar./Tt.Ar., Ct.Th. 
•  Fluctuation in Ps.Pm., Ecc.
•  Repeated radiation exposure 
ê Ecc. 
•  Repeated radiation exposure 
did not affect any other 
trabecular or cortical 
outcome of the proximal 
tibia
•  No effect of in vivo versus 
ex vivo scanning 
•  Smaller sample size needed 
to detect differences 
between Sham and OVX 
groups with in vivo scanning 
•  Scanning with different 
voxel sizes alters absolute 
but not relative differences 
between groups  
•  All scan parameters tested 
are able to determine 
differences between Sham 
and OVX groups
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 Study 1 to 3 of this thesis were methodological in nature and further characterize 
the use of in vivo and ex vivo imaging of preclinical models of osteoporosis by µCT.  
Results of these methodological studies influenced the experimental design of Study 4 
(Chapter 7) in several ways: providing a time course for the changes to bone structure 
following Sham and OVX surgery at 3 months of age, providing confidence in the 
method and safety of repeated in vivo scanning of the proximal tibia, highlighting the 
necessity of conducting Sham and OVX surgeries independently, and refining the scan 
settings used to provide high image quality.   
A summary of the major research findings from Study 4 is reported in Figure 8-2. 
Results of this nutritional intervention demonstrate that a PUFA intervention of varying 
n-3 source and n-6 to n-3 ratio can modulate bone microarchitecture during periods of 
rapid growth, but that this may not be an adequate strategy for the prevention and 
treatment of OVX-induced bone loss.  Feeding diets of 5:1 (Flaxseed) from 1 through 3 
months of age reduced Tb.Th., and Ma.Ar. and increased Ct.Ar./Tt.Ar. compared to rats 
receiving diets with a 10:1 PUFA ratio in the proximal tibia.  These changes to the 
cortical bone in young, growing rats are suggestive of a response to consuming a lower 
PUFA ratio when n-3 is provided primarily as ALA from flaxseed oil, but not as EPA 
and DHA from menhaden oil.  At 6 months of age, an effect of diet was observed in only 
some cortical indices.  To determine the effect of diet and hormone status following 
randomization to Sham or OVX surgery only, the change in microarchitecture outcomes 
from 3 through 6 months of age can be quantified in each animal.  This analysis removed 
any initial effect of diet on bone outcomes from 1 through 3 months of age.  When the 
change from 3 to 6 months of age was analyzed, diet had a significant effect on cortical 
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BMD and Ecc. only.  Together, these results suggest that bone of the proximal tibia is 
responsive to PUFA intervention (specifically when supplied in a 5:1 ratio with n-3 
provided as ALA from flaxseed oil) during periods of rapid growth, but that these 
changes are not maintained following Sham or OVX surgery. 
 When LV4 was analyzed in a subset of rats at 3 months of age (n=4-6/group), 
fewer main effects of diet were uncovered, highlighting the skeletal-site specific response 
to an intervention in the rat.  This is most likely due to an altered loading pattern and the 
mechanical forces that are applied to the proximal tibia compared to the LV4 in the rat.  
Rats are quadrupeds, and therefore their spines experience less loading than bipeds.  Of 
importance to note, LV4 analysis was done ex vivo.  Following from results from Study 
3, the removal of soft tissue surrounding LV3 may have had an effect on the 
quantification of bone outcomes.  Also, the exposure of the organs and abdominal tissues 
to the radiation exposure necessary to acquire a high quality image was a concern and 
prevented in vivo measurements at this skeletal site.  
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Figure 8-2. Summary of the major research findings from Study 4
Proximal Tibia:
•  10:1 (Flaxseed) ê cBMD 
(compared to all groups) 
•  5:1 (Flaxseed) é Ct.Ar./Tt.Ar., 
ê Ma.Ar.  
 
 
LV4: 
•  10:1(Menhaden) é BV/TV and 
Tb.N. (compared to 
5:1(Flaxseed)) 
 
Serum Biomarkers: 
•  No effect of diet on OPG, RANKL, or their ratio 
Proximal Tibia:
•  5:1 (Flaxseed) ê Tb.Th.,  
é Ct.Ar./Tt.Ar. 
(compared to 10:1 groups) 
•  5:1 (Flaxseed) ê Ma.Ar. 
(compared to 10:1 
(Flaxseed)) 
 
LV4: 
•  10:1 (Menhaden) ê DA 
(compared to Flaxseed 
groups)
Use of μCT for the evaluation of lifelong PUFA-supplementation
Growth (1-3 months) Following SHAM/OVX
Change from 3-6 months
SHAM only
Proximal Tibia:
•  10:1 (Flaxseed) ê cBMD 
(compared to all groups) 
Trabecular Outcomes
Proximal Tibia:
•  5:1 (Menhaden) é tBMD, 
BV/TV, Tb.N., ê Tb.Sp. 
(compared to 5:1 (Flaxseed)) 
  
LV4: 
•  5:1 (Menhaden) é Tb.N. 
(compared to 10:1 (Flaxseed)) 
OVX only
Cortical Outcomes
Proximal Tibia:
•  5:1 (Menhaden) ê Ct.Ar., 
Ma.Ar. (compared to 10:1 
(Flaxseed)) 
•  5:1 (Menhaden) é Ct.Th. 
(compared to all diets) 
•  5:1 diets ê Ct.Ar./Tt.Ar. 
(compared to 10:1 diets)  
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 Because of the robust effect of OVX on the microarchitecture of bone, Sham and 
OVX rats were examined independently.  When this was done, Sham and OVX rats 
experienced diet-related changes to trabecular and cortical bone, respectively.  Benefits 
were observed to bone health in both groups when rats received diets with a low PUFA 
ratio (5:1 compared to 10:1).  The finding that different bone types responded to diet in 
different surgery-type rats is most likely because of the bone that was available for the 
nutrients to influence.  Following OVX or menopause, trabecular bone is lost more 
rapidly, not because of its composition, but because of its increased surface area on which 
bone multicellular units can be initiated (16).  Therefore, in the 3-months post-OVX, the 
nutritional intervention that rats were randomized to is only able to influence cortical 
bone structure, as almost all trabeculae have been resorbed.  This finding strongly 
suggests against the adequacy of a nutritional intervention, specifically dietary PUFA, to 
protect against such drastic and deleterious trabecular bone loss induced by OVX.     
 Study 4 also examined the effect of diet and hormone status on body composition 
using in vivo µCT.  In contrast to many findings reported in the literature, hormone status 
did not have an effect on lean, non-lean, or bone mass.  Following OVX, rats experience 
significant increases in fat mass compared to their Sham counterparts (17).  This 
discrepancy is likely due to the relatively small ROI under investigation.  Body 
composition was measured in the abdominal region surrounding LV3 only, a relatively 
small region compared to length of multiple vertebrae when assessed by DXA (17) and in 
validation studies of µCT (18-20).  Diet did however have an effect on body composition.  
Within Sham rats, those receiving diets of 5:1 (Menhaden) had lower percent lean mass 
volume compared to all other Sham rats and greater non-lean volume relative to VOI 
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length compared to 5:1 (Flaxseed) fed Sham rats.  This result is in line with the findings 
in bone, that ALA fed groups experience greater benefits to health, including lower non-
lean (fat) mass and greater lean mass compared to fish oil fed rats. 
 This intervention study also examined bone biomarkers in an effort to determine 
the mechanism by which bone structure is changing.  As expected, OVX significantly 
increased serum RANKL, lower serum OPG and the ratio of OPG to RANKL compared 
to Sham rats (21-23), but there was no effect of diet on these markers.  The lack of 
findings may be due to the timing of blood collection, as treatment-induced effects on 
markers of bone turnover occur rapidly in rat blood and skeletal tissue (21, 24, 25).  
Limited studies in cell culture models have suggested that n-6 PUFA stimulate 
osteoclastogenesis and downstream bone resorption through the OPG/RANKL pathway 
(26, 27), but no studies have investigated the role of ALA on the expression of OPG and 
RANKL or in comparison with the longer chain n-3 PUFA.  While findings from this 
thesis do not suggest that the changes to bone structure are through altered expression of 
OPG and RANKL, studies in cell culture should be undertaken before this mechanism is 
dismissed. 
Implications for Future Research using µCT 
 
 The findings from this thesis highlight the safety of repeated in vivo µCT 
scanning of the hind limb of the rat at a monthly radiation exposure of 600 mGy.  This 
amount of X-ray radiation, applied directly to the hind limb, can be attained with settings 
necessary for the acquisition of high-quality images and appropriate X-ray transmission 
levels.  The hormone status (Sham versus OVX) of the rat does not alter its resistance to 
repeated X-ray radiation. 
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 When examining the proximal tibia, in vivo and ex vivo scanning does not affect 
the trabecular or cortical outcomes assessed.  Scanning the proximal tibia at a voxel size 
of 18µm does however significantly change the absolute values of some 
microarchitecture outcomes compared to scanning at 9µm voxel size.  Scanning at these 
voxel sizes do not result in relative differences.  Therefore, timely and costly endpoint in 
vivo scanning can be replaced with ex vivo scanning in future experiments.  Also, relative 
(but not absolute) values can be compared across studies of different voxel size and scan 
settings. 
Implications for Future Research using the OVX Rat Model of 
Postmenopausal Osteoporosis 
 
 The findings from this thesis provide a basis for the further use of the 3-month 
OVX SD rat as a model of postmenopausal osteoporosis.  This rat model can be used for 
the assessment of changes to trabecular bone of the proximal tibia.  Trabecular bone of 
the 3-month OVX rat experiences characteristic declines in BMD, bone volume, and 
trabecular microarchitecture indices over a 3-month time course.  While Sham-operated 
rats do not experience changes to the trabecular bone microarchitecture from 3 through 6 
months of age, suggesting these rats do not experience substantial growth between these 
time points.  This model should not be used for the assessment of changes to cortical 
bone at this skeletal-site.  Further study should be undertaken to determine if the 
diaphysis or midpoint of the tibia or femur is a more appropriate skeletal-site when 
analyzing cortical bone.  
 The applicability of this model to the menopausal transition in women should 
however be strongly considered when designing future experiments.  Unlike the human 
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condition, OVX causes a severe and abrupt end to endogenous hormone production with 
the complete removal of the ovaries.  While the natural transition to menopause in 
humans is experienced over a period of several years.  With this slowed loss of estrogen 
production, women experience a ‘window of opportunity’ during the 5-10 year period 
coinciding with the transition in which bone turnover is greatly up-regulated and bone 
cells may be more responsive to treatment (28, 29).  To appeal this difference when 
designing preclinical studies, the intervention should be of sufficient duration to be 
equivalent to a one-year study in humans.  The average bone turnover cycle in humans 
and rats is roughly 200 and 40 days, respectively (30, 31).  Therefore, a 12-week study in 
the rat is approximately two complete remodeling cycles, which is roughly equivalent to 
a 1.5-year trial in humans. 
Dietary PUFA as Prevention for Postmenopausal Osteoporosis 
In Animals 
 Results from this thesis (Study 4, Chapter 7) are not supportive of a dietary PUFA 
intervention of varying PUFA ratio and n-3 source as a prevention of OVX-induced bone 
loss.  Although varying the PUFA ratio and n-3 source to levels attainable in the human 
diet through healthful nutrition patterns altered aspects of bone structure during periods 
of rapid growth, these changes were not sustained following OVX.   
 These findings support the notion that nutrients are not drugs, and at levels 
attainable through diet alone and not with supplementation, do not act on the skeleton like 
drugs.  This is especially true after the abrupt hormonal-insult of OVX.  These 
conclusions however, are not a cause for concern, or a reason to abandon all healthful 
eating habits.  As summarized in Chapter 2, there are several studies in the literature 
supporting the intake of a lower PUFA ratio and n-3’s from either plant or fish oils on 
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bone health outcomes in a preclinical model.  Not surprisingly, these positive findings are 
often observed when an intervention diet is compared to a control diet with very high n-6 
content (i.e., safflower oil-fed control, corn oil-fed control) and a very high PUFA ratio.  
A major strength of this thesis (Study 4) was the composition of the four intervention 
diets, and their physiologically relevant PUFA ratios.  If a 5th diet were to be included as 
an n-6 ‘control diet’, it is hypothesized that all PUFA intervention diets would have 
significantly improved all bone-related outcomes by comparison.  This was not the 
objective of the current study, however, as we aimed to determine changes to bone health 
with PUFA levels attainable through diet alone.  While PUFA-intervention alone was not 
an adequate strategy for the prevention of OVX-related trabecular bone loss, flaxseed has 
been shown to improve bone mass and strength in combination with low dose estrogen 
(32).  Therefore, PUFA may be a novel pairing in future research of food-drug synergy 
and the prevention of postmenopausal osteoporosis. 
 A major strength of this thesis was the study of exposure to PUFA interventions 
over the life course and the repeated in vivo imaging of the proximal tibia throughout 
periods of growth and following OVX.  Unlike studies of a nutritional intervention 
introduced immediately following OVX, this design applied to human diet patterns, 
which remain relatively constant throughout the lifespan (33, 34).  Therefore, the 
nutritional intervention was tested as a preventative approach, rather than a treatment.  
And unfortunately, a lifelong PUFA intervention does not protect against trabecular bone 
loss induced by OVX at 3 months of age in the rat model. 
In Humans 
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Worldwide, the incidence of fragility fracture varies substantially and this 
variation may be attributable to difference in lifestyle, including dietary patterns (35).  
The relation between PUFA intake and aspects of bone health have been tested in several 
observational studies and RCTs of postmenopausal women and in general, have yielded 
strong associations between some PUFAs and bone health in the observational studies, 
but not with the RCTs (Table 2-12).   
There are several reasons that positive findings have been found with 
observational studies, but null effects have been reported in RCTs.  First, the diet pattern 
of an individual remains fairly stable throughout the lifespan (33, 34).  Therefore, when 
assessing dietary patterns through observational studies, the nutrient under investigation 
has existed in the individual, having its biological effect, for years at a time.  This major 
difference between observational studies and RCTs was taken into consideration when 
designing Study 4, aimed at determining the effect of PUFA supplementation over the 
life course in the rat.  Furthermore, RCTs assessing bone health outcomes in response to a 
change in PUFA intake have generally resulted in a null effect because the experiment 
follows a design specifically developed for the testing of drugs (36) and as mentioned 
above, nutrients are not drugs.   
To begin, no RCTs reviewed in this thesis measured the basal PUFA status, 
although some studies did exclude participants based on consumption of flaxseed 
products, n-3 supplements, or high intakes of fish (37-39).  It is important to have an 
understanding (or a nominal value) of a participant’s baseline nutritional status, because 
this will change the response of the nutrient under investigation.  For example, if the 
participant is deficient or consuming lower than recommended levels of a nutrient or food 
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component, supplementation will produce a measurable benefit, whereas, if the 
participant is replete, supplementation will produce a null effect.  Similarly, the 
nutritional intervention being tested must be large enough to effectively change the 
nutrient status.  RCTs of ALA supplementation reviewed in this thesis have provided 
between 5.75 – 17.3 g ALA/d as flaxseed with no observed benefit to bone health (37, 
38).  Rather than assuming no benefit to bone occurs with ALA supplementation in 
postmenopausal women, the nutrient range that provides a benefit may have been 
exceeded.  This is supported by prospective studies reporting a decrease total fracture risk 
and increase lumbar spine BMD with increasing ALA intake above 0.08 g ALA/d and 
above 1.02 g ALA/d, respectively (40, 41).  Therefore, what may be more pertinent to our 
understanding of ALA (and EPA+DHA) are studies intended to quantify the transition 
between inadequate to adequate nutrient status and the relevant range of intake necessary 
for a response.  
Finally, and arguably most difficult, when testing the effect of specific nutrients, 
co-nutrient status must also be considered and controlled for.  Nutrients interact with one 
another (i.e., PUFA ratio, calcium and vitamin D) therefore, all other interacting nutrients 
should also be considered.  Specifically, in studies of bone health, it is important to 
control for calcium, vitamin D, and protein intake.  Failure to control for these other 
bone-supporting nutrients may influence individual results, and the overall findings of a 
study. 
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Chapter 9: Conclusions 
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Conclusions 
 
Study 1: Time-course of the changes to bone microarchitecture in the 3-month OVX 
rat model of postmenopausal osteoporosis 
 
• Randomization to surgery at 3-months of age resulted in characteristic declines in 
trabecular and cortical BMD, BV/TV, Tb.N., and Ec.Pm., and increases in Tb.Sp. 
in OVX rats but not in Sham-control rats. 
• Sham rats experienced decreased Ps.Pm., and Ma.Ar. 
• OVX rats experience decreased Ec.Pm., Ma.Ar., and increased Ct.Ar./Tt.Ar., and 
Ct.Th. 
Study 2: Characterization of the effect of repeated radiation exposure by in vivo 
µCT scanning in rat tibia 
 
• Monthly repeated radiation exposure did not affect the trabecular 
microarchitecture of the proximal tibia in Sham or OVX rats. 
• Monthly repeated radiation exposure reduced mean Ecc. of the proximal tibia.  No 
other cortical microarchitecture outcome was affected by repeated radiation 
exposure in Sham or OVX rats. 
Study 3: Comparison of ex vivo and in vivo µCT of rat tibia at different scanning 
settings 
 
• Scanning of the proximal tibia in vivo or ex vivo did not affect the quantification 
of trabecular or cortical microarchitecture in Sham or OVX rats. 
• Scanning of the proximal tibia at 18µm voxel size overestimated Tb.Th., Ct.Ar., 
Ct.Th., DA, Ct.Ar./Tt.Ar., and underestimated Conn.D. compared to 9µm voxel 
size scans. 
• Regardless of scan protocol, significant differences between Sham and OVX rats 
can be detected for all microarchitecture outcomes, expect Tb.Th. 
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Study 4: Lifelong intake of flaxseed or menhaden oil to provide varying n-6 to n-3 
PUFA ratios modulate bone microarchitecture during growth, but not after OVX 
 
• Feeding ALA from flaxseed in a 5:1 ratio from 1 through 3 months of age 
resulted in decreased Tb.Th., Ma.Ar., and increased Ct.Ar./Tt.Ar. of the proximal 
tibia and increased DA of the LV4. 
• Diet had no effect on the trabecular bone microarchitecture of the proximal tibia 
at 6 months of age or when the change from 3 to 6 months of age was assessed. 
• Within Sham rats, feeding EPA+DHA from menhaden oil in a 5:1 ratio 
favourably altered some trabecular bone outcomes compared to 5:1 (Flaxseed) fed 
rats. 
• Within OVX rats, diet had an effect on cortical but not trabecular 
microarchitecture. 
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Chapter 10: Future Research 
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Future Research 
  
 The results of this thesis have identified a number of areas for future research. 
Findings from Study 1 do not support the use of the cortical bone of the proximal tibia as 
an appropriate model for use in drug and nutrition therapies, but an investigation into the 
time course of changes to the midpoint of the tibia in the 3-month OVX rat model should 
be undertaken.  At the midpoint, high-resolution imaging can be used to quantify cortical 
porosity and changes to intra-cortical remodeling.  As the guidelines for designing 
preclinical studies to support the approval of therapies intended for the treatment of 
osteoporosis suggests, a time course of changes to bone microarchitecture should be 
completed in a second, larger non-rodent species with more extensive cortical 
remodeling, similar to in humans.   
 Further research should also be conducted to test the effect of scanning in vivo 
compared to ex vivo at a second skeletal site, such as the LV.  Results from Study 3 
cannot simply be extrapolated to this site that is surrounded by significantly more soft 
tissue.  Similarly, the effect of repeated radiation exposure to the organs surrounding the 
LV should be elucidated to determine the safety of ionizing radiation to this region of the 
body.  
 Although the OVX rat experiences changes to bone quantity and quality that are 
characteristic of postmenopausal women, the development and use of a preclinical model 
that more closely mimics the human situation during the menopausal transition is an area 
for future research.  Unlike in humans, OVX causes an abrupt end to endogenous 
hormone production, and a substantial and rapid decline in skeletal quantity and quality.  
Future investigation should be focused on the development of a model that is still 
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relatively inexpensive, can be studied over the short-term, has a similar skeletal anatomy 
to humans, and can be raised in standardized conditions, but undergoes a steady transition 
from pre- to post-menopause.  With a model that more closely mimics the human 
condition, whether PUFA-supplementation over the life course more effectively protects 
against the hormone-induced bone loss can be determined.  Such a model would also 
allow us to identify other dietary modulations that promote and support bone health 
during the menopausal transition and the ‘window of opportunity’. 
 As seen in Study 4, supplementation with a lower PUFA ratio when n-3 was 
provided as ALA from flaxseed oil resulted in changes to the growing skeleton, 
potentially increasing peak bone mass in the rat.  Although this did not result in any 
protection against the abrupt hormonal insult of OVX, whether long-term intake of a 
similar PUFA profile can increase peak bone mass in young adults and protect against the 
natural loss of bone in the postmenopausal situation is a novel research question.  
Moreover, the mechanism(s) by which ALA and EPA+DHA exert their effects on bone 
health during periods of rapid growth are an area of future research needed to further our 
understanding.  With knowledge of the mechanism of action of these n-3 PUFA, food-
drug synergy experiments can be explored as potential therapies for the prevention and 
protection against the development of postmenopausal osteoporosis. 
 249 
References 
 
1. Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M, Peterson 
JM, Melton LJ, 3rd. Effects of sex and age on bone microstructure at the 
ultradistal radius: a population-based noninvasive in vivo assessment. J Bone 
Miner Res 2006;21(1):124-31 
2. Francisco JI, Yu Y, Oliver RA, Walsh WR. Relationship between age, skeletal 
site, and time post-ovariectomy on bone mineral and trabecular microarchitecture 
in rats. J Orthop Res 2011;29(2):189-96 
3. US Department of Health and Human Services. Osteoporosis: Nonclinical 
Evaluaion of Drugs Intended for Treatment. Guidance for Industry: Food and 
Drug Administration, Center for Drug Evaluation and Research (CDER), 2016. 
4. Szulc P, Seeman E, Duboeuf F, Sornay-Rendu E, Delmas PD. Bone fragility: 
failure of periosteal apposition to compensate for increased endocortical 
resorption in postmenopausal women. J Bone Miner Res 2006;21(12):1856-63 
5. Turner AS. Animal models of osteoporosis--necessity and limitations. Eur Cell 
Mater 2001;1:66-81 
6. Turner RT, Maran A, Lotinun S, Hefferan T, Evans GL, Zhang M, Sibonga JD. 
Animal models for osteoporosis. Rev Endocr Metab Disord 2001;2(1):117-27 
7. Iwaniec U, Turner R. Animal models of osteoporosis. Osteoporosis 2008;2:985-
1009 
8. Jee WS, Yao W. Animal models of bone diseases. Introduction. J Musculoskelet 
Neuronal Interact 2001;1(3):183-4 
9. Liu CC, Kalu DN. Human parathyroid hormone-(1-34) prevents bone loss and 
augments bone formation in sexually mature ovariectomized rats. J Bone Miner 
Res 1990;5(9):973-82 
10. Ominsky MS, Li X, Asuncion FJ, Barrero M, Warmington KS, Dwyer D, Stolina 
M, Geng Z, Grisanti M, Tan HL, et al. RANKL inhibition with osteoprotegerin 
increases bone strength by improving cortical and trabecular bone architecture in 
ovariectomized rats. J Bone Miner Res 2008;23(5):672-82 
11. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey 
DL, Dunstan CR. OPG and PTH-(1-34) have additive effects on bone density and 
mechanical strength in osteopenic ovariectomized rats. Endocrinology 
2001;142(10):4295-304 
12. Dempster DW, Lambing CL, Kostenuik PJ, Grauer A. Role of RANK ligand and 
denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a 
review of preclinical and clinical data. Clin Ther 2012;34(3):521-36 
13. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. 
Guidelines for assessment of bone microstructure in rodents using micro-
computed tomography. J Bone Miner Res 2010;25(7):1468-86 
14. MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quantitative 
computed tomography for measurement of bone quality. Med Eng Phys 
2007;29(10):1096-105 
15. Nazarian A, Snyder BD, Zurakowski D, Muller R. Quantitative micro-computed 
tomography: a non-invasive method to assess equivalent bone mineral density. 
Bone 2008;43(2):302-11 
 250 
16. Seeman E. Bone quality: the material and structural basis of bone strength. J Bone 
Miner Metab 2008;26(1):1-8 
17. Jiang JM, Sacco SM, Ward WE. Ovariectomy-induced hyperphagia does not 
modulate bone mineral density or bone strength in rats. J Nutr 
2008;138(11):2106-10 
18. Granton PV, Norley CJ, Umoh J, Turley EA, Frier BC, Noble EG, Holdsworth 
DW. Rapid in vivo whole body composition of rats using cone beam muCT. J 
Appl Physiol (1985) 2010;109(4):1162-9 
19. Hillebrand JJ, Langhans W, Geary N. Validation of computed tomographic 
estimates of intra-abdominal and subcutaneous adipose tissue in rats and mice. 
Obesity (Silver Spring) 2010;18(4):848-53 
20. Luu YK, Lublinsky S, Ozcivici E, Capilla E, Pessin JE, Rubin CT, Judex S. In 
vivo quantification of subcutaneous and visceral adiposity by micro-computed 
tomography in a small animal model. Med Eng Phys 2009;31(1):34-41 
21. Sacco SM, Chen J, Ganss B, Thompson LU, Ward WE. Flaxseed enhances the 
beneficial effect of low-dose estrogen therapy at reducing bone turnover and 
preserving bone microarchitecture in ovariectomized rats. Appl Physiol Nutr 
Metab 2014;39(7):801-10 
22. Ma B, Zhang Q, Wu D, Wang YL, Hu YY, Cheng YP, Yang ZD, Zheng YY, 
Ying HJ. Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of 
postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta 
Pharmacol Sin 2012;33(4):479-89 
23. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, 
Bai XC. Metformin stimulates osteoprotegerin and reduces RANKL expression in 
osteoblasts and ovariectomized rats. J Cell Biochem 2011;112(10):2902-9 
24. Wronski TJ, Cintron M, Dann LM. Temporal relationship between bone loss and 
increased bone turnover in ovariectomized rats. Calcif Tissue Int 1988;43(3):179-
83 
25. Zhang Y, Lai WP, Leung PC, Wu CF, Wong MS. Short- to mid-term effects of 
ovariectomy on bone turnover, bone mass and bone strength in rats. Biol Pharm 
Bull 2007;30(5):898-903 
26. Coetzee M, Haag M, Kruger MC. Effects of arachidonic acid, docosahexaenoic 
acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and 
RANKL secretion by MC3T3-E1 osteoblast-like cells. J Nutr Biochem 
2007;18(1):54-63 
27. Poulsen RC, Wolber FM, Moughan PJ, Kruger MC. Long chain polyunsaturated 
fatty acids alter membrane-bound RANK-L expression and osteoprotegerin 
secretion by MC3T3-E1 osteoblast-like cells. Prostaglandins Other Lipid Mediat 
2008;85(1-2):42-8 
28. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, 
Lo JC, Johnston JM, Cauley JA, Danielson ME, et al. Bone mineral density 
changes during the menopause transition in a multiethnic cohort of women. J Clin 
Endocrinol Metab 2008;93(3):861-8 
29. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark 
JD. Bone turnover markers and bone density across the menopausal transition. J 
Clin Endocrinol Metab 1996;81(9):3366-71 
 251 
30. Eriksen EF, Melsen F, Mosekilde L. Reconstruction of the resorptive site in iliac 
trabecular bone: a kinetic model for bone resorption in 20 normal individuals. 
Metab Bone Dis Relat Res 1984;5(5):235-42 
31. Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA Guidelines and animal 
models for osteoporosis. Bone 1995;17(4 Suppl):125S-33S 
32. Sacco SM, Jiang JM, Reza-Lopez S, Ma DW, Thompson LU, Ward WE. 
Flaxseed combined with low-dose estrogen therapy preserves bone tissue in 
ovariectomized rats. Menopause 2009;16(3):545-54 
33. Mikkila V, Rasanen L, Raitakari OT, Pietinen P, Viikari J. Consistent dietary 
patterns identified from childhood to adulthood: the cardiovascular risk in Young 
Finns Study. Br J Nutr 2005;93(6):923-31 
34. Hosking D, Danthiir V. Retrospective lifetime dietary patterns are associated with 
demographic and cardiovascular health variables in an older community-dwelling 
Australian population. Br J Nutr 2013;110(11):2069-83 
35. Lau EM, Lee JK, Suriwongpaisal P, Saw SM, Das De S, Khir A, Sambrook P. 
The incidence of hip fracture in four Asian countries: the Asian Osteoporosis 
Study (AOS). Osteoporos Int 2001;12(3):239-43 
36. Heaney RP. Guidelines for optimizing design and analysis of clinical studies of 
nutrient effects. Nutr Rev 2014;72(1):48-54 
37. Brooks JD, Ward WE, Lewis JE, Hilditch J, Nickell L, Wong E, Thompson LU. 
Supplementation with flaxseed alters estrogen metabolism in postmenopausal 
women to a greater extent than does supplementation with an equal amount of 
soy. The American journal of clinical nutrition 2004;79(2):318-25 
38. Cornish SM, Chilibeck PD. Alpha-linolenic acid supplementation and resistance 
training in older adults. Appl Physiol Nutr Metab 2009;34(1):49-59 
39. Dodin S, Lemay A, Jacques H, Legare F, Forest JC, Masse B. The effects of 
flaxseed dietary supplement on lipid profile, bone mineral density, and symptoms 
in menopausal women: a randomized, double-blind, wheat germ placebo-
controlled clinical trial. J Clin Endocrinol Metab 2005;90(3):1390-7 
40. Jarvinen R, Tuppurainen M, Erkkila AT, Penttinen P, Karkkainen M, Salovaara 
K, Jurvelin JS, Kroger H. Associations of dietary polyunsaturated fatty acids with 
bone mineral density in elderly women. Eur J Clin Nutr 2012;66(4):496-503 
41. Orchard TS, Cauley JA, Frank GC, Neuhouser ML, Robinson JG, Snetselaar L, 
Tylavsky F, Wactawski-Wende J, Young AM, Lu B, et al. Fatty acid consumption 
and risk of fracture in the Women's Health Initiative. The American journal of 
clinical nutrition 2010;92(6):1452-60 
 
